

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Arthritis and Rheumatology

68, 1-26

DOI: [10.1002/art.39480](https://doi.org/10.1002/art.39480)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Marine oil supplements for rheumatoid arthritis. The Cochrane Library, 2012, , .	1.5	0
2	Update of the Mexican College of Rheumatology Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis. Reumatología Clínica (English Edition), 2014, 10, 227-240.	0.2	14
3	Asymptomatic colitis induced by low-dose methotrexate. BMJ Case Reports, 2016, 2016, bcr2016217771.	0.2	5
4	Updated RA guidelines recommend treat-to-target approach. Pharmacy Today, 2016, 22, 24-25.	0.0	0
5	Minocycline: Rheumatoid Arthritis. Hospital Pharmacy, 2016, 51, 535-538.	0.4	6
6	Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Preference and Adherence, 2016, Volume 10, 2217-2228.	0.8	64
7	An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1088-1102.	0.5	24
8	Usability and Workflow Evaluation of "Rheumatic Disease Activity" (READY). Applied Clinical Informatics, 2016, 07, 1007-1024.	0.8	18
9	Effective abatacept therapy in a hemodialysis patient with rheumatoid arthritis. Nihon Toseki Igakkai Zasshi, 2016, 49, 593-597.	0.2	1
10	Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis. Journal of Korean Medical Science, 2016, 31, 1907.	1.1	7
11	Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1176-1181.	0.5	9
12	Hepatitis B Serology in Patients with Rheumatic Diseases. Open Rheumatology Journal, 2016, 10, 39-48.	0.1	15
13	The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis. BioMed Research International, 2016, 2016, 1-10.	0.9	7
14	Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Patient Preference and Adherence, 2016, Volume 10, 1509-1519.	0.8	44
15	Rate of Proven Rheumatic Diseases in a Large Collective of Referrals to an Outpatient Rheumatology Clinic under Routine Conditions. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2016, 9, CMAMD.S40361.	0.3	12
16	Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1457-1471.	0.5	33
17	FRIO181...Changing Use of Methotrexate (MTX) and Biologics in The Treatment of Rheumatoid Arthritis (RA) in The United States (US): Results of A Comprehensive Pharmaceutical Claims Analysis: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 495.2-495.	0.5	1
18	Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. Patient Preference and Adherence, 2016, 10, 1101.	0.8	26

#	ARTICLE	IF	CITATIONS
19	Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. <i>ClinicoEconomics and Outcomes Research</i> , 2016, Volume 8, 707-715.	0.7	26
20	Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. <i>Arthritis and Rheumatology</i> , 2016, 68, 2328-2337.	2.9	150
21	Treat-to-target as an approach in inflammatory arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 297-302.	2.0	45
22	Self-Reported Barriers to Healthcare Access for Rheumatoid Arthritis Patients in Rural and Northern Saskatchewan: A Mixed Methods Study. <i>Musculoskeletal Care</i> , 2016, 14, 243-251.	0.6	16
23	Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 1315-1316.	2.9	4
24	Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. <i>Arthritis and Rheumatology</i> , 2016, 68, 2083-2089.	2.9	42
25	The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Should Include New Standards for Hepatitis B Screening: Comment on the Article by Singh et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 1314-1315.	2.9	7
27	Regarding the Ambiguity of the Medical Terms "Biologics" and "Biological Agents". <i>Internal Medicine</i> , 2016, 55, 2327-2327.	0.3	0
28	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.5	160
29	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. <i>RMD Open</i> , 2016, 2, e000302.	1.8	57
30	Risk of obstructive sleep apnoea in patients with rheumatoid arthritis: a nationwide population-based retrospective cohort study. <i>BMJ Open</i> , 2016, 6, e013151.	0.8	27
31	Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. <i>RMD Open</i> , 2016, 2, e000287.	1.8	46
32	Severe bone marrow aplasia secondary to a combination of methotrexate and leflunomide in a patient with rheumatoid arthritis of the elderly. <i>Revista Colombiana De ReumatologÃa (English Edition)</i> , 2016, 23, 275-276.	0.1	0
33	Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. <i>Rheumatology</i> , 2017, 56, kew442.	0.9	49
34	Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients. <i>Current Medical Research and Opinion</i> , 2016, 32, 1959-1967.	0.9	7
35	Aplasia medular severa secundaria a la combinaciÃ³n de metotrexato y leflunomida en un paciente con artritis reumatoide del anciano. <i>Revista Colombiana De ReumatologÃa</i> , 2016, 23, 275-276.	0.0	1
36	Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000262.	1.8	24
37	Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions. <i>Medical Clinics of North America</i> , 2016, 100, 719-731.	1.1	17

#	ARTICLE	IF	CITATIONS
38	Quality of life: a valid perspective for patients with rheumatoid arthritis. <i>British Journal of Nursing</i> , 2016, 25, 374-376.	0.3	0
39	Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster. <i>Drug Safety</i> , 2016, 39, 823-840.	1.4	28
40	The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 613-624.	1.0	15
41	Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study. <i>Journal of Rheumatology</i> , 2016, 43, 1581-1588.	1.0	21
42	Precursor miR-499a Variant but not miR-196a2 is Associated with Rheumatoid Arthritis Susceptibility in an Egyptian Population. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 279-295.	1.6	46
43	Rheumatoid Arthritis Therapy and Joint-replacement Surgery: Are We Making a Difference?. <i>Journal of Rheumatology</i> , 2016, 43, 833-835.	1.0	5
44	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. <i>The Cochrane Library</i> , 2016, 2016, CD010227.	1.5	64
45	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1579-1590.	1.5	43
46	Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies. <i>Current Rheumatology Reports</i> , 2016, 18, 61.	2.1	32
47	Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe?. <i>Rheumatology International</i> , 2016, 36, 1535-1542.	1.5	37
48	Chemical JAK inhibitors for the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2215-2225.	0.9	22
49	Combination therapy with biologic agents in rheumatic diseases: current and future prospects. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 192-202.	1.2	32
50	Review of head-to-head study designs in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 279-285.	1.6	18
51	Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1303-1309.	1.4	21
52	Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 107-118.	1.2	21
53	Measuring transaminases in patients with rheumatoid arthritis on weekly methotrexate: does timing of blood testing matter?. <i>Clinical Rheumatology</i> , 2016, 35, 3053-3056.	1.0	1
54	Peripheral blood T helper type 17 frequency shows an inverse correlation with disease activity and magnetic resonance imaging-based osteitis and erosions in disease-modifying anti-rheumatic drug- and steroid-naïve established rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2016, 186, 313-320.	1.1	9
55	Treatment of rheumatoid arthritis. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 176-180.	0.1	3

#	ARTICLE	IF	CITATIONS
56	Immunization in patients with inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 946-963.	1.4	13
57	Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. <i>Clinical Therapeutics</i> , 2016, 38, 2628-2641.e5.	1.1	44
58	What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1403-1411.	1.3	7
59	Drugs That May Cause or Exacerbate Heart Failure. <i>Circulation</i> , 2016, 134, e32-69.	1.6	320
60	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. <i>Lancet, The</i> , 2016, 388, 2763-2774.	6.3	144
61	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). <i>The Cochrane Library</i> , 2016, 2016, CD012437.	1.5	27
62	Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 259.	1.6	0
63	Current complications and treatment of aspirin-exacerbated respiratory disease. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1305-1316.	1.0	9
64	Folypolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2016, 6, 35615.	1.6	35
65	Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1355-1359.	1.9	21
66	Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. <i>BMJ, The</i> , 2016, 354, i4205.	3.0	200
67	Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2538-2547.	0.9	18
68	Increased risk of vertebral fracture in patients with rheumatoid arthritis. <i>Medicine (United States)</i> , 2016, 95, e5262.	0.4	32
69	Nurse Practitioners' Education, Awareness, and Therapeutic Approaches for the Management of Fibromyalgia. <i>Orthopaedic Nursing</i> , 2016, 35, 317-322.	0.2	8
70	Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2527-2537.	0.9	16
71	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2016, 2016, CD012183.	1.5	51
72	The Use of Low-Dose Oral Glucocorticoids Was Minimized in the 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis: Comment on the Article by Singh et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 1314-1314.	2.9	4
73	Contemporary management of TMJ involvement in JIA patients and its orofacial consequences. <i>EPMA Journal</i> , 2016, 7, 12.	3.3	24

#	ARTICLE	IF	CITATIONS
74	Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. <i>Lancet</i> , The, 2016, 388, 343-355.	6.3	197
75	Beyond methotrexate monotherapy for early rheumatoid arthritis. <i>Lancet</i> , The, 2016, 388, 309-310.	6.3	0
76	Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2016, 33, 807-823.	1.3	12
78	Mirror, mirror on the wall: which microbiomes will help heal them all?. <i>BMC Medicine</i> , 2016, 14, 72.	2.3	31
79	Rheumatoid arthritis and metabolic syndrome. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 93-94.	0.7	0
80	Prevention of HBV reactivation in patients treated with biologic agents. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 579-589.	1.3	11
81	Missed opportunities in the 2015 ACR guideline for RA treatment. <i>Nature Reviews Rheumatology</i> , 2016, 12, 135-136.	3.5	1
82	Vaccinations for rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 330-336.	2.0	22
83	Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 319-326.	1.5	7
84	Older anti-TNF- α agents: why not group them for common indications in the EU?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-4.	0.7	3
85	Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2829-2834.	1.0	17
86	Eficacia a 2 años de tocilizumab en pacientes con artritis reumatoide activa en la práctica clínica habitual. <i>Reumatología Clínica</i> , 2017, 13, 78-84.	0.2	4
87	Impacto de variantes genéticas del transportador de membrana que une ATP B1, la aicar transformilasa/IMP ciclohidrolasa, la folilpoliglutamatosintetasa y la metilen-tetrahidrofolatorreductasa en la toxicidad de metotrexato. <i>Reumatología Clínica</i> , 2017, 13, 318-325.	0.2	6
88	Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. <i>Journal of Medical Economics</i> , 2017, 20, 464-473.	1.0	29
89	Design and Synthesis of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Treatment of Rheumatoid Arthritis. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1159-1170.	2.9	104
90	IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide. <i>Scientific Reports</i> , 2017, 7, 41143.	1.6	24
92	Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 361, 229-244.	1.3	23
93	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 694-700.	0.5	83

#	ARTICLE	IF	CITATIONS
94	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.5	393
95	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017, 2017, CD012591.	1.5	44
96	Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 1154-1164.	2.9	160
97	Osteoporosis: Treat-to-Target. <i>Current Osteoporosis Reports</i> , 2017, 15, 103-109.	1.5	16
98	Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. <i>Clinical Rheumatology</i> , 2017, 36, 1013-1022.	1.0	20
99	The emerging safety profile of JAK inhibitors in rheumatic disease. <i>Nature Reviews Rheumatology</i> , 2017, 13, 234-243.	3.5	420
100	Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. <i>Journal of Rheumatology</i> , 2017, 44, 565-570.	1.0	9
101	Antimalarial myopathy in a systemic lupus erythematosus patient with quadriplegia and seizures: a case-based review. <i>Clinical Rheumatology</i> , 2017, 36, 1437-1444.	1.0	7
102	Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) – A prospective, multicenter, single arm pilot clinical trial. <i>Modern Rheumatology</i> , 2017, 27, 930-937.	0.9	6
103	Improved survival in rheumatoid arthritis: a general population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 408-413.	0.5	85
104	Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 840-847.	0.5	244
105	Step Therapy – Clinical Algorithms, Legislation, and Optimal Prescribing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 801.	3.8	14
106	Effects of antirheumatic drug underutilization on rheumatoid arthritis disease activity. <i>Inflammopharmacology</i> , 2017, 25, 431-438.	1.9	1
107	Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 96-104.	0.5	86
108	Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2017, 3, 7.	0.4	3
109	Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 1075-1082.	1.5	13
110	bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. <i>Rheumatology and Therapy</i> , 2017, 4, 1-24.	1.1	34
111	DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. <i>RMD Open</i> , 2017, 3, e000382.	1.8	71

#	ARTICLE	IF	CITATIONS
112	Impact of ultrasonography on treatment decision in rheumatoid arthritis: the IMPULSAR study. <i>Rheumatology International</i> , 2017, 37, 891-896.	1.5	15
113	The role and therapeutic targeting of IL-6 in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 535-551.	1.3	166
114	Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials. <i>British Journal of Dermatology</i> , 2017, 177, 978-986.	1.4	41
115	Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 748-755.	0.5	251
116	Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 133-142.	1.6	26
117	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1348-1356.	0.5	36
119	Baseline MRI bone erosion predicts the subsequent radiographic progression in early rheumatoid arthritis patients who achieved sustained good clinical response. <i>Modern Rheumatology</i> , 2017, 27, 961-966.	0.9	6
120	Tackling comorbidity associated with rheumatic diseases in standard practice. <i>British Journal of Nursing</i> , 2017, 26, 380-387.	0.3	1
121	Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 75.	1.6	13
122	Association Between Medications and Herpes Zoster in Japanese Patients with Rheumatoid Arthritis: A 5-year Prospective Cohort Study. <i>Journal of Rheumatology</i> , 2017, 44, 988-995.	1.0	14
123	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017, 5, CD012657.	1.5	47
124	Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 165-169.	1.6	10
125	Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. <i>Cell Host and Microbe</i> , 2017, 21, 603-610.e3.	5.1	306
126	Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. <i>Clinical Rheumatology</i> , 2017, 36, 1237-1245.	1.0	23
127	High Methotrexate Triglutamate Level Is an Independent Predictor of Adverse Effects in Asian Indian Rheumatoid Arthritis Patients—A Preliminary Study. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 157-163.	1.0	13
128	Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1559-1565.	0.5	108
129	Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 193-199.	0.5	13
130	Doctors'™ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment. <i>Arthritis Research and Therapy</i> , 2017, 19, 78.	1.6	7

#	ARTICLE	IF	CITATIONS
131	Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice. <i>Clinical Rheumatology</i> , 2017, 36, 1-8.	1.0	25
132	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017, 69, 728-734.	2.9	39
133	Gaps in Aging Research as it Applies to Rheumatologic Clinical Care. <i>Clinics in Geriatric Medicine</i> , 2017, 33, 119-133.	1.0	13
134	Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective. <i>Rheumatology International</i> , 2017, 37, 1423-1434.	1.5	24
135	Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. <i>Rheumatology</i> , 2017, 56, 940-946.	0.9	44
136	Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study. <i>Arthritis Care and Research</i> , 2017, 69, 1484-1494.	1.5	39
137	Screening and Treatment of Latent Tuberculosis Among Patients Receiving Biologic Agents. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 6-11.	0.5	6
138	Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study. <i>Rheumatology International</i> , 2017, 37, 1709-1718.	1.5	18
139	Tocilizumab for giant cell arteritis with corticosteroid-resistant progressive anterior ischemic optic neuropathy. <i>Joint Bone Spine</i> , 2017, 84, 615-619.	0.8	13
140	Berberine ameliorates collagen-induced arthritis in rats by suppressing Th17 cell responses via inducing cortistatin in the gut. <i>FEBS Journal</i> , 2017, 284, 2786-2801.	2.2	35
141	Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 47.	1.6	22
142	Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 1715-1720.	1.0	11
143	Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. <i>Rheumatology International</i> , 2017, 37, 1111-1123.	1.5	10
144	A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?. <i>Clinical Rheumatology</i> , 2017, 36, 1215-1220.	1.0	16
145	Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 989-999.	1.4	10
146	Disseminated Tuberculosis Resulting From Reinfection in a Pediatric Patient Sequentially Treated With Etanercept and Adalimumab. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 109-110.	1.1	7
147	Maintenance of remission with combination etanercept+DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. <i>Rheumatology International</i> , 2017, 37, 1469-1479.	1.5	16
148	Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. <i>BioDrugs</i> , 2017, 31, 369-377.	2.2	41

#	ARTICLE	IF	CITATIONS
149	Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000410.	1.8	28
150	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. <i>Journal of Autoimmunity</i> , 2017, 80, 10-27.	3.0	114
151	Visceral Leishmaniasis in a Rheumatoid Arthritis Patient Receiving Methotrexate. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2017, 13, 354-356.	0.2	2
152	Two-year Efficacy of tocilizumab in Patients With Active Rheumatoid Arthritis in Clinical Practice. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2017, 13, 78-84.	0.2	2
153	Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1279-1284.	0.5	64
154	Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?. <i>Rheumatology International</i> , 2017, 37, 905-913.	1.5	10
155	2016 update of the EULAR recommendations for the management of rheumatoid arthritis: a utopia beyond patients in low/middle income countries?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e47-e47.	0.5	11
157	Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. <i>Journal of Medical Economics</i> , 2017, 20, 703-714.	1.0	15
158	â€œOfficial Viewâ€ on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements. <i>Arthritis Care and Research</i> , 2017, 69, 1134-1141.	1.5	39
159	Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 1510-1518.	1.5	102
160	A Multiâ€Biomarker Disease Activity Score and the Choice of Secondâ€Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. <i>Arthritis and Rheumatology</i> , 2017, 69, 953-963.	2.9	27
161	Executive Summary of the NHLBI Workshop Report: Leveraging Current Scientific Advancements to Understand Sarcoidosis Variability and Improve Outcomes. <i>Annals of the American Thoracic Society</i> , 2017, 14, S415-S420.	1.5	20
162	Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. <i>RMD Open</i> , 2017, 3, e000496.	1.8	16
163	Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. <i>RMD Open</i> , 2017, 3, e000465.	1.8	10
164	Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. <i>Rheumatology and Therapy</i> , 2017, 4, 391-404.	1.1	5
165	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. <i>Advances in Therapy</i> , 2017, 34, 2422-2435.	1.3	28
166	Impact of Genetic Variants of ATP Binding Cassette B1, AICAR Transformylase/IMP Cyclohydrolase, Folyl-polyglutamate Synthetase, and Methylenetetrahydrofolate Reductase on Methotrexate Toxicity. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2017, 13, 318-325.	0.2	1
167	Mechanisms of the Innate Defense Regulator Peptide-1002 Anti-Inflammatory Activity in a Sterile Inflammation Mouse Model. <i>Journal of Immunology</i> , 2017, 199, 3592-3603.	0.4	39

#	ARTICLE	IF	CITATIONS
168	Development of a Canadian Core Clinical Dataset to Support High-quality Care for Canadian Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1813-1822.	1.0	11
169	The role of nurse practitioners in delivering rheumatology care and services. <i>Journal of the American Association of Nurse Practitioners</i> , 2017, 29, 673-681.	0.5	13
170	A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor. <i>JAAD Case Reports</i> , 2017, 3, 498-500.	0.4	6
171	Studies with herpes zoster vaccines in immune compromised patients. <i>Expert Review of Vaccines</i> , 2017, 16, 1217-1230.	2.0	21
172	Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy. <i>Rheumatology</i> , 2017, 56, 2179-2189.	0.9	5
173	Treatment with Biologicals in Rheumatoid Arthritis: An Overview. <i>Rheumatology and Therapy</i> , 2017, 4, 247-261.	1.1	115
174	Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2017, 4, 309-332.	1.1	20
175	A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1525-1533.	0.9	19
176	The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 1969-1977.	2.9	103
177	Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. <i>Rheumatology International</i> , 2017, 37, 1789-1798.	1.5	20
178	Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 49-54.	0.5	4
179	Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. <i>The Cochrane Library</i> , 2017, 2017, CD007649.	1.5	40
180	Genome Engineering for Personalized Arthritis Therapeutics. <i>Trends in Molecular Medicine</i> , 2017, 23, 917-931.	3.5	54
181	Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- α and Interleukin-17 Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2283-2291.	2.9	27
182	Two new drugs for rheumatoid arthritis. <i>Drug and Therapeutics Bulletin</i> , 2017, 55, 102.1-105.	0.3	2
183	Efficiency and Safety of CRAC Inhibitors in Human Rheumatoid Arthritis Xenograft Models. <i>Journal of Immunology</i> , 2017, 199, 1584-1595.	0.4	33
184	Outcomes of Treatment for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease Receiving Biologic Therapy. <i>Gastroenterology</i> , 2017, 152, S579-S580.	0.6	4
185	Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. <i>Journal of Pediatrics</i> , 2017, 189, 31-39.	0.9	3

#	ARTICLE	IF	CITATIONS
186	Retrospective Study of Patients on Etanercept Therapy for Rheumatic Diseases in Patients With Chronic Hepatitis C Virus. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 252-257.	0.5	8
187	Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2017, 39, 1680-1694.e2.	1.1	17
188	Efficacy of baricitinib in the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1399-1407.	0.9	28
189	Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 364-369.	1.0	21
190	Small molecule therapeutics for inflammation-associated chronic musculoskeletal degenerative diseases: Past, present and future. <i>Experimental Cell Research</i> , 2017, 359, 1-9.	1.2	17
191	Patient-reported outcomes in Takayasu's arteritis. <i>Presse Medicale</i> , 2017, 46, e225-e227.	0.8	4
192	The Role of Epigenetics in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2017, 17, 89.	1.7	69
193	Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies. <i>Current Medical Research and Opinion</i> , 2017, 33, 1635-1642.	0.9	4
194	DMARD de-escalation "let the patient guide you. <i>Nature Reviews Rheumatology</i> , 2017, 13, 637-638.	3.5	14
195	Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1345580.	0.8	33
196	Preference for shared decision-making in Japanese patients with rheumatoid arthritis. <i>Cogent Medicine</i> , 2017, 4, 1353262.	0.7	8
197	Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. <i>Clinical Rheumatology</i> , 2017, 36, 2187-2192.	1.0	6
198	Effect of Qianghuo Erhuang Decoction on T Regulatory and T Helper 17 Cells in Treatment of Adjuvant-induced Arthritis in Rats. <i>Scientific Reports</i> , 2017, 7, 17198.	1.6	12
199	Tuberculosis and biologics in rheumatology: A special situation. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1313-1325.	0.9	22
200	Do TNF inhibitors influence lymphoma development?. <i>Nature Reviews Rheumatology</i> , 2017, 13, 697-698.	3.5	1
201	Herpes zoster vaccine live: A 10-year review of post-marketing safety experience. <i>Vaccine</i> , 2017, 35, 7231-7239.	1.7	80
202	Drug updates and approvals. <i>Nurse Practitioner</i> , 2017, 42, 8-16.	0.2	2
203	REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients. <i>Heliyon</i> , 2017, 3, e00452.	1.4	7

#	ARTICLE	IF	CITATIONS
204	Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. <i>Nature Reviews Rheumatology</i> , 2017, 13, 707-718.	3.5	139
205	Glucocorticoids. , 2017, , 1467-1484.		0
206	Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. <i>Hospital Pharmacy</i> , 2017, 52, 667-668.	0.4	3
207	Educational website incorporating rheumatoid arthritis patient needs for Latin American and Caribbean countries. <i>Clinical Rheumatology</i> , 2017, 36, 2789-2797.	1.0	14
208	JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 843-862.	21.5	759
209	Biosimilars in rheumatology – why, how and when in 2017. <i>Nature Reviews Rheumatology</i> , 2017, 13, 701-703.	3.5	4
210	Patient Endorsement of the Outcome Measures in Rheumatology (OMERACT) Total Joint Replacement (TJR) clinical trial draft core domain set. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 111.	0.8	23
211	Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy. <i>Advances in Therapy</i> . 2017. 34. 1936-1952.	1.3	46
212	Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 81.	1.6	8
213	Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. <i>Arthritis Research and Therapy</i> , 2017, 19, 92.	1.6	17
214	Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. <i>Arthritis Research and Therapy</i> , 2017, 19, 130.	1.6	2
215	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1937-1948.	2.9	32
216	Measuring fatigue with multiple instruments in a Brazilian cohort of early rheumatoid arthritis patients. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 431-437.	0.7	9
217	Safety profile of biological therapies for treating rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1089-1103.	1.4	30
218	Immune-Mediated Heart Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1003, 145-171.	0.8	12
219	Development and validation of a bioanalytical method based on LC-MS/MS analysis for the quantitation of CIGB-814 peptide in plasma from Rheumatoid Arthritis patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 143, 130-140.	1.4	9
220	Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature. <i>Clinical Rheumatology</i> , 2017, 36, 1699-1706.	1.0	12
221	Hepatitis B Reactivation in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 133-149.	0.8	34

#	ARTICLE	IF	CITATIONS
222	Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?. <i>Cell Metabolism</i> , 2017, 25, 233-241.	7.2	37
223	Pharmacotherapy Pearls for the Geriatrician. <i>Clinics in Geriatric Medicine</i> , 2017, 33, 1-15.	1.0	5
224	Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 537-543.	1.6	25
225	Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2017, 69, 277-290.	2.9	146
226	Vaccines and Disease-Modifying Antirheumatic Drugs. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 1-13.	0.8	53
227	Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab. <i>Modern Rheumatology</i> , 2017, 27, 246-251.	0.9	4
228	Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2017, 69, 439-446.	2.9	24
229	Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. <i>Clinical Rheumatology</i> , 2017, 36, 15-24.	1.0	22
230	The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study. <i>Clinical Rheumatology</i> , 2017, 36, 35-43.	1.0	30
231	Interaction Between Low-Dose Methotrexate and Nonsteroidal Anti-inflammatory Drugs, Penicillins, and Proton Pump Inhibitors. <i>Annals of Pharmacotherapy</i> , 2017, 51, 163-178.	0.9	29
232	Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. <i>Clinical Rheumatology</i> , 2017, 36, 25-34.	1.0	27
233	Kala-azar en un paciente con artritis reumatoide tratada con metotrexato. <i>Reumatología Clínica</i> , 2017, 13, 354-356.	0.2	10
234	Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. <i>Arthritis and Rheumatology</i> , 2017, 69, 506-517.	2.9	310
235	Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?. <i>Arthritis Care and Research</i> , 2017, 69, 989-996.	1.5	8
236	Underuse of Methotrexate in the Treatment of Rheumatoid Arthritis: A National Analysis of Prescribing Practices in the US. <i>Arthritis Care and Research</i> , 2017, 69, 794-800.	1.5	31
237	Single-center, single-dose, open-label, randomized, two-period crossover study on the bioavailability of methotrexate administered using a novel prefilled, needle-free delivery system. <i>Current Medical Research and Opinion</i> , 2017, 33, 605-611.	0.9	4
238	Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. <i>Modern Rheumatology</i> , 2017, 27, 773-777.	0.9	23
239	cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis. <i>Immunologic Research</i> , 2017, 65, 307-325.	1.3	10

#	ARTICLE	IF	CITATIONS
240	Chronic Disease and Self-Injection: Ethnographic Investigations into the Patient Experience During Treatment. <i>Rheumatology and Therapy</i> , 2017, 4, 445-463.	1.1	38
241	Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment. <i>Internal Medicine</i> , 2017, 56, 2271-2275.	0.3	8
242	Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. <i>BMJ: British Medical Journal</i> , 2017, 357, j1415.	2.4	514
243	High Disease Activity May Increase Fear-Avoidance Beliefs in Rheumatoid Arthritis. <i>Archives of Rheumatology</i> , 2017, 32, 325-332.	0.3	4
244	Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. <i>RMD Open</i> , 2017, 3, e000491.	1.8	33
245	Frontiers in Drug Research and Development for Inflammatory Bowel Disease. <i>Frontiers in Pharmacology</i> , 2017, 8, 400.	1.6	40
246	Managing the drug treatment of rheumatoid arthritis. <i>Australian Prescriber</i> , 2017, 40, 51-58.	0.5	57
247	Diagnosis and Treatment of Inflammatory Joint Disease. <i>Hip and Pelvis</i> , 2017, 29, 211.	0.6	39
248	The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms. <i>Open Access Rheumatology: Research and Reviews</i> , 2017, Volume 9, 139-150.	0.8	48
249	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1969-1978.	2.0	11
250	Patients' conceptions of their own influence on good treatment response to biological therapy in chronic inflammatory arthritis. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1057-1067.	0.8	4
251	Neutrophils in Rheumatoid Arthritis: A Target for Discovering New Therapies Based on Natural Products. , 0, , .		12
252	Are Illness Perceptions Associated With Disease Activity or Psychological Well-Being in Rheumatoid Arthritis? A Study With the Evidence of Confirmatory Factor Analysis. <i>Archives of Rheumatology</i> , 2017, 32, 315-324.	0.3	6
253	Extracellular Vesicles Transfer the Receptor Programmed Death-1 in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2017, 8, 851.	2.2	33
254	The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges. <i>Frontiers in Medicine</i> , 2017, 4, 78.	1.2	38
255	Polymorphism rs2073618 of the TNFRSF11B (OPG) Gene and Bone Mineral Density in Mexican Women with Rheumatoid Arthritis. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	0.9	10
256	Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. <i>International Journal of Rheumatology</i> , 2017, 2017, 1-15.	0.9	24
257	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1593-1603.	2.0	85

#	ARTICLE	IF	CITATIONS
258	Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment. <i>Internal Medicine</i> , 2017, 56, 903-906.	0.3	12
259	Novel Drug Delivery Systems Tailored for Improved Administration of Glucocorticoids. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1836.	1.8	53
260	European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 14, 15-29.	0.9	20
261	Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2017, Volume 9, 67-79.	0.8	77
262	Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis. <i>Frontiers in Endocrinology</i> , 2017, 8, 179.	1.5	20
263	Evidence and consensus recommendations for the pharmacological management of pain in India. <i>Journal of Pain Research</i> , 2017, Volume 10, 709-736.	0.8	21
264	Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2017, 12, e0177057.	1.1	23
265	Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. <i>PLoS ONE</i> , 2017, 12, e0179179.	1.1	37
266	Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways. <i>PLoS ONE</i> , 2017, 12, e0183928.	1.1	33
267	Immunosuppressive Therapy for Rheumatic Disease. <i>Journal of the Nihon University Medical Association</i> , 2017, 76, 24-27.	0.0	0
268	Glucocorticoid management in rheumatoid arthritis: morning or night low dose?. <i>Reumatologia</i> , 2017, 55, 189-197.	0.5	28
269	Micro-structural bone changes in early rheumatoid arthritis persist over 1-year despite use of disease modifying anti-rheumatic drug therapy. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 521.	0.8	11
270	Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 183.	1.0	25
271	Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 591.	0.7	14
272	A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study. <i>Arthritis Research and Therapy</i> , 2017, 19, 185.	1.6	11
273	High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. <i>Arthritis Research and Therapy</i> , 2017, 19, 194.	1.6	50
274	Decreased ex vivo production of interferon-gamma is associated with severity and poor prognosis in patients with lupus. <i>Arthritis Research and Therapy</i> , 2017, 19, 193.	1.6	14
275	Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. <i>Arthritis Research and Therapy</i> , 2017, 19, 208.	1.6	48

#	ARTICLE	IF	CITATIONS
276	Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation. <i>Arthritis Research and Therapy</i> , 2017, 19, 212.	1.6	35
277	Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. <i>Arthritis Research and Therapy</i> , 2017, 19, 276.	1.6	10
278	Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 600-610.	0.7	23
279	Beneficial effect of 20-hydroxyecdysone exerted by modulating antioxidants and inflammatory cytokine levels in collagen-induced arthritis: A model for rheumatoid arthritis. <i>Molecular Medicine Reports</i> , 2017, 16, 6162-6169.	1.1	7
280	Leveraging electronic medical record data for population health management in the Veterans Health Administration: Successes and lessons learned. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 1447-1459.	0.5	26
281	Age-related trends in injection site reaction incidence induced by the tumor necrosis factor- α inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. <i>International Journal of Medical Sciences</i> , 2017, 14, 102-109.	1.1	21
282	Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis. <i>Reumatologia</i> , 2017, 55, 284-289.	0.5	6
283	Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1133-1142.	0.8	14
284	Rheumatoid Arthritis Comorbidity Index (RACI): Development and Validation of a New Comorbidity Index for Rheumatoid Arthritis Patients. <i>Journal of Arthritis</i> , 2017, 06, .	0.3	2
285	Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis. <i>Pakistan Journal of Medical Sciences</i> , 2017, 33, 840-843.	0.3	0
286	Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series. <i>European Journal of Rheumatology</i> , 2017, 4, 194-199.	1.3	10
287	Rheumatoid Arthritis in Sickle-Cell Population: Pathophysiologic Insights, Clinical Evaluation and Management. <i>Rheumatology (Sunnyvale, Calif)</i> , 2017, 07, .	0.3	8
288	Recent advances in the treatment of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 231-237.	2.0	41
289	Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease. <i>Respiratory Medicine</i> , 2018, , 121-161.	0.1	4
291	Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2018, 18, 539-545.	0.9	14
292	Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Impact of Residual Inflammation Detected via Imaging Techniques, Drug Levels and Patient Characteristics on the Outcome of Dose Tapering of Adalimumab in Clinical Remission Rheumatoid Arthritis (RA) patients (PREDICTRA). <i>BMI Open</i> , 2018, 8, e019007.	0.8	7
293	New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 77-87.	1.1	40
294	Scores versus clinical profiles in therapeutic decisions: a positive example from the Italian Medicines Agency (AIFA) decisions in the field of osteoporosis. <i>Clinical Rheumatology</i> , 2018, 37, 575-578.	1.0	1

#	ARTICLE	IF	CITATIONS
295	Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 658-666.	0.5	22
296	A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. <i>Rheumatology and Therapy</i> , 2018, 5, 21-42.	1.1	97
297	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling) <i>Tj ETQq0 0 0 28 /Overlok 10 Tf</i>	0.8	10
298	Prediction of response to methotrexate in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 419-429.	1.3	23
299	Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis. <i>Rheumatology and Therapy</i> , 2018, 5, 43-55.	1.1	4
300	Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2106-2112.	0.9	14
301	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. <i>RMD Open</i> , 2018, 4, e000564.	1.8	29
302	The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. <i>Personalized Medicine</i> , 2018, 15, 291-301.	0.8	18
304	Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. <i>Clinical Rheumatology</i> , 2018, 37, 2043-2053.	1.0	9
305	Antimalarial Drugs for the Prevention of Chronic Kidney Disease in Patients with Rheumatoid Arthritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 679-680.	2.2	5
306	Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1419-1428.	2.9	21
307	Optical spectral transmission to assess inflammation in hand and wrist joints of rheumatoid arthritis patients. <i>Rheumatology</i> , 2018, 57, 865-872.	0.9	17
308	Role of Methotrexate in the Management of Psoriatic Arthritis. <i>Drugs</i> , 2018, 78, 611-619.	4.9	20
309	Tumor necrosis factor-α inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. <i>International Journal of Cancer</i> , 2018, 143, 1062-1071.	2.3	42
310	Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach. <i>Rheumatology and Therapy</i> , 2018, 5, 87-98.	1.1	1
311	Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic-Naïve Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2018, 70, 997-1004.	1.5	8
312	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2018-213030.	0.5	183
313	Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2018, 37, 3201-3214.	1.0	5

#	ARTICLE	IF	CITATIONS
314	Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly. <i>Drugs and Aging</i> , 2018, 35, 379-387.	1.3	7
315	Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice. <i>Clinical Rheumatology</i> , 2018, 37, 1189-1197.	1.0	44
316	Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole. <i>Clinical Rheumatology</i> , 2018, 37, 3215-3220.	1.0	17
317	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune) Tj ETQq1 1 0.784314 rgBT /Overlock 10 24. S10-S20.	2.8	139
318	TGF- β 2 signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2018, 90, 49-58.	3.0	39
319	Clearing up potential misconceptions about the treatment of rheumatoid arthritis and the use of methotrexate in combination therapy. <i>Canadian Pharmacists Journal</i> , 2018, 151, 94-97.	0.4	1
320	Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 320-328.	1.0	28
321	Safety, and Humoral and Cell-mediated Immune Responses to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 465-469.	1.0	8
322	Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. <i>Rheumatology and Therapy</i> , 2018, 5, 203-214.	1.1	10
323	Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. <i>Clinical Therapeutics</i> , 2018, 40, 309-319.	1.1	18
324	Experience and Context Shape Patient and Clinician Goals For Treatment of Rheumatoid Arthritis: A Qualitative Study. <i>Arthritis Care and Research</i> , 2018, 70, 1614-1620.	1.5	16
325	Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 832-840.	2.9	103
326	Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 841-854.	2.9	44
327	Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 1695-1700.	1.0	18
328	Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study. <i>Rheumatology and Therapy</i> , 2018, 5, 215-229.	1.1	3
329	Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2018, 40, 156-165.e5.	1.1	31
331	Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting. <i>Modern Rheumatology</i> , 2018, 28, 780-788.	0.9	14
332	Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation. <i>Rheumatology International</i> , 2018, 38, 599-606.	1.5	6

#	ARTICLE	IF	CITATIONS
333	Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 402-414.	0.9	12
334	The clinical course of patients with rheumatoid arthritis who underwent orthopaedic surgeries under disease control by tofacitinib. <i>Modern Rheumatology</i> , 2018, 28, 1063-1065.	0.9	8
335	Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 1885-1895.	0.9	82
336	“Like No One Is Listening to Me”: A Qualitative Study of Patient-Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 1439-1447.	1.5	23
337	Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. <i>Rheumatology</i> , 2018, 57, 309-317.	0.9	12
338	Glucocorticoids, Inflammation and Bone. <i>Calcified Tissue International</i> , 2018, 102, 592-606.	1.5	59
339	The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. <i>Drug Safety</i> , 2018, 41, 473-488.	1.4	30
341	Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 673-687.	0.9	6
342	Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2272-2277.	0.9	13
343	Involvement of miR-126 in autoimmune disorders. <i>Clinical and Molecular Allergy</i> , 2018, 16, 11.	0.8	23
344	Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 50.	1.6	28
345	Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1964-1973.e1.	2.4	47
346	Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. <i>Current Opinion in Pharmacology</i> , 2018, 40, 110-119.	1.7	63
347	Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients. <i>Internal Medicine</i> , 2018, 57, 663-670.	0.3	30
348	Evaluation of a Janus kinase 1 inhibitor, PF04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1776-1788.	1.1	37
349	Short report: correlates of functional disability with disease activity in elderly patients with rheumatoid arthritis. <i>Psychology, Health and Medicine</i> , 2018, 23, 668-673.	1.3	4
350	Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2018-213222.	0.5	131
351	Low conversion rate of QuantiFERON-TB Gold screening tests in patients treated with tumor necrosis factor inhibitors: A retrospective cohort study identifying an important practice gap. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 169-171.	0.6	12

#	ARTICLE	IF	CITATIONS
352	Patient Satisfaction and Costs of Multidisciplinary Models of Care in Rheumatology: a Review of the Recent Literature. <i>Current Rheumatology Reports</i> , 2018, 20, 19.	2.1	12
353	The effect of interactive digital interventions on physical activity in people with inflammatory arthritis: a systematic review. <i>Rheumatology International</i> , 2018, 38, 1623-1634.	1.5	22
354	Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. <i>RMD Open</i> , 2018, 4, e000615.	1.8	20
355	Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 935-947.	1.5	89
356	Maintenance of Remission with Etanerceptâ€“DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2018, 5, 149-158.	1.1	1
357	Tocilizumab in the treatment of adult rheumatoid arthritis. <i>Immunotherapy</i> , 2018, 10, 447-464.	1.0	15
358	A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept. <i>Journal of General Internal Medicine</i> , 2018, 33, 769-772.	1.3	10
359	Predicting methotrexate resistance in rheumatoid arthritis patients. <i>Inflammopharmacology</i> , 2018, 26, 699-708.	1.9	22
360	Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2018, 57, 273-282.	0.9	23
361	Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Crossâ€“National Comparison Between the US and Taiwan. <i>Arthritis Care and Research</i> , 2018, 70, 30-38.	1.5	10
362	Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 13-23.	1.0	13
363	Determinants of Perceived Health Nonimprovement in Early Rheumatoid Arthritis Patients With Favorable Treatment Outcomes. <i>Arthritis Care and Research</i> , 2018, 70, 510-515.	1.5	14
364	Rheumatoid Arthritis Patientsâ€™ Motivations for Accepting or Resisting Diseaseâ€“Modifying Antirheumatic Drug Treatment Regimens. <i>Arthritis Care and Research</i> , 2018, 70, 533-541.	1.5	18
365	Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6<sc>PDH</sc>â€“Deficient Patients. <i>Arthritis Care and Research</i> , 2018, 70, 481-485.	1.5	72
366	Impact of Costâ€“Sharing Increases on Continuity of Specialty Drug Use: A Quasiâ€“Experimental Study. <i>Health Services Research</i> , 2018, 53, 2735-2757.	1.0	22
367	Anti-rheumatoid activity of ethanolic extract of <i>Sesamum indicum</i> seed extract in Freund's complete adjuvant induced arthritis in Wistar albino rats. <i>Journal of Traditional and Complementary Medicine</i> , 2018, 8, 377-386.	1.5	23
368	Tofacitinib in the treatment of active rheumatoid arthritis in adults. <i>Immunotherapy</i> , 2018, 10, 39-56.	1.0	12
369	Twoâ€“year persistence of golimumab as secondâ€“line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: realâ€“life data from the <sc>LORHEN</sc> registry. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 422-430.	0.9	22

#	ARTICLE	IF	CITATIONS
370	A Bayesian model that jointly considers comparative effectiveness research and patients'™ preferences may help inform GRADE recommendations: an application to rheumatoid arthritis treatment recommendations. <i>Journal of Clinical Epidemiology</i> , 2018, 93, 56-65.	2.4	14
371	Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 679-684.	1.5	36
372	Intra-articular methotrexate versus corticosteroid injections in medium-sized joints of rheumatoid arthritis patients: an intervention study. <i>Clinical Rheumatology</i> , 2018, 37, 331-337.	1.0	11
373	Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis patients over time: response data from the tREACH study. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 178-184.	0.6	4
374	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. <i>Quality of Life Research</i> , 2018, 27, 755-764.	1.5	52
375	Comparative evaluation of treatment patterns and healthcare utilization of newly-diagnosed rheumatoid arthritis patients by anti-cyclic citrullinated peptide antibody status. <i>Journal of Medical Economics</i> , 2018, 21, 231-240.	1.0	1
376	Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs. <i>Modern Rheumatology</i> , 2018, 28, 599-605.	0.9	3
377	Rehabilitation of Older Patients with Rheumatic Diseases. <i>Practical Issues in Geriatrics</i> , 2018, , 225-236.	0.3	0
378	Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease. <i>Arthritis Care and Research</i> , 2018, 70, 834-841.	1.5	5
379	Dorsal Root Ganglion Field Stimulation Prevents Inflammation and Joint Damage in a Rat Model of Rheumatoid Arthritis. <i>Neuromodulation</i> , 2018, 21, 247-253.	0.4	24
380	Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 444-451.	0.9	6
381	Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2018, 70, 724-731.	1.5	28
382	Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database. <i>Therapeutic Innovation and Regulatory Science</i> , 2018, 52, 339-347.	0.8	4
383	Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Population-Level Analysis. <i>Arthritis Care and Research</i> , 2018, 70, 877-883.	1.5	51
384	Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies. <i>Advances in Therapy</i> , 2018, 35, 100-115.	1.3	18
385	Defining and characterizing sustained remission in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 885-893.	1.0	6
386	Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 62-67.	0.6	20
387	Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 650-657.	0.5	36

#	ARTICLE	IF	CITATIONS
388	Drug-Induced Gastrointestinal and Hepatic Disease Associated with Biologics and Nonbiologic Disease-Modifying Antirheumatic Drugs. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 29-43.	0.8	12
389	Gastrointestinal and Hepatic Disease in Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 153-164.	0.8	4
390	Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 362-372.	0.9	8
391	CNT06785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study. <i>Journal of Rheumatology</i> , 2018, 45, 22-31.	1.0	17
392	Short-term application of tocilizumab during myocardial infarction (STAT-MI). <i>Rheumatology International</i> , 2018, 38, 59-66.	1.5	23
393	Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor- α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study. <i>Journal of Rheumatology</i> , 2018, 45, 32-39.	1.0	42
394	Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting. <i>Journal of Rheumatology</i> , 2018, 45, 170-176.	1.0	24
395	Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. <i>Journal of Rheumatology</i> , 2018, 45, 177-187.	1.0	18
396	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 289-292.	0.5	22
397	Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 40-44.	1.0	32
398	Factors associated with use of disease modifying agents for rheumatoid arthritis in the National Hospital and Ambulatory Medical Care Survey. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 649-653.	1.6	10
399	Gene Delivery to Joints by Intra-Articular Injection. <i>Human Gene Therapy</i> , 2018, 29, 2-14.	1.4	92
400	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. <i>Modern Rheumatology</i> , 2018, 28, 583-591.	0.9	36
401	Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 472-477.	1.6	19
402	Wolf's post-herpetic isotopic response to tocilizumab for rheumatoid arthritis. <i>Australasian Journal of Dermatology</i> , 2018, 59, e135-e137.	0.4	2
403	Interleukin (IL-6) Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028456.	2.3	223
404	Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2018, 57, 419-428.	0.9	11
405	Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis. <i>European Journal of Rheumatology</i> , 2018, 5, 160-164.	1.3	10

#	ARTICLE	IF	CITATIONS
406	Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis. <i>Medicine (United States)</i> , 2018, 97, e12658.	0.4	37
407	Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis. <i>Chinese Medical Journal</i> , 2018, 131, 2683-2692.	0.9	28
408	Automatic Hand Skeletal Shape Estimation from Radiographs. , 2018, , .		0
409	Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies. <i>Revista Colombiana De ReumatologÃa</i> , 2018, 25, 233-244.	0.0	3
410	Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis. <i>European Journal of Rheumatology</i> , 2018, 5, 85-91.	1.3	4
411	Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies. <i>Revista Colombiana De ReumatologÃa (English Edition)</i> , 2018, 25, 233-244.	0.1	0
412	Maintenance of low disease activity and remission with etanerceptâ€“disease-modifying antirheumatic drug (DMARD) combination therapy compared with treatment with DMARDs alone in Latin American patients with active rheumatoid arthritis. <i>Medicine (United States)</i> , 2018, 97, e11989.	0.4	0
413	Systems-Mapping of Herbal Effects on Complex Diseases Using the Network-Perturbation Signatures. <i>Frontiers in Pharmacology</i> , 2018, 9, 1174.	1.6	18
414	Long-term prognosis and quality of life in patients with early rheumatoid arthritis treated according to the 2015 ACR guideline (LELAND): protocol for a multicentre prospective observational study in Southern China. <i>BMJ Open</i> , 2018, 8, e023798.	0.8	0
415	Salvianolic Acid B Suppresses Inflammatory Mediator Levels by Downregulating NF-Î®B in a Rat Model of Rheumatoid Arthritis. <i>Medical Science Monitor</i> , 2018, 24, 2524-2532.	0.5	38
416	Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 211.	1.0	30
417	The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies. <i>Arthritis Research and Therapy</i> , 2018, 20, 256.	1.6	10
418	Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3799-3805.	2.0	13
419	Non-Hepatic Alkaline Phosphatase, hs-CRP and Progression of Vertebral Fracture in Patients with Rheumatoid Arthritis: A Population-Based Longitudinal Study. <i>Journal of Clinical Medicine</i> , 2018, 7, 439.	1.0	18
420	Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 57-70.	2.0	99
421	Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 1-9.	0.8	1
422	Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations. <i>Archives of Rheumatology</i> , 2018, 33, 251-272.	0.3	3
423	Prediction of treatment response in rheumatoid arthritis patients using genomeâ€“wide SNP data. <i>Genetic Epidemiology</i> , 2018, 42, 754-771.	0.6	15

#	ARTICLE	IF	CITATIONS
424	Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome. <i>RMD Open</i> , 2018, 4, e000739.	1.8	5
425	Abatacept in combination with methotrexate in Japanese biologic-naïve patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. <i>RMD Open</i> , 2018, 4, e000813.	1.8	11
426	The Clinical Value of Autoantibodies in Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 339.	1.2	64
427	Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients. <i>PLoS ONE</i> , 2018, 13, e0208240.	1.1	23
428	Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0208534.	1.1	40
429	Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 805-819.	0.7	3
430	Neutrophil Function in an Inflammatory Milieu of Rheumatoid Arthritis. <i>Journal of Immunology Research</i> , 2018, 2018, 1-12.	0.9	53
431	Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2097-2111.	0.9	4
432	Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?. <i>Rheumatology</i> , 2018, 57, vii1-vii4.	0.9	1
433	Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2018, 5, 507-523.	1.1	11
434	Tumor Necrosis Factor Inhibitor Therapy and The Risk of Developing Depression Among Working-Age Adults with Rheumatoid Arthritis. <i>Value in Health</i> , 2018, 21, S192.	0.1	3
435	Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs—a single-center analysis of 2054 patients. <i>Clinical Rheumatology</i> , 2018, 37, 2963-2970.	1.0	23
436	Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. <i>Reumatologia</i> , 2018, 56, 203-211.	0.5	21
437	Mesenchymal Stem Cell Engineering. <i>Methods in Molecular Biology</i> , 2018, 1868, 145-150.	0.4	3
438	A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement and selection of attributes and levels. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1537-1555.	0.8	11
439	What Is Most Important in Rheumatoid Arthritis Treatment “Where You Are, Who You Are, or Where You Are Going?”. <i>Journal of Rheumatology</i> , 2018, 45, 1341-1343.	1.0	1
440	Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism. <i>Journal of Medical Investigation</i> , 2018, 65, 166-170.	0.2	12
441	Clinical and radiologic analysis of on-demand use of etanercept for disease flares in patients with rheumatoid arthritis for 2 years. <i>Medicine (United States)</i> , 2018, 97, e12462.	0.4	4

#	ARTICLE	IF	CITATIONS
442	Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data. <i>Rheumatology International</i> , 2018, 38, 2111-2120.	1.5	23
443	Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids. <i>Rheumatology and Therapy</i> , 2018, 5, 525-536.	1.1	10
444	Poor Dietary Quality Is Associated with Increased Inflammation in Swedish Patients with Rheumatoid Arthritis. <i>Nutrients</i> , 2018, 10, 1535.	1.7	29
445	Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: Results from a nationwide Korean College of Rheumatology BIOlogics (KOBIO) registry. <i>PLoS ONE</i> , 2018, 13, e0205651.	1.1	13
446	Cationic nanoparticle as an inhibitor of cell-free DNA-induced inflammation. <i>Nature Communications</i> , 2018, 9, 4291.	5.8	129
447	Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2007-2014.	0.8	5
448	Intensive therapy and remissions in rheumatoid arthritis: a systematic review. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 389.	0.8	25
449	The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases. <i>Patient</i> , 2018, 11, 515-526.	1.1	5
450	Optimization of fermentation conditions for an <i>Escherichia coli</i> strain engineered using the response surface method to produce a novel therapeutic DNA vaccine for rheumatoid arthritis. <i>Journal of Biological Engineering</i> , 2018, 12, 22.	2.0	13
451	Serum P-glycoprotein level: a potential biomarker of DMARD failure in patients with rheumatoid arthritis. <i>Inflammopharmacology</i> , 2018, 26, 1375-1381.	1.9	9
452	Co-Delivery of Teriflunomide and Methotrexate from Hydroxyapatite Nanoparticles for the Treatment of Rheumatoid Arthritis: In Vitro Characterization, Pharmacodynamic and Biochemical Investigations. <i>Pharmaceutical Research</i> , 2018, 35, 201.	1.7	20
453	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1705-1709.	0.5	83
455	Sarilumab: patient-reported outcomes in rheumatoid arthritis. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 275-284.	0.7	14
456	A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy. <i>Current Rheumatology Reports</i> , 2018, 20, 64.	2.1	6
457	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 349-358.	0.8	19
458	Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis. <i>Medicine (United States)</i> , 2018, 97, e11609.	0.4	3
459	Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. <i>PLoS ONE</i> , 2018, 13, e0203084.	1.1	43
460	Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review. <i>Case Reports in Rheumatology</i> , 2018, 2018, 1-5.	0.2	8

#	ARTICLE	IF	CITATIONS
461	FKBP51 modulates steroid sensitivity and NF κ B signalling: A novel anti-inflammatory drug target. <i>European Journal of Immunology</i> , 2018, 48, 1904-1914.	1.6	42
463	A novel fusion protein attenuates collagen-induced arthritis by targeting interleukin 17A and tumor necrosis factor α . <i>International Journal of Pharmaceutics</i> , 2018, 547, 72-82.	2.6	12
464	Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky005.	0.3	33
465	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. <i>Rheumatology and Therapy</i> , 2018, 5, 341-353.	1.1	9
466	Liver enzyme abnormalities of inpatients with rheumatic diseases: a 10-year retrospective study in a Korean medical hospital. <i>Phytotherapy Research</i> , 2018, 32, 1784-1794.	2.8	2
467	Hyaluronic acid-conjugated pH-sensitive liposomes for targeted delivery of prednisolone on rheumatoid arthritis therapy. <i>Nanomedicine</i> , 2018, 13, 1037-1049.	1.7	40
468	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2018, 18, 528-538.	0.9	42
469	Reducing Missed Opportunities for Influenza Vaccination in Patients with Rheumatoid Arthritis: Evaluation of a Multisystem Intervention. <i>Journal of Rheumatology</i> , 2018, 45, 1220-1228.	1.0	6
470	Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2173-2182.	0.9	83
471	Admitting What We Do Not Know in Rheumatologic Disease—The First Step Toward Learning More—Reply. <i>JAMA Internal Medicine</i> , 2018, 178, 724.	2.6	0
472	Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic Diseases. <i>International Journal of Rheumatology</i> , 2018, 2018, 1-12.	0.9	2
473	Methotrexate-associated lymphoproliferative disorder complicated by severe acute respiratory failure and ileal perforation: a case report. <i>Fukushima Journal of Medical Sciences</i> , 2018, 64, 82-88.	0.1	6
474	Drugs Used in Rheumatic Disease. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, 15, 39-76.	0.1	2
475	The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia. <i>Rheumatology International</i> , 2018, 38, 1911-1918.	1.5	23
476	Biosimilars Have Arrived: Rituximab. <i>Arthritis</i> , 2018, 2018, 1-6.	2.0	30
477	Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs. <i>Rheumatology International</i> , 2018, 38, 1465-1470.	1.5	7
478	Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. <i>Rheumatology and Therapy</i> , 2018, 5, 383-401.	1.1	11
480	Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000602.	1.8	13

#	ARTICLE	IF	CITATIONS
481	Individual Drugs in Rheumatology and the Risk of Infection. , 2018, , 445-464.		0
482	Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients. Rheumatic Disease Clinics of North America, 2018, 44, 371-391.	0.8	12
483	Nephritis, cerebritis, and myositis after adalimumab therapy in a patient with rheumatoid arthritis: a case report. International Journal of General Medicine, 2018, Volume 11, 151-154.	0.8	3
484	Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Annals of the Rheumatic Diseases, 2018, 77, 1566-1572.	0.5	23
485	Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 344-352.	0.5	20
486	Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. Clinical Rheumatology, 2018, 37, 2381-2390.	1.0	26
487	The Effectiveness and Safety of Tripterygium wilfordii Hook. F Extracts in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2018, 9, 356.	1.6	46
488	New strategies for patenting biological medicines used in rheumatoid arthritis treatment. Expert Opinion on Therapeutic Patents, 2018, 28, 635-646.	2.4	16
489	Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology, 2018, 57, 2022-2031.	0.9	19
490	Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Design, Development and Therapy, 2018, Volume 12, 1685-1695.	2.0	80
491	The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients. Drugs in R and D, 2018, 18, 211-219.	1.1	4
492	14-3-3 β protein: a promising biomarker for rheumatoid arthritis. Biomarkers in Medicine, 2018, 12, 917-925.	0.6	20
493	Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. Current Therapeutic Research, 2018, 89, 1-6.	0.5	19
494	Methotrexate Baffles anti-drug antibodies. Nature Reviews Rheumatology, 2018, 14, 505-506.	3.5	7
495	A Rapidly Fatal Case of Low-Dose Methotrexate Toxicity. Case Reports in Medicine, 2018, 2018, 1-4.	0.3	22
496	The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil. Advances in Rheumatology, 2018, 58, 9.	0.8	22
497	Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate. Open Access Rheumatology: Research and Reviews, 2018, Volume 10, 97-101.	0.8	3
498	Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment. Frontiers in Immunology, 2018, 9, 621.	2.2	21

#	ARTICLE	IF	CITATIONS
499	Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. <i>Clinical Rheumatology</i> , 2018, 37, 2611-2620.	1.0	33
500	Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. <i>MAbs</i> , 2018, 10, 934-943.	2.6	43
501	Increased Risk of Herpes Zoster Infection in Patients With Inflammatory Bowel Diseases in Korea. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1928-1936.e2.	2.4	49
502	Comorbidities in Patients With Rheumatic Disease. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, , 15-37.	0.1	0
503	The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States. <i>Journal of Medical Economics</i> , 2018, 21, 1057-1066.	1.0	0
504	An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1010-1017.	0.5	14
505	Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. <i>Arthritis Research and Therapy</i> , 2018, 20, 1.	1.6	53
506	Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug. <i>Arthritis Research and Therapy</i> , 2018, 20, 39.	1.6	26
507	Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis. <i>Journal of Translational Medicine</i> , 2018, 16, 18.	1.8	33
508	Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 67.	0.7	32
509	Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 8.	1.6	29
510	One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. <i>Arthritis Research and Therapy</i> , 2018, 20, 2.	1.6	21
511	Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?. <i>Arthritis Research and Therapy</i> , 2018, 20, 15.	1.6	8
512	Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 60.	1.6	46
513	Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2018, 38, 7.	1.5	17
514	Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair. <i>Inflammation and Regeneration</i> , 2018, 38, 4.	1.5	32
515	Discovery of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDsâ€™CAIs) for the Management of Rheumatoid Arthritis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4961-4977.	2.9	53
516	An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity. <i>Arthritis and Rheumatology</i> , 2018, 70, 1557-1564.	2.9	17

#	ARTICLE	IF	CITATIONS
517	Practical Pearls About Current Rheumatic Medications. Primary Care - Clinics in Office Practice, 2018, 45, 193-212.	0.7	0
518	A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States. Rheumatology and Therapy, 2018, 5, 255-270.	1.1	13
519	Early Diagnosis and Treatment of Rheumatoid Arthritis. Primary Care - Clinics in Office Practice, 2018, 45, 237-255.	0.7	190
520	EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212662.	0.5	173
521	Geographic variation in incidence and prevalence rates for rheumatoid arthritis in Saskatchewan, Canada 2001-2014. Canadian Journal of Public Health, 2018, 109, 427-435.	1.1	8
522	Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology International, 2018, 38, 1363-1383.	1.5	41
523	Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology, 2018, 57, 1423-1431.	0.9	31
524	The relationship between bristol rheumatoid arthritis fatigue scales and disease activity of patients with rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 2927-2932.	1.0	2
525	Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adoption of the 2015 American College of Rheumatology guidelines. Clinical Rheumatology, 2018, 37, 2947-2959.	1.0	13
526	Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. Journal of Translational Medicine, 2018, 16, 156.	1.8	6
527	Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs. Drugs - Real World Outcomes, 2018, 5, 169-179.	0.7	18
528	Era of steroid sparing in the management of immune-mediated inflammatory diseases. Immunological Medicine, 2018, 41, 6-11.	1.4	13
529	The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. Drug Design, Development and Therapy, 2018, Volume 12, 1421-1429.	2.0	13
530	Dr. Johnson and Dr. BahÅse-AltuntaÅ reply. Journal of Rheumatology, 2018, 45, 876.2-876.	1.0	0
531	Naturalistic Decision Making and the Practice of Health Care. Journal of Cognitive Engineering and Decision Making, 2018, 12, 178-193.	0.9	12
532	Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?. Frontiers in Medicine, 2018, 5, 140.	1.2	7
533	Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 816-825.	2.9	83
534	A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNF± monoclonal antibody with biosimilar potential. Immunologic Research, 2018, 66, 392-405.	1.3	4

#	ARTICLE	IF	CITATIONS
535	Epitope-based ligation of ICAM-1: Therapeutic target for protection against the development of rheumatoid arthritis. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 450-455.	1.0	3
536	Physcion 8- β -glucopyranoside extracted from <i>Polygonum 1/2cuspidatum</i> exhibits anti-proliferative and anti-inflammatory effects on MH7A rheumatoid arthritis-derived fibroblast-like synoviocytes through the TGF β /MAPK pathway. <i>International Journal of Molecular Medicine</i> , 2018, 42, 745-754.	1.8	25
537	Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS). <i>BioDrugs</i> , 2018, 32, 377-390.	2.2	10
538	Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis. <i>Drugs</i> , 2018, 78, 929-940.	4.9	66
539	Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population. <i>Rheumatology and Therapy</i> , 2018, 5, 355-369.	1.1	27
540	Clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1246-1253.	0.9	20
541	Obesity and response to anti-tumor necrosis factor- α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0195123.	1.1	196
542	Feasibility of Measurement and Adherence to System Performance Measures for Rheumatoid Arthritis in 5 Models of Care. <i>Journal of Rheumatology</i> , 2018, 45, 1501-1508.	1.0	15
543	Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2018, 391, 2503-2512.	6.3	280
544	Assessing the possible association of anti-TNF use with new malignancies: A neglected methodological consideration. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 894-901.	0.9	1
545	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 391, 2513-2524.	6.3	316
546	Vaccination with a Novel Antigen-Specific Tolerizing DNA Vaccine Encoding <i>CCOL2A1</i> Protects Rats from Experimental Rheumatoid Arthritis. <i>Human Gene Therapy</i> , 2019, 30, 69-78.	1.4	7
547	Pragmaticism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2019, 71, 620-628.	1.5	12
548	Efficacy and safety of biological agents in the older rheumatoid arthritis patients compared to Young: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 799-807.	1.6	16
549	Comparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 163-170.	0.5	7
550	Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment. <i>Arthritis Care and Research</i> , 2019, 71, 512-520.	1.5	9
551	Inflammatory arthritis in systemic sclerosis: What to do?. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 3-16.	1.0	6
552	Preference Phenotypes in Support of Shared Decision-Making at Point-of-Care for Patients With Rheumatoid Arthritis: A Proof-of-Concept Study. <i>Arthritis Care and Research</i> , 2019, 71, 629-637.	1.5	12

#	ARTICLE	IF	CITATIONS
553	Contraception Use Among Reproductive-Age Women With Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2019, 71, 1132-1140.	1.5	22
554	Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan: Results of long-term postmarketing surveillance. <i>Modern Rheumatology</i> , 2019, 29, 737-746.	0.9	5
555	The price of good health care. <i>Rheumatology</i> , 2019, 58, 931-932.	0.9	1
556	Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. <i>Archives of Medical Science</i> , 2019, 15, 134-140.	0.4	30
557	Role and translational implication of galectins in arthritis pathophysiology and treatment: A systematic literature review. <i>Journal of Cellular Physiology</i> , 2019, 234, 1588-1605.	2.0	12
558	Effects of Language, Insurance, and Race/Ethnicity on Measurement Properties of the PROMIS Physical Function Short Form 10a in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 925-935.	1.5	9
559	Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 1-8.	0.6	19
560	Management of inflammatory rheumatic conditions in the elderly. <i>Rheumatology</i> , 2019, 58, 748-764.	0.9	24
561	Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6. <i>Arthritis Care and Research</i> , 2019, 71, 71-79.	1.5	5
562	Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1237.	1.0	19
563	Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis. <i>Journal of General Internal Medicine</i> , 2019, 34, 2232-2245.	1.3	17
564	Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. <i>Rheumatology and Therapy</i> , 2019, 6, 461-471.	1.1	52
565	Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). <i>Drugs</i> , 2019, 79, 1511-1528.	4.9	35
566	The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. <i>Pharmacological Research</i> , 2019, 147, 104392.	3.1	62
567	Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study. <i>Clinical Rheumatology</i> , 2019, 38, 3391-3400.	1.0	16
568	Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. <i>Rheumatology and Therapy</i> , 2019, 6, 503-520.	1.1	12
569	Increased Nonexudative Age-Related Macular Degeneration Diagnosis Among Medicare Beneficiaries With Rheumatoid Arthritis. , 2019, 60, 3520.		13
570	Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2019, 36, 2287-2295.	1.3	9

#	ARTICLE	IF	CITATIONS
571	Practice Patterns of Pneumocystis Pneumonia Prophylaxis in Connective Tissue Diseases: A Survey of Infectious Disease Physicians. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz315.	0.4	7
572	Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial). <i>BMJ Open</i> , 2019, 9, e028517.	0.8	19
573	Endogenous stimulation is responsible for the high frequency of IL-17A-producing neutrophils in patients with rheumatoid arthritis. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 44.	0.9	6
574	Benefits and Safety of Tripterygium Glycosides and Total Glucosides of Paeony for Rheumatoid Arthritis: An Overview of Systematic Reviews. <i>Chinese Journal of Integrative Medicine</i> , 2019, 25, 696-703.	0.7	20
575	Evidence to support or guide glucocorticoid tapering in rheumatoid arthritis is lacking. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1733-1734.	0.5	9
576	Efficacy of leflunomide combined with ligustrazine in the treatment of rheumatoid arthritis: prediction with network pharmacology and validation in a clinical trial. <i>Chinese Medicine</i> , 2019, 14, 26.	1.6	15
577	Effectiveness and safety of physician-pharmacist collaborative care for rheumatoid arthritis patients: The Changi General Hospital's experience. <i>Proceedings of Singapore Healthcare</i> , 2019, 28, 184-192.	0.2	2
578	Health-related quality of life in patients with rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 34.	0.6	47
579	Tumour necrosis factor inhibitor exposure and radiographic outcomes in Veterans with rheumatoid arthritis: a longitudinal cohort study. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz015.	0.3	1
580	CMV Ileitis: To Treat or Not to Treat? Implications of Initiating Biologic Therapy for Concurrent Crohn's Disease. <i>Case Reports in Gastrointestinal Medicine</i> , 2019, 2019, 1-4.	0.2	1
581	The prevalence and types of discordance between physician perception and objective data from standardized measures of rheumatoid arthritis disease activity in real-world clinical practice in the US. <i>BMC Rheumatology</i> , 2019, 3, 25.	0.6	3
582	Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2019, 39, 1483-1497.	1.5	9
583	Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. <i>American Journal of Medicine</i> , 2019, 132, e771-e777.	0.6	15
584	Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2019, 59, 72-92.	0.3	61
585	Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 309.	3.8	11
586	Arthritis in Two Patients With Partial Recombination Activating Gene Deficiency. <i>Frontiers in Pediatrics</i> , 2019, 7, 235.	0.9	11
587	Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 879-887.	0.5	6
588	The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease) Tj ETQq1 1 0.784314 rgBJ /Overlo	1.0	5

#	ARTICLE	IF	CITATIONS
589	Radiological Signs of Latent Tuberculosis on Chest Radiography: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.4	19
590	Prevalence of methotrexate intolerance among patients with rheumatoid arthritis using the Arabic version of the methotrexate intolerance severity score. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1572-1577.	0.9	5
591	Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada. <i>Rheumatology International</i> , 2019, 39, 1621-1630.	1.5	5
592	Sarcoidosis. <i>Nature Reviews Disease Primers</i> , 2019, 5, 45.	18.1	274
593	Optimising low-dose methotrexate for rheumatoid arthritis—A review. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2228-2234.	1.1	36
594	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 164.	1.6	24
595	Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2019, 6, 611-616.	1.1	11
596	Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). <i>Rheumatology and Therapy</i> , 2019, 6, 559-571.	1.1	15
597	A Lipid Micellar System Loaded with Dexamethasone Palmitate Alleviates Rheumatoid Arthritis. <i>AAPS PharmSciTech</i> , 2019, 20, 316.	1.5	11
598	Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1454-1462.	0.5	115
599	Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease. <i>ACR Open Rheumatology</i> , 2019, 1, 542-545.	0.9	4
600	Real-World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 560-570.	0.9	11
601	Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity. <i>ESC Heart Failure</i> , 2019, 6, 1326-1330.	1.4	7
602	Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy. <i>Reumatologia</i> , 2019, 57, 214-220.	0.5	3
603	Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2019, 6, 573-586.	1.1	29
604	An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance. <i>Frontiers in Endocrinology</i> , 2019, 10, 729.	1.5	17
605	Early Lyme Borreliosis in Patients Treated with Tumour Necrosis Factor-Alpha Inhibitors. <i>Journal of Clinical Medicine</i> , 2019, 8, 1857.	1.0	9
606	Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions. <i>Rheumatology and Therapy</i> , 2019, 6, 473-477.	1.1	2

#	ARTICLE	IF	CITATIONS
607	Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1313-1322.	1.3	10
608	The multifaceted impact of anxiety and depression on patients with rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 43.	0.6	25
609	Quality of life in Ecuadorian patients with rheumatoid arthritis: A cross-sectional study. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 296-300.	0.2	1
610	Burden of rheumatoid arthritis on patients'™ work productivity and quality of life. <i>Advances in Rheumatology</i> , 2019, 59, 47.	0.8	43
611	2019 American College of Rheumatology Recommended Patient-Reported Functional Status Assessment Measures in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 1531-1539.	1.5	39
612	2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. <i>Arthritis Care and Research</i> , 2019, 71, 1540-1555.	1.5	157
613	The "Treat to Target" Approach to Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 487-504.	0.8	17
614	Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. <i>ACR Open Rheumatology</i> , 2019, 1, 471-479.	0.9	5
615	Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 214.	1.6	17
616	Can we wean patients with inflammatory arthritis from biological therapies?. <i>Autoimmunity Reviews</i> , 2019, 18, 102399.	2.5	5
617	A systematic review of guidelines for managing rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 42.	0.6	50
618	Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor. <i>Arthritis Research and Therapy</i> , 2019, 21, 216.	1.6	20
619	Remicade® (infliximab): 20 years of contributions to science and medicine. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 139-178.	3.0	78
620	Prevalence of complementary and alternative medicine use among rheumatoid arthritis patients in Saudi Arabia. <i>Saudi Pharmaceutical Journal</i> , 2019, 27, 939-944.	1.2	11
621	Top 100 cited articles on rheumatoid arthritis. <i>Medicine (United States)</i> , 2019, 98, e14523.	0.4	35
622	Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. <i>Drugs</i> , 2019, 79, 1741-1755.	4.9	39
623	Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0221823.	1.1	22
624	Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient with Metastatic Gastric Adenocarcinoma. <i>Clinical Drug Investigation</i> , 2019, 39, 1251-1254.	1.1	3

#	ARTICLE	IF	CITATIONS
625	Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. <i>Lancet Rheumatology</i> , The, 2019, 1, e23-e34.	2.2	25
626	Dynamic profiles, biodistribution and integration evaluation after intramuscular/intravenous delivery of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in vaccinated normal rodent. <i>Journal of Nanobiotechnology</i> , 2019, 17, 94.	4.2	12
627	Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. <i>Journal of Clinical Medicine</i> , 2019, 8, 1394.	1.0	35
628	Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritis. <i>EBioMedicine</i> , 2019, 47, 563-577.	2.7	32
629	Anti-arthritis effect of Î²-caryophyllene and its ameliorative role on methotrexate and/or leflunomide-induced side effects in arthritic rats. <i>Life Sciences</i> , 2019, 233, 116750.	2.0	31
630	Linkage of Periodontitis and Rheumatoid Arthritis: Current Evidence and Potential Biological Interactions. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4541.	1.8	115
631	Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?. <i>BMC Rheumatology</i> , 2019, 3, 36.	0.6	7
632	Rheumatologists's awareness of hepatitis B reactivation before immunosuppressive therapy. <i>Rheumatology International</i> , 2019, 39, 2077-2085.	1.5	5
633	Regulation of CP-25 on P-glycoprotein in synoviocytes of rats with adjuvant arthritis. <i>Biomedicine and Pharmacotherapy</i> , 2019, 119, 109432.	2.5	14
634	Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries. <i>Rheumatology and Therapy</i> , 2019, 6, 529-542.	1.1	23
635	Synthesis and Biological Activities of Chemical Drugs for the Treatment of Rheumatoid Arthritis. <i>Topics in Current Chemistry</i> , 2019, 377, 28.	3.0	24
636	<p>Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1073-1079.	0.9	14
637	Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. <i>Journal of Clinical Medicine</i> , 2019, 8, 1548.	1.0	36
638	Vaccination status of patients using anti-TNF therapy and the physicians's behavior shaping the phenomenon: Mixed-methods approach. <i>PLoS ONE</i> , 2019, 14, e0223594.	1.1	8
639	Costimulatory pathway targets for autoimmune and inflammatory conditions: clinical successes, failures, and hope for the future. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 99-106.	1.9	6
640	Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 99-110.	0.7	0
641	Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2019, 45, 348-357.	0.4	4
642	Treat-to-target in rheumatoid arthritis " are we there yet?. <i>Nature Reviews Rheumatology</i> , 2019, 15, 180-186.	3.5	86

#	ARTICLE	IF	CITATIONS
643	Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management. <i>Postgraduate Medicine</i> , 2019, 131, 185-198.	0.9	127
644	Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. <i>Rheumatology</i> , 2019, 58, 1367-1377.	0.9	22
645	Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. <i>PLoS ONE</i> , 2019, 14, e0210459.	1.1	31
646	Overuse of glucocorticoids in rheumatoid arthritis: a national survey of primary care physicians. <i>Rheumatology Advances in Practice</i> , 2019, 3, rky049.	0.3	0
647	Update upon the infection risk in patients receiving TNF alpha inhibitors. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 219-229.	1.0	37
648	Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D. <i>Health Affairs</i> , 2019, 38, 303-312.	2.5	18
649	The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients. <i>Journal of Medical Economics</i> , 2019, 22, 350-358.	1.0	6
650	Impact of Cumulative Corticosteroid Dosage on Preventable Hospitalization among Taiwanese Patients with Ankylosing Spondylitis and Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 614.	1.0	3
651	<p>Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy</p>. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 179-191.	1.0	15
652	Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2019, 41, 1080-1089.e5.	1.1	8
653	“Living a normal life” a qualitative study of patients’™ views of medication withdrawal in rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 2.	0.6	13
654	Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice. <i>Rheumatology and Therapy</i> , 2019, 6, 421-433.	1.1	1
655	Upregulation of sphingosine-1-phosphate receptor 3 on fibroblast-like synoviocytes is associated with the development of collagen-induced arthritis via increased interleukin-6 production. <i>PLoS ONE</i> , 2019, 14, e0218090.	1.1	19
656	Development and validation of a methotrexate adherence assay. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1192-1197.	0.5	13
657	Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. <i>RMD Open</i> , 2019, 5, e000898.	1.8	14
658	Pulmonary Complications of Rheumatoid Arthritis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 194-207.	0.8	29
659	A tool for empirical equipoise assessment in multigroup comparative effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 934-941.	0.9	6
660	Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naïve or tumor necrosis factor inhibitor inadequate responders. <i>Clinical Rheumatology</i> , 2019, 38, 2747-2756.	1.0	4

#	ARTICLE	IF	CITATIONS
661	Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015. <i>Drug Safety</i> , 2019, 42, 1091-1102.	1.4	1
662	Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. <i>Rheumatology</i> , 2019, 58, 2193-2202.	0.9	34
663	Preventing Rheumatoid Arthritis: A Global Challenge. <i>Clinical Therapeutics</i> , 2019, 41, 1355-1365.	1.1	10
664	Rheumatoid Arthritis: A Severe Disease That Preventive Approaches Would Greatly Benefit. <i>Clinical Therapeutics</i> , 2019, 41, 1240-1245.	1.1	13
665	Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs. <i>Rheumatology and Therapy</i> , 2019, 6, 339-352.	1.1	21
666	Headache and vision changes in an elderly man with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1331-1334.	0.9	0
667	Management of Fibrosing Interstitial Lung Diseases. <i>Advances in Therapy</i> , 2019, 36, 1518-1531.	1.3	27
668	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <i>Lancet, The</i> , 2019, 393, 2303-2311.	6.3	237
669	Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 415-425.	1.0	33
670	Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis. <i>Clinical Rheumatology</i> , 2019, 38, 2451-2459.	1.0	8
671	Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial. <i>Clinical Rheumatology</i> , 2019, 38, 2461-2471.	1.0	7
672	Deciphering the pharmacological mechanism of Guan-Jie-Kang in treating rat adjuvant-induced arthritis using omics analysis. <i>Frontiers of Medicine</i> , 2019, 13, 564-574.	1.5	6
673	Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 770-779.	0.5	28
674	Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. <i>Rheumatology</i> , 2019, 58, 1509-1510.	0.9	0
675	Centre effects and case-mix in early rheumatoid arthritis observational cohorts: a narrative review. <i>Rheumatology</i> , 2019, 58, 1991-1999.	0.9	1
676	Abatacept induced granulomatous hepatitis with a sarcoidosis-like reaction: a blinded trial in mice. <i>BMC Pharmacology & Toxicology</i> , 2019, 20, 26.	1.0	2
677	Two cases of severe neutropenia in patients on low-dose methotrexate and ceftriaxone. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 804-809.	0.5	3
678	Pain Relieving Effect of-NSAIDs-CAIs Hybrid Molecules: Systemic and Intra-Articular Treatments against Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1923.	1.8	25

#	ARTICLE	IF	CITATIONS
679	How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?â€”MTX in the Treat-to-Target Strategy. <i>Journal of Clinical Medicine</i> , 2019, 8, 515.	1.0	54
680	Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1226-1232.	0.9	24
681	Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review. <i>Current Rheumatology Reports</i> , 2019, 21, 24.	2.1	7
682	Early clinical response and long-term radiographic progression in recent-onset rheumatoid arthritis: Clinical remission within six months remains the treatment target. <i>Joint Bone Spine</i> , 2019, 86, 594-599.	0.8	6
683	Potential role of MRN-100, an iron-based compound, in upregulating production of cytokine IL-10 in human dendritic cells to promote an anti-inflammatory response in vitro. <i>International Journal of Immunopathology and Pharmacology</i> , 2019, 33, 205873841984493.	1.0	3
684	Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. <i>Advances in Therapy</i> , 2019, 36, 1337-1357.	1.3	11
685	Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. <i>Arthritis Research and Therapy</i> , 2019, 21, 102.	1.6	43
686	Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 2501-2508.	1.0	2
687	Latent tuberculosis infection in patients with rheumatic diseases. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20190023.	0.4	24
688	R�ponse clinique pr�coce et progression radiographique � long terme dans la polyarthrite rhumato�de d�butante: la r�mission clinique � 6 mois reste l'objectif � atteindre. <i>Revue Du Rhumatisme</i> , (Edition Francaise), 2019, 86, 367-372.		0
689	Methotrexate in Our Hearts. <i>Journal of Rheumatology</i> , 2019, 46, 447-449.	1.0	1
690	The superb microvascular imaging is more sensitive than conventional power Doppler imaging in detection of active synovitis in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 2613-2620.	1.0	21
691	Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 73.	1.0	3
692	Low-dose methotrexate toxicity. <i>Cmaj</i> , 2019, 191, E423-E423.	0.9	19
694	Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. <i>Clinical Rheumatology</i> , 2019, 38, 2411-2421.	1.0	4
695	Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritis. <i>BMC Rheumatology</i> , 2019, 3, 6.	0.6	24
696	An Anti-hTNF-� Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira� in a Transgenic Mouse Autoimmune Polyarthritis Disease Model. <i>Frontiers in Immunology</i> , 2019, 10, 526.	2.2	20
697	The impact of physical activity on serum levels of inflammatory markers in rheumatoid arthritis: a systematic literature review. <i>Rheumatology International</i> , 2019, 39, 793-804.	1.5	18

#	ARTICLE	IF	CITATIONS
698	Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1094-1106.	0.9	12
699	Useful message in choosing optimal biological agents for patients with autoimmune arthritis. <i>Biochemical Pharmacology</i> , 2019, 165, 99-111.	2.0	9
700	Rheumatology practice in Japan: challenges and opportunities. <i>Rheumatology International</i> , 2019, 39, 1499-1505.	1.5	2
701	Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Patients With Rheumatoid Arthritis in Clinical Remission. <i>Arthritis and Rheumatology</i> , 2019, 71, 1034-1041.	2.9	19
702	Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. <i>RMD Open</i> , 2019, 5, e000742.	1.8	28
703	Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort. <i>PLoS ONE</i> , 2019, 14, e0213219.	1.1	6
704	Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 281.	1.0	3
705	Use of systemic glucocorticoids in patients with psoriatic arthritis by Argentinian and other Latin-American rheumatologists. <i>Rheumatology International</i> , 2019, 39, 723-727.	1.5	8
706	Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 222-228.	1.6	42
707	Clinical profile of the functionally selective glucocorticoid receptor agonist BI 653048 in healthy male subjects. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 489-496.	1.9	3
709	Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis. <i>Annals of Pharmacotherapy</i> , 2019, 53, 947-953.	0.9	98
710	Antinociceptive and anti-arthritic effects of aqueous whole plant extract of <i>Trianthema portulacastrum</i> in rodents: Possible mechanisms of action. <i>Journal of Ethnopharmacology</i> , 2019, 238, 111831.	2.0	10
711	<p>New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 275-284.	0.9	15
712	Cardiac and vascular complications in rheumatoid arthritis. <i>Reumatologia</i> , 2019, 57, 27-36.	0.5	43
713	MicroRNA-19a promotes rheumatoid arthritis fibroblast-like synoviocytes via targeting SOCS3. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 11624-11632.	1.2	13
714	Digital Interventions to Build a Patient Registry for Rheumatology Research. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 173-186.	0.8	33
715	The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity. <i>PLoS ONE</i> , 2019, 14, e0214717.	1.1	2
716	Adenosine and the Cardiovascular System. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 449-464.	1.0	67

#	ARTICLE	IF	CITATIONS
717	Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial. <i>Rheumatology and Therapy</i> , 2019, 6, 245-254.	1.1	11
718	Medication adherence and cost-related medication non-adherence in patients with rheumatoid arthritis: A cross-sectional study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 555-566.	0.9	13
719	Therapy with Biologic Agents After Diagnosis of Solid Malignancies: Results from the Corrona Registry. <i>Journal of Rheumatology</i> , 2019, 46, 1438-1444.	1.0	11
720	Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1472-1482.	2.9	129
721	Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 746-753.	0.5	42
722	Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?. <i>Drugs and Aging</i> , 2019, 36, 493-510.	1.3	16
723	<p>Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 117-128.	0.7	7
724	Towards personalized treatment in atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 469-476.	1.4	12
725	Structural Changes over a Short Period Are Associated with Functional Assessments in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 676-684.	1.0	12
726	A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2019, 37, 829-843.	1.7	16
727	Elevated serum IL-35 levels in rheumatoid arthritis are associated with disease activity. <i>Journal of Investigative Medicine</i> , 2019, 67, 707-710.	0.7	22
728	Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time. <i>RMD Open</i> , 2019, 5, e000836.	1.8	5
729	MR and ultrasound of the hands and wrists in rheumatoid arthritis. Part II. Added clinical value. <i>Skeletal Radiology</i> , 2019, 48, 837-857.	1.2	12
730	Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, i17-i26.	0.9	130
731	Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. <i>Arthritis Care and Research</i> , 2019, 71, 1317-1325.	1.5	41
732	The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22862.	0.9	9
733	Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor I± inhibitors: systematic literature review and network meta-analyses. <i>RMD Open</i> , 2019, 5, e000798.	1.8	14
734	Current advances in the treatment of giant cell arteritis: the role of biologics. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1982722.	1.2	9

#	ARTICLE	IF	CITATIONS
735	Risk profiling for a refractory course of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 211-217.	1.6	62
736	Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. <i>RMD Open</i> , 2019, 5, e001017.	1.8	9
737	A systematic review of the factors associated with the initiation of biologicals in patients with rheumatological conditions. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 163-169.	0.5	4
738	Mania induced by isoniazid preventive therapy during steroid treatment for rheumatoid arthritis and organising pneumonia. <i>BMJ Case Reports</i> , 2019, 12, e231919.	0.2	3
739	Body Mass Index and Clinical Response to Tocilizumab in Patients With Rheumatoid Arthritis. <i>Archives of Rheumatology</i> , 2019, 34, 406-413.	0.3	3
740	Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF- α Transgenic Mice. <i>Mediators of Inflammation</i> , 2019, 2019, 1-12.	1.4	2
741	Marine oil supplements for rheumatoid arthritis. <i>The Cochrane Library</i> , 2019, , .	1.5	0
742	Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice. <i>RMD Open</i> , 2019, 5, e001050.	1.8	14
743	Extraction of Rheumatoid Arthritis Disease Activity Measures From Electronic Health Records Using Automated Processing Algorithms. <i>ACR Open Rheumatology</i> , 2019, 1, 632-639.	0.9	1
744	Tuberculosis and Biologic Therapies. <i>Clinics in Chest Medicine</i> , 2019, 40, 721-739.	0.8	49
745	How thorough clinical observational studies on rheumatoid arthritis can have an impact on the field. <i>Arthritis Research and Therapy</i> , 2019, 21, 227.	1.6	0
746	Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. <i>The Cochrane Library</i> , 2019, 2019, CD010455.	1.5	33
747	A pilot study of peripheral blood DNA methylation models as predictors of knee osteoarthritis radiographic progression: data from the Osteoarthritis Initiative (OAI). <i>Scientific Reports</i> , 2019, 9, 16880.	1.6	12
748	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. <i>RMD Open</i> , 2019, 5, e001040.	1.8	28
749	Inferring disease severity in rheumatoid arthritis using predictive modeling in administrative claims databases. <i>PLoS ONE</i> , 2019, 14, e0226255.	1.1	16
750	Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov-Smirnov Algorithm. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 369-375.	0.4	3
751	Evaluating the therapeutic efficacy of the Chinese herbal medicine Yishen Tongbi decoction in patients with active rheumatoid arthritis: protocol for a randomized, controlled, noninferiority trial. <i>Trials</i> , 2019, 20, 801.	0.7	0
752	Treatment of Latent Tuberculosis Infection—An Update. <i>Clinics in Chest Medicine</i> , 2019, 40, 839-848.	0.8	30

#	ARTICLE	IF	CITATIONS
753	Association between pain phenotype and disease activity in rheumatoid arthritis patients: a non-interventional, longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2019, 21, 257.	1.6	19
754	Estrogen-Related Receptor β Induces Angiogenesis and Extracellular Matrix Degradation of Temporomandibular Joint Osteoarthritis in Rats. <i>Frontiers in Pharmacology</i> , 2019, 10, 1290.	1.6	23
755	Outcomes of Cyanoacrylate Tissue Adhesive Application in Corneal Thinning and Perforation. <i>Cornea</i> , 2019, 38, 668-673.	0.9	44
756	Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2019, 59, 145-155.	0.3	17
757	Patient preferences for rheumatoid arthritis treatment. <i>Current Opinion in Rheumatology</i> , 2019, 31, 256-263.	2.0	23
758	Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients. <i>Journal of Orthopaedic Surgery and Research</i> , 2019, 14, 421.	0.9	14
759	Opioid use in rheumatoid arthritis: trends, efficacy, safety, and best practices. <i>Current Opinion in Rheumatology</i> , 2019, 31, 264-270.	2.0	19
760	Suspected colonic cancer turns out to be disseminated tuberculosis in a kidney transplant recipient. <i>Medicine (United States)</i> , 2019, 98, e16995.	0.4	4
761	Genetic polymorphisms of ACE I/D, IL-1 β G α and IL-4 VNTR among Egyptian subjects with rheumatoid arthritis. <i>Archives of Physiology and Biochemistry</i> , 2022, 128, 576-585.	1.0	11
762	Safety of Intra-articular Methotrexate Injection With and Without Electroporation for Inflammatory Small Joints in Patients With Rheumatoid Arthritis. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2019, 12, 117954411988630.	0.3	3
763	Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage. <i>JAMA Network Open</i> , 2019, 2, e1917053.	2.8	15
764	How Much Information and Participation Do Patients with Inflammatory Rheumatic Diseases Prefer in Interaction with Physicians? Results of a Participatory Research Project. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 2145-2158.	0.8	11
765	Clinical effectiveness and long-term retention of abatacept in elderly rheumatoid arthritis patients: Results from a multicenter registry system. <i>Modern Rheumatology</i> , 2019, 29, 910-918.	0.9	13
766	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. <i>Journal of Rheumatology</i> , 2019, 46, 7-18.	1.0	207
767	Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 976-982.	1.6	20
768	Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. <i>Arthritis Care and Research</i> , 2019, 71, 1326-1335.	1.5	19
769	The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients. <i>Rheumatology</i> , 2019, 58, 131-134.	0.9	14
770	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 171-178.	0.5	66

#	ARTICLE	IF	CITATIONS
771	Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 895-902.	0.9	9
772	Identifying Preanalytic and Postanalytic Laboratory Quality Gaps Using a Data Warehouse and Structured Multidisciplinary Process. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 518-524.	1.2	3
773	Association between cumulative methotrexate dose, noninvasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 214-221.	0.9	28
774	Severity Indices in Rheumatoid Arthritis: A Systematic Review. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 146-151.	0.2	2
775	Upadacitinib for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 13-25.	1.3	50
776	Targets of monoclonal antibodies for immunological diseases. <i>Archives of Pharmacal Research</i> , 2019, 42, 293-304.	2.7	4
777	Uptake and Clinical Utility of Multibiomearker Disease Activity Testing in the United States. <i>Journal of Rheumatology</i> , 2019, 46, 237-244.	1.0	3
778	Perioperative Management of the Rheumatoid Patient. <i>Clinics in Podiatric Medicine and Surgery</i> , 2019, 36, 115-130.	0.2	9
779	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. <i>RMD Open</i> , 2019, 5, e000585.	1.8	41
780	Adjunctive Corticosteroids decreased the risk of mortality of non-HIV Pneumocystis Pneumonia. <i>International Journal of Infectious Diseases</i> , 2019, 79, 109-115.	1.5	21
781	Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 849-850.	0.5	7
782	Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1867-1872.	0.5	5
783	Frequency of Herpes Zoster Vaccination Among Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 345-351.	0.9	18
784	Methotrexate in Patients With Rheumatoid Arthritis in Spain: Subanalysis of the AR Excellence Project. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 338-342.	0.2	1
785	Melatonin attenuates TNF α and IL-1 β expression in synovial fibroblasts and diminishes cartilage degradation: Implications for the treatment of rheumatoid arthritis. <i>Journal of Pineal Research</i> , 2019, 66, e12560.	3.4	115
786	Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 153-154.	0.5	0
787	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019, 71, 1556-1565.	1.5	43
788	Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores. <i>Clinical Rheumatology</i> , 2019, 38, 437-445.	1.0	9

#	ARTICLE	IF	CITATIONS
789	Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis. <i>Rheumatology</i> , 2019, 58, 352-360.	0.9	17
790	Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 958-966.	1.6	9
791	Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2019, 71, 1459-1472.	1.5	28
792	Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. <i>Rheumatology</i> , 2019, 58, 481-491.	0.9	17
793	Higher risk of hospitalized infection, cardiovascular disease, and fracture in patients with rheumatoid arthritis determined using the Japanese health insurance database. <i>Modern Rheumatology</i> , 2019, 29, 788-794.	0.9	11
794	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	2.9	312
795	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	1.5	264
796	Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. <i>Modern Rheumatology</i> , 2019, 29, 756-766.	0.9	10
797	Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multi-biomarker Disease Activity Score and Autoantibody Status. <i>Journal of Rheumatology</i> , 2019, 46, 460-466.	1.0	9
798	Effect of Physical State on Pain Mediated Through Emotional Health in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 1216-1223.	1.5	13
799	Association learning of Chinese herbal medicines and disease treatment efficacy. <i>International Journal of Production Research</i> , 2019, 57, 683-702.	4.9	2
800	A statistical method to convert published response rates into marginal distributions with an example application in psoriasis. <i>Pharmaceutical Statistics</i> , 2019, 18, 4-21.	0.7	1
801	Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 343-350.	1.0	17
802	MMP-8 and TIMP-1 are associated to periodontal inflammation in patients with rheumatoid arthritis under methotrexate immunosuppression - First results of a cross-sectional study. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 386-394.	1.5	20
803	Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - A three-year study in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 141-150.	1.5	25
804	Índices de gravedad en la artritis reumatoide: una revisión sistemática. <i>Reumatología Clínica</i> , 2019, 15, 146-151.	0.2	1
805	Calidad de vida en pacientes ecuatorianos con artritis reumatoide: un estudio transversal. <i>Reumatología Clínica</i> , 2019, 15, 296-300.	0.2	5
806	Effects of non-surgical periodontal therapy on periodontal laboratory and clinical data as well as on disease activity in patients with rheumatoid arthritis. <i>Clinical Oral Investigations</i> , 2019, 23, 141-151.	1.4	56

#	ARTICLE	IF	CITATIONS
807	Optimal sequencing of heterogeneous, non-instantaneous interventions. <i>Annals of Operations Research</i> , 2019, 276, 109-135.	2.6	1
808	Sex and Management of Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 333-345.	2.9	126
809	Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative Study. <i>Arthritis Care and Research</i> , 2019, 71, 80-87.	1.5	34
810	Metotrexato en pacientes con artritis reumatoide en España: subanálisis del proyecto AR Excellence. <i>Reumatología Clínica</i> , 2019, 15, 338-342.	0.2	4
811	Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 31-40.	0.9	104
812	Eficacia y seguridad de los glucocorticoides en la artritis reumatoide: revisión sistemática de la literatura. <i>Reumatología Clínica</i> , 2020, 16, 222-228.	0.2	9
813	Longitudinal Occurrence and Predictors of Patient-Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis: A Case-Control Study. <i>Arthritis Care and Research</i> , 2020, 72, 18-26.	1.5	1
814	Estimating Optimal Dynamic Treatment Regimes With Survival Outcomes. <i>Journal of the American Statistical Association</i> , 2020, 115, 1531-1539.	1.8	27
815	Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. <i>Arthritis Care and Research</i> , 2020, 72, 353-359.	1.5	23
816	Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review. <i>Joint Bone Spine</i> , 2020, 87, 13-23.	0.8	8
817	Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 933-941.	1.5	9
818	Hand Rheumatoid Arthritis. , 2020, , 179-184.		0
820	Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2020, 47, 176-187.	1.0	45
821	Systematic Review and Appraisal of the Cross-Cultural Validity of Functional Status Assessment Measures in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 798-805.	1.5	6
822	Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 326-333.	1.5	19
823	Systematic Review of Recommendations on the Use of Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer. <i>Arthritis Care and Research</i> , 2020, 72, 309-318.	1.5	20
824	Treat to target approach for asthma. <i>Journal of Asthma</i> , 2020, 57, 687-690.	0.9	7
825	Improving access in rheumatology: Evaluating the validity of a paper triage process involving an advanced practice physiotherapist through a retrospective chart review. <i>Physiotherapy Theory and Practice</i> , 2020, 36, 203-210.	0.6	4

#	ARTICLE	IF	CITATIONS
826	Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network. <i>Rheumatology</i> , 2020, 59, 1272-1280.	0.9	17
827	Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory Phenotype. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 391-406.	0.9	21
828	Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2020, 47, 826-834.	1.0	17
829	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 809-819.	1.0	16
830	Relevance of the antioxidant properties of methotrexate and doxycycline to their treatment of cardiovascular disease. , 2020, 205, 107413.		14
831	Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series. <i>Modern Rheumatology</i> , 2020, 30, 1009-1015.	0.9	4
832	Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study. <i>Arthritis Care and Research</i> , 2020, 72, 176-183.	1.5	11
833	Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis. <i>Arthritis Care and Research</i> , 2020, 72, 959-964.	1.5	3
834	Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study. <i>Modern Rheumatology</i> , 2020, 30, 434-441.	0.9	2
835	How do neuropathic pain-like symptoms affect health-related quality of life among patients with rheumatoid arthritis?: A comparison of multiple pain-related parameters. <i>Modern Rheumatology</i> , 2020, 30, 828-834.	0.9	5
836	Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis. <i>PharmacoEconomics - Open</i> , 2020, 4, 105-117.	0.9	16
837	Questioning a publication bias between industry-funded and non-industry-funded randomized controlled trials on biological and small molecule therapy for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 7-11.	1.6	6
838	The Laboratory Role in anti-TNF Biological Therapy Era. <i>Immunological Investigations</i> , 2020, 49, 317-332.	1.0	11
839	Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 273-281.	1.0	18
840	A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA. <i>PharmacoEconomics</i> , 2020, 38, 39-56.	1.7	6
841	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 88-93.	0.5	63
842	Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea. <i>Current Medical Research and Opinion</i> , 2020, 36, 343-351.	0.9	5
843	The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 85-99.	2.5	8

#	ARTICLE	IF	CITATIONS
844	Systematic review of perioperative use of immunosuppressive agents in patients undergoing bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 144-157.	1.0	2
845	Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence: qualitative results. <i>Rheumatology</i> , 2020, 59, 1662-1670.	0.9	42
846	Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 228-236.	1.6	17
847	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. <i>BioDrugs</i> , 2020, 34, 27-37.	2.2	35
848	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. <i>Internal Medicine Journal</i> , 2020, 50, 1085-1090.	0.5	75
849	Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020, 7, 165-171.	1.1	4
850	Prospective evaluation of phosphorus-32 radiation synovectomy in patients with severe and chronic rheumatoid arthritis unresponsive to conventional medical treatment. <i>Nuclear Medicine Communications</i> , 2020, 41, 65-72.	0.5	5
851	Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer. <i>Clinical Rheumatology</i> , 2020, 39, 787-794.	1.0	7
852	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 94-102.	0.5	13
853	Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 207-228.	1.3	47
855	Intra-articular injection of indomethacin-methotrexate in situ hydrogel for the synergistic treatment of rheumatoid arthritis. <i>Journal of Materials Chemistry B</i> , 2020, 8, 993-1007.	2.9	46
856	Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2020, 15, e0226754.	1.1	8
857	Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives. <i>Patient</i> , 2020, 13, 225-234.	1.1	12
858	Risk of preventable hospitalization before and after diagnosis among rheumatoid arthritis patients compared to non-rheumatoid arthritis controls. <i>Joint Bone Spine</i> , 2020, 87, 149-156.	0.8	5
859	Variation and implications of treatment decisions in early rheumatoid arthritis: results from a nationwide cohort study. <i>Rheumatology</i> , 2020, 59, 2035-2042.	0.9	8
860	Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset. <i>Journal of Rheumatology</i> , 2020, 47, 1174-1181.	1.0	10
861	Genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a multicenter cohort study. <i>Pharmacogenomics Journal</i> , 2020, 20, 433-442.	0.9	5
862	Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 222-228.	0.2	1

#	ARTICLE	IF	CITATIONS
863	Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 211-220.	0.5	1
864	Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa020.	0.3	16
865	Traditional therapies of Zhuang medicine improve pain and joint dysfunction of patients in rheumatoid arthritis. <i>Medicine (United States)</i> , 2020, 99, e22264.	0.4	4
866	The relationship between dietary patterns and rheumatoid arthritis: a case-control study. <i>Nutrition and Metabolism</i> , 2020, 17, 75.	1.3	15
867	Critical roles of super-enhancers in the pathogenesis of autoimmune diseases. <i>Inflammation and Regeneration</i> , 2020, 40, 16.	1.5	12
868	Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1246-1256.	0.5	2
869	Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. <i>ACR Open Rheumatology</i> , 2020, 2, 588-594.	0.9	3
870	Synthetically Engineered Adeno-Associated Virus for Efficient, Safe, and Versatile Gene Therapy Applications. <i>ACS Nano</i> , 2020, 14, 14262-14283.	7.3	33
871	Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. <i>Rheumatology</i> , 2020, 59, 3906-3916.	0.9	64
872	Secondary prevention after CABG: do new agents change the paradigm?. <i>Current Opinion in Cardiology</i> , 2020, 35, 664-672.	0.8	5
873	Complexity of TNF- α Signaling in Heart Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3267.	1.0	76
874	Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1532-1543.	0.5	23
875	Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients. <i>Network and Systems Medicine</i> , 2020, 3, 91-104.	2.7	26
876	JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 519-531.	1.6	124
877	Measures of Rheumatoid Arthritis Disease Activity. <i>Arthritis Care and Research</i> , 2020, 72, 4-26.	1.5	9
878	Factors associated with disability in patients with rheumatoid arthritis with persistent moderate disease activity: a retrospective cohort study. <i>BMC Rheumatology</i> , 2020, 4, 63.	0.6	4
879	Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. <i>Reumatologia Clínica</i> , 2022, 18, 33-41.	0.2	4
880	What Next after Biologic Therapy Fails in Rheumatoid Arthritis?. <i>New England Journal of Medicine</i> , 2020, 383, 1588-1589.	13.9	4

#	ARTICLE	IF	CITATIONS
881	Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. <i>RMD Open</i> , 2020, 6, e001091.	1.8	16
882	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093713.	1.2	10
883	Incidence and Complication Rates for Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Across Four Decades. <i>Rheumatology and Therapy</i> , 2020, 7, 685-702.	1.1	17
884	Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy. <i>Crohn's & Colitis</i> 360, 2020, 2, .	0.5	5
886	<p>Using a Discrete-Choice Experiment in a Decision Aid to Nudge Patients Towards Value-Concordant Treatment Choices in Rheumatoid Arthritis: A Proof-of-Concept Study</p> Patient Preference and Adherence, 2020, Volume 14, 829-838.	0.8	12
887	Adult-onset Still's disease - Taming the beast: The path less taken. <i>Medical Journal Armed Forces India</i> , 2020, , .	0.3	0
888	A Targeted Screening Program for Latent Tuberculosis Infection Among Hematopoietic Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa224.	0.4	1
889	Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?. <i>Drugs</i> , 2020, 80, 1183-1201.	4.9	34
890	Musculoskeletal Pain in Older Adults. <i>Medical Clinics of North America</i> , 2020, 104, 855-872.	1.1	16
891	JAK inhibitors and infections risk: focus on herpes zoster. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093605.	1.2	72
892	Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBServe Studies. <i>Rheumatology and Therapy</i> , 2020, 7, 949-965.	1.1	30
893	Intravenous tocilizumab in the management of rheumatoid arthritis: Clinical practice findings from a 6-month international, multicentre, observational study in Central America and the Caribbean. <i>Revista Colombiana De ReumatologÃa</i> , 2020, 27, 245-255.	0.0	0
894	Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden. <i>Rheumatology</i> , 2021, 60, 2755-2764.	0.9	2
895	Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 741-757.	1.1	37
896	<p>A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 589-594.	0.7	1
897	Correspondence to â€ˆComparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry studyâ€™. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e224-e224.	0.5	1
898	Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2020, 173, 870-878.	2.0	97
899	The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa041.	0.3	10

#	ARTICLE	IF	CITATIONS
900	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 172, 369.	2.0	126
901	Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2020, 10, 220.	1.1	6
902	Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Journal of Rheumatology</i> , 2021, 48, 1322-1329.	1.0	10
903	Maintaining Hepatitis B Protection in Immunocompromised Pediatric Rheumatology and Inflammatory Bowel Disease Patients. <i>Journal of Rheumatology</i> , 2020, 48, jrheum.200283.	1.0	5
904	Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 3732-3745.	1.3	11
905	Efficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial. <i>Archives of Rheumatology</i> , 2020, 35, 170-179.	0.3	1
906	Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1058-1063.	1.6	6
907	New Rheumatoid Arthritis Treatments for “Old” Patients: Results of a Systematic Review. <i>Advances in Therapy</i> , 2020, 37, 3676-3691.	1.3	2
908	Tapering glucocorticoids in rheumatoid arthritis. <i>Lancet, The</i> , 2020, 396, 218-219.	6.3	6
909	Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids. <i>Arthritis Care and Research</i> , 2021, 73, 1597-1605.	1.5	14
910	The endocannabinoid signaling pathway as an emerging target in pharmacotherapy, earmarking mitigation of destructive events in rheumatoid arthritis. <i>Life Sciences</i> , 2020, 257, 118109.	2.0	13
911	Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic. <i>Journal of Pharmacy Practice</i> , 2020, , 089719002094265.	0.5	8
912	Methotrexate Enhances Apoptosis of Transmembrane TNF-Expressing Cells Treated With Anti-TNF Agents. <i>Frontiers in Immunology</i> , 2020, 11, 2042.	2.2	2
913	Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review. <i>Expert Review of Vaccines</i> , 2020, 19, 727-744.	2.0	0
914	A Review of Clinical Applications and Side Effects of Methotrexate in Ophthalmology. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-11.	0.6	12
915	Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications. <i>Cells</i> , 2020, 9, 1852.	1.8	75
916	Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. <i>Cells</i> , 2020, 9, 1876.	1.8	27
917	Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. <i>Ocular Immunology and Inflammation</i> , 2020, , 1-5.	1.0	2

#	ARTICLE	IF	CITATIONS
918	Chebularin exerts its anti-inflammatory and anti-arthritic effects via inhibiting NF- κ B and MAPK activation in collagen-induced arthritis mice. <i>International Immunopharmacology</i> , 2020, 88, 106823.	1.7	10
919	Approaching Inflammation Paradoxesâ€™ Proinflammatory Cytokine Blockages Induce Inflammatory Regulators. <i>Frontiers in Immunology</i> , 2020, 11, 554301.	2.2	28
920	Fibrinogen-Like Protein 1 Is a Novel Biomarker for Predicting Disease Activity and Prognosis of Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2020, 11, 579228.	2.2	21
921	Exploring healthcare professionalsâ€™ knowledge, attitudes and experiences of shared decision making in rheumatology. <i>RMD Open</i> , 2020, 6, e001121.	1.8	23
922	Implementation and Evaluation of Audit and Feedback for Monitoring Treat-to-Target (T2T) Strategies in Rheumatoid Arthritis Using Performance Measures. <i>Rheumatology and Therapy</i> , 2020, 7, 909-925.	1.1	8
923	Potential Advantages of Bioactive Compounds Extracted From Traditional Chinese Medicine to Inhibit Bone Destructions in Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2020, 11, 561962.	1.6	18
924	Increased monocyte chemoattractant protein-1 and nitrotyrosine are associated with increased body weight in patients with rheumatoid arthritis after etanercept therapy. <i>Neuropeptides</i> , 2020, 84, 102100.	0.9	5
925	<p>Tuberculosis Arthritis in the Wrist While Using Rituximab for Rheumatoid Arthritis Treatment</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2020, Volume 12, 203-206.	0.8	4
926	The Effect of Vitamin D Supplementation on Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 596007.	1.2	28
927	Use of Herbal Medications for Treatment of Osteoarthritis and Rheumatoid Arthritis. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 67.	0.7	37
928	Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 18715.	1.6	10
929	The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1236-1242.	0.5	3
930	Infectious disease considerations in immunocompromised patients. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2020, 33, 16-25.	0.1	18
931	Bacillus Calmette-GuÃ©rin Cervical Lymphadenitis in a 6-Year-Old Boy on Infliximab for Inflammatory Bowel Disease. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e242-e244.	1.1	0
932	<p>â€œMastering a New Life Situationâ€•â€œ Patientsâ€™ Preferences of Treatment Outcomes in Early Rheumatoid Arthritis â€œ A Longitudinal Qualitative Study</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 1421-1433.	0.8	11
933	Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE. <i>Rheumatology and Therapy</i> , 2020, 7, 851-866.	1.1	18
934	Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands. <i>PLoS Medicine</i> , 2020, 17, e1003296.	3.9	52
935	Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 889-898.	0.5	8

#	ARTICLE	IF	CITATIONS
936	B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2,3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model. <i>BMC Clinical Pathology</i> , 2020, 13, 2632010X2095181.	0.7	9
937	Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e689-e697.	2.2	37
938	Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 822-826.	1.6	10
939	DAS28â€CRP Cutoffs for High Disease Activity and Remission Are Lower Than DAS28â€ESR in Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2020, 2, 507-511.	0.9	28
940	Association of Epsteinâ€Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiencyâ€associated lymphoproliferative disorders in patients with autoimmune diseases. <i>Hematological Oncology</i> , 2020, 38, 799-807.	0.8	7
941	Neoplasm Risk in Rheumatic Diseases Has No Correlation With Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs Usageâ€A Population-Based Nested Caseâ€Control Study. <i>Frontiers in Medicine</i> , 2020, 7, 473.	1.2	3
942	Posttraumatic Stress Disorder, Depression, Anxiety, and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2020, 2, 555-564.	0.9	4
943	Adaptive treatment strategies for chronic conditions: shared-parameter G-estimation with an application to rheumatoid arthritis. <i>Biostatistics</i> , 2022, 23, 430-448.	0.9	2
944	High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS). <i>Advances in Rheumatology</i> , 2020, 60, 43.	0.8	9
945	Complementary and Alternative Medicine Use in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2020, 22, 61.	2.1	15
946	Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings. <i>Rheumatology and Therapy</i> , 2020, 7, 811-824.	1.1	3
948	Arthritis and the role of endogenous glucocorticoids. <i>Bone Research</i> , 2020, 8, 33.	5.4	32
949	Wearable Activity Trackers in the Management of Rheumatic Diseases: Where Are We in 2020?. <i>Sensors</i> , 2020, 20, 4797.	2.1	17
950	Prevalence and correlates of prehypertension and hypertension among adults in Delta State, Nigeria: a cross-sectional community-based study. <i>Ghana Medical Journal</i> , 2020, 54, 48-57.	0.1	6
951	Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib. <i>Journal of the American Veterinary Medical Association</i> , 2020, 257, 507-516.	0.2	14
952	Nonvitamin, Nonmineral Dietary Supplement Use in Individuals with Rheumatoid Arthritis. <i>Journal of Nutrition</i> , 2020, 150, 2451-2459.	1.3	6
953	Comparison of Lutetium-177 tin colloid and Rhenium-188 tin colloid radiosynovectomy in chronic knee arthritis. <i>Nuclear Medicine Communications</i> , 2020, 41, 721-726.	0.5	3
954	FIRST LINE OF SUBCUTANEOUS ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS: A PROSPECTIVE COHORT STUDY. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1217-1225.	1.3	2

#	ARTICLE	IF	CITATIONS
955	Intravenous tocilizumab in the management of rheumatoid arthritis: Clinical practice findings from a 6-month international, multicentre, observational study in Central America and the Caribbean. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2020, 27, 245-255.	0.1	0
956	Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 284.	1.6	28
957	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i> , 2020, 6, e001395.	1.8	100
958	Development of Monitoring System for Assessing Rheumatoid Arthritis within 5 Minutes Using a Drop of Bio-Fluids. <i>Journal of Clinical Medicine</i> , 2020, 9, 3499.	1.0	5
959	Assessment of Liver Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate. <i>Internal Medicine Journal</i> , 2020, , .	0.5	5
960	Empirical evidence of disease activity thresholds used to indicate need for major therapeutic change in US veterans with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 253.	1.6	0
961	Immunsuppression und postoperative Risiken chirurgischen Eingriffe bei Patienten mit rheumatoider Arthritis. <i>Karger Kompass Autoimmun</i> , 2020, 2, 111-112.	0.0	0
962	ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2020, 22, 252.	1.6	10
963	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. <i>Drugs</i> , 2020, 80, 849-857.	4.9	20
964	<p>Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 213-222.	0.7	14
965	Cationic Block Copolymer Nanoparticles with Tunable DNA Affinity for Treating Rheumatoid Arthritis. <i>Advanced Functional Materials</i> , 2020, 30, 2000391.	7.8	29
966	Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. <i>Drug Safety</i> , 2020, 43, 711-725.	1.4	37
967	Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians. <i>Rheumatology and Therapy</i> , 2020, 7, 383-400.	1.1	14
968	Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. <i>JAMA Neurology</i> , 2020, 77, 937.	4.5	78
969	Periarticular osteophyte formation protects against total knee arthroplasty in rheumatoid arthritis patients with advanced joint damage. <i>Clinical Rheumatology</i> , 2020, 39, 3331-3339.	1.0	3
970	The Emerging Roles of Long Noncoding RNAs in Bone Homeostasis and Their Potential Application in Bone-Related Diseases. <i>DNA and Cell Biology</i> , 2020, 39, 926-937.	0.9	16
971	Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2020, 72, 1621-1631.	2.9	55
972	Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs). <i>Journal of Medical Economics</i> , 2020, 23, 1025-1031.	1.0	2

#	ARTICLE	IF	CITATIONS
973	Patient and clinician views on an app for rheumatoid arthritis disease monitoring: Function, implementation and implications. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 813-827.	0.9	20
974	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1114-1124.	1.5	10
975	Defining Minimally Important Changes for the Patient Activity Scale. <i>Arthritis Care and Research</i> , 2020, 73, 1456-1460.	1.5	1
976	Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in Cuban patients with early rheumatoid arthritis. <i>Rheumatology International</i> , 2020, 40, 1873-1881.	1.5	4
977	Response to: "Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis" by Bugatti et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e56-e56.	0.5	1
978	Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren's syndrome enrolled in a large observational US registry. <i>Rheumatology International</i> , 2020, 40, 1239-1248.	1.5	8
979	Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232091602.	1.1	6
980	Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece. <i>Clinical Rheumatology</i> , 2020, 39, 3643-3652.	1.0	8
981	Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study. <i>PLoS ONE</i> , 2020, 15, e0233159.	1.1	4
982	Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1027-1038.	0.5	2
983	Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. <i>Arthritis Research and Therapy</i> , 2020, 22, 139.	1.6	21
984	Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 0, , .	1.5	8
985	Cumulative patient-based disease activity monitoring in rheumatoid arthritis " predicts sustained remission, flare and treatment escalation. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 749-758.	1.6	1
986	Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. <i>BMC Rheumatology</i> , 2020, 4, 42.	0.6	10
987	Effect of antiresorptive and bone forming treatments in bone erosions in rheumatoid arthritis. <i>Medicina Clínica (English Edition)</i> , 2020, 154, 358-365.	0.1	1
988	Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase-deficient patient with COVID-19 infection. <i>European Journal of Haematology</i> , 2020, 105, 512-513.	1.1	11
989	Mycobacterial Infections Potentiated by Biologics. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 413-423.	1.9	4
990	lncRNA PlncRNA-1 participates in rheumatoid arthritis by regulating transforming growth factor β 1. <i>Autoimmunity</i> , 2020, 53, 297-302.	1.2	10

#	ARTICLE	IF	CITATIONS
991	Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies. <i>Arthritis Care and Research</i> , 2021, 73, 1461-1469.	1.5	8
992	A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. <i>Clinical Rheumatology</i> , 2020, 39, 2797-2802.	1.0	37
993	Vaccinations and Biologics. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 425-450.	1.9	0
994	Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 271-310.	1.9	4
995	A guide to managing reproductive health in rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 411-412.	3.5	2
996	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. <i>Advances in Rheumatology</i> , 2020, 60, 32.	0.8	53
997	Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. <i>Arthritis Research and Therapy</i> , 2020, 22, 136.	1.6	16
998	Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial. <i>Rheumatology and Therapy</i> , 2020, 7, 327-344.	1.1	25
999	The Micro-Immunotherapy Medicine 2LARTHÁ® Reduces Inflammation and Symptoms of Rheumatoid Arthritis <i>In Vivo</i>. <i>International Journal of Rheumatology</i> , 2020, 2020, 1-9.	0.9	16
1000	Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. <i>Nature Reviews Rheumatology</i> , 2020, 16, 282-292.	3.5	76
1001	Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database. <i>PLoS ONE</i> , 2020, 15, e0229998.	1.1	19
1002	Important determinants of the patient choice between TNF- vs. non-TNF Biologic disease-modifying anti-rheumatic drugs (DMARDs) for active rheumatoid arthritis (RA). <i>Joint Bone Spine</i> , 2020, 87, 307-313.	0.8	4
1003	Mixed methods study of a new model of care for chronic disease: co-design and sustainable implementation of group consultations into clinical practice. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa003.	0.3	6
1004	Tuberculosis osteomyelitis in an old fused hip; activated by prednisolone, salazosulfapyridine, and low-dose methotrexate therapy in a patient with rheumatoid arthritis. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 171-175.	0.3	2
1005	Exosomes: Effectual players in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2020, 19, 102511.	2.5	55
1006	Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 285-294.	0.5	3
1007	Les bronchectasies dans la polyarthrite rhumatoïde: Évaluation clinique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, 87, 353-358.	0.0	0
1008	Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient-reported outcomes. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa013.	0.3	21

#	ARTICLE	IF	CITATIONS
1009	Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis. <i>Clinical Drug Investigation</i> , 2020, 40, 827-838.	1.1	6
1010	Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study. <i>Chinese Medical Journal</i> , 2020, 133, 1397-1403.	0.9	2
1011	Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2017.	1.0	0
1012	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1606-1616.	1.5	35
1013	Cancer and Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 445-462.	0.8	19
1014	Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. <i>BMJ</i> , The, 2020, 370, m2288.	3.0	39
1015	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1607-1620.	2.9	126
1016	Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis. <i>Medicine (United States)</i> , 2020, 99, e20824.	0.4	11
1017	First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study. <i>BMC Rheumatology</i> , 2020, 4, 34.	0.6	2
1018	Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity. <i>Frontiers in Immunology</i> , 2020, 11, 1336.	2.2	8
1019	Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment. <i>Current Rheumatology Reports</i> , 2020, 22, 44.	2.1	15
1020	Tuberculin skin test conversion in patients under treatment with anti-tumor necrotizing factor alpha agents. <i>BMC Infectious Diseases</i> , 2020, 20, 464.	1.3	2
1021	Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 170-175.	0.5	29
1022	<p></p>Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 119-131.	0.8	20
1023	Obesity and its role in the management of rheumatoid and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 1039-1047.	1.0	32
1024	Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Naïve T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 194.	2.2	16
1025	Injection Techniques for Common Chronic Pain Conditions of the Foot: A Comprehensive Review. <i>Pain and Therapy</i> , 2020, 9, 145-160.	1.5	27
1026	Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. <i>Clinical and Translational Science</i> , 2020, 13, 743-751.	1.5	5

#	ARTICLE	IF	CITATIONS
1027	<p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>. Infection and Drug Resistance, 2020, Volume 13, 513-532.	1.1	4
1028	A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis. Journal of Medical Economics, 2020, 23, 624-630.	1.0	1
1029	14-3-3Î· Protein in Rheumatoid Arthritis: Promising Diagnostic Marker and Independent Risk Factor for Osteoporosis. Laboratory Medicine, 2020, 51, 529-539.	0.8	9
1030	Tumour necrosis factor alpha promotes secretion of 14-3-3Î· by inducing necroptosis in macrophages. Arthritis Research and Therapy, 2020, 22, 24.	1.6	16
1031	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. Annals of the Rheumatic Diseases, 2020, 79, 445-452.	0.5	42
1032	Implications of Anti-Inflammatory Nature of Exosomes in Knee Arthritis. Cartilage, 2020, , 194760352090476.	1.4	9
1034	Technology-Enabled Outreach to Patients Taking High-Risk Medications Reduces a Quality Gap in Completion of Clinical Laboratory Testing. Population Health Management, 2020, 23, 3-11.	0.8	6
1035	Factors Influencing Placebo Responses in Rheumatoid Arthritis Clinical Trials: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Drug Investigation, 2020, 40, 197-209.	1.1	6
1036	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs, 2020, 80, 99-113.	4.9	58
1037	Emotional eating is more frequent in obese rheumatoid arthritis patients. Clinical Nutrition ESPEN, 2020, 35, 81-84.	0.5	1
1038	Patient and clinician perspectives on a patientâ€œfacing dashboard that visualizes patient reported outcomes in rheumatoid arthritis. Health Expectations, 2020, 23, 846-859.	1.1	17
1039	Association of High Serum Interleukinâ€œ6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis and Rheumatology, 2020, 72, 1456-1466.	2.9	30
1040	Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort. Arthritis Research and Therapy, 2020, 22, 96.	1.6	8
1041	Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. Arthritis Research and Therapy, 2020, 22, 97.	1.6	22
1042	Modulating inflammatory macrophages with an apoptotic body-inspired nanoparticle. Acta Biomaterialia, 2020, 108, 250-260.	4.1	38
1043	The impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patients. Seminars in Arthritis and Rheumatism, 2020, 50, 423-431.	1.6	12
1044	Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opinion on Investigational Drugs, 2020, 29, 475-482.	1.9	36
1045	Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology, 2020, 59, 3303-3313.	0.9	41

#	ARTICLE	IF	CITATIONS
1046	Rapid development of severe acute respiratory distress syndrome after abatacept treatment in a patient with rheumatoid arthritis. <i>BMJ Case Reports</i> , 2020, 13, e231725.	0.2	2
1047	What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?. <i>Frontiers in Immunology</i> , 2020, 11, 589.	2.2	18
1048	Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. <i>Journal of Clinical Medicine</i> , 2020, 9, 1082.	1.0	68
1049	Suboptimal Immunization Coverage among Canadian Rheumatology Patients in Routine Clinical Care. <i>Journal of Rheumatology</i> , 2020, 47, 770-778.	1.0	30
1050	Glucocorticoids in rheumatoid arthritis: current status and future studies. <i>RMD Open</i> , 2020, 6, e000536.	1.8	89
1051	New galaxies in the universe of shared decision-making and rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 273-278.	2.0	19
1052	Management issues in rheumatoid arthritis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2020, 32, 255-263.	2.0	39
1053	Reconsidering the Role of Melatonin in Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2877.	1.8	29
1054	Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2020, 37, 2356-2372.	1.3	35
1055	Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: Data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA). <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1414-1420.	1.6	3
1056	Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 701-715.	0.6	130
1057	Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 669-671.	0.5	12
1058	A Population-Based Approach to Reporting System-Level Performance Measures for Rheumatoid Arthritis Care. <i>Arthritis Care and Research</i> , 2021, 73, 640-648.	1.5	12
1059	Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors. <i>Modern Rheumatology</i> , 2021, 31, 80-87.	0.9	0
1060	Association of Rural Setting With Poorer Disease Outcomes for Patients With Rheumatic Diseases: Results From a Systematic Review of the Literature. <i>Arthritis Care and Research</i> , 2021, 73, 666-670.	1.5	6
1061	Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 123-132.	1.0	1
1062	Nanomedicine for the Treatment of Rheumatoid Arthritis. <i>Molecular Pharmaceutics</i> , 2021, 18, 539-549.	2.3	33
1063	Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift. <i>Arthritis and Rheumatology</i> , 2021, 73, 181-193.	2.9	114

#	ARTICLE	IF	CITATIONS
1064	Methotrexate and rheumatoid arthritis associated interstitial lung disease. <i>European Respiratory Journal</i> , 2021, 57, 2000337.	3.1	114
1065	Distinct decrease in peripheral lymphocytes in EBER-positive cases of MTX-LPD. <i>Modern Rheumatology</i> , 2021, 31, 88-93.	0.9	3
1066	Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis. <i>Current Medical Research and Opinion</i> , 2021, 37, 157-166.	0.9	4
1067	Tailoring biologic therapy for real-world rheumatoid arthritis patients. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 661-674.	1.4	4
1068	Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 432-439.	0.5	14
1069	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 518-526.	0.5	54
1070	Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data. <i>Clinical Rheumatology</i> , 2021, 40, 867-875.	1.0	4
1071	Pharmacokinetics and Bioequivalence of 2 Immediate-Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 535-541.	0.8	3
1072	Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 96-102.	0.5	35
1073	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021, 60, 256-262.	0.9	14
1074	Pop a pill or give myself a shot? Patient perspectives of disease-modifying anti-rheumatic drug choice for rheumatoid arthritis. <i>Joint Bone Spine</i> , 2021, 88, 105053.	0.8	3
1075	Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021, 73, 471-480.	1.5	12
1076	Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib. <i>Clinical Rheumatology</i> , 2021, 40, 1273-1281.	1.0	6
1077	State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 205-218.	0.9	12
1078	Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 293-303.	0.5	32
1079	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.5	224
1080	Circadian Variation in Efficacy of Medications. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1457-1488.	2.3	16
1081	Methotrexate use does not increase the prevalence of hepatic steatosis: a real-world retrospective nested case-control study. <i>Clinical Rheumatology</i> , 2021, 40, 2037-2045.	1.0	8

#	ARTICLE	IF	CITATIONS
1082	Investigating the safety and compliance of using csDMARDs in rheumatoid arthritis treatment through face-to-face interviews: a cross-sectional study in China. <i>Clinical Rheumatology</i> , 2021, 40, 1789-1798.	1.0	7
1083	Traitement anti-TNF ou non anti-TNF dans la polyarthrite rhumatoïde active: facteurs déterminant le choix des patients. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 49-55.	0.0	0
1084	Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2021, 48, 804-812.	1.0	12
1085	Knowledge and attitudes about influenza vaccination in rheumatic diseases patients. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1420-1425.	1.4	22
1086	Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 286-292.	0.5	35
1087	Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait. <i>Clinical Rheumatology</i> , 2021, 40, 1759-1765.	1.0	5
1088	Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients. <i>Joint Bone Spine</i> , 2021, 88, 105057.	0.8	4
1089	Total-Body PET Imaging of Musculoskeletal Disorders. <i>PET Clinics</i> , 2021, 16, 99-117.	1.5	11
1090	A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2021, 8, 167-181.	1.1	6
1091	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). <i>Modern Rheumatology</i> , 2022, 32, 59-67.	0.9	6
1092	The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 639-647.	1.4	12
1093	Relationship Between Depression and Disease Activity in United States Veterans With Early Rheumatoid Arthritis Receiving Methotrexate. <i>Journal of Rheumatology</i> , 2021, 48, 813-820.	1.0	3
1094	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. <i>Arthritis and Rheumatology</i> , 2021, 73, 759-768.	2.9	29
1095	Patient global assessment to define remission in rheumatoid arthritis: quo vadis?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 277-279.	0.5	14
1096	Traditional and modern management strategies for rheumatoid arthritis. <i>Clinica Chimica Acta</i> , 2021, 512, 142-155.	0.5	33
1097	Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. <i>Rheumatology</i> , 2021, 60, 2256-2266.	0.9	12
1098	Salivary and serum concentrations of monocyte chemoattractant protein-1, macrophage inhibitory factor, and fractalkine in relation to rheumatoid arthritis and periodontitis. <i>Journal of Periodontology</i> , 2021, 92, 1295-1305.	1.7	7
1099	Response to interleukin-6 receptor antagonists in patients with rheumatoid arthritis is independent of the number of prior used TNF inhibitors: A systematic review and metaanalysis. <i>Joint Bone Spine</i> , 2021, 88, 105112.	0.8	1

#	ARTICLE	IF	CITATIONS
1100	What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review. <i>Patient</i> , 2021, 14, 505-532.	1.1	2
1101	Ibuprofen-loaded calcium phosphate granules: A new bone substitute for local relieving symptoms of osteoarthritis. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 158, 105679.	1.9	6
1102	Tapering and discontinuation of oral glucocorticoids without deterioration of disease status in patients with rheumatoid arthritis under a stable treatment. <i>Modern Rheumatology</i> , 2021, 31, 1-10.	0.9	1
1103	Le risque d'hospitalisation évitable avant et après le diagnostic chez des patients atteints de polyarthrite rhumatoïde comparativement à des témoins sans polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Française)</i> , 2021, 88, 40-48.	0.0	0
1104	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 85-100.	1.3	14
1105	The patient perspective of nurse-led care in early rheumatoid arthritis: A systematic review of qualitative studies with thematic analysis. <i>Journal of Clinical Nursing</i> , 2021, 30, 145-160.	1.4	12
1106	Post-marketing surveillance of high-dose methotrexate (>8mg/week) in Japanese patients with rheumatoid arthritis: A post hoc sub-analysis of patients according to duration of prior methotrexate use. <i>Modern Rheumatology</i> , 2021, 31, 575-586.	0.9	3
1107	A multimodal intervention increases influenza vaccine uptake in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 575-579.	1.0	8
1108	Dose tapering of biologic agents in patients with rheumatoid arthritis—results from a cohort study in Germany. <i>Clinical Rheumatology</i> , 2021, 40, 887-893.	1.0	1
1109	Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corona registry data. <i>Rheumatology International</i> , 2021, 41, 381-390.	1.5	10
1110	Patients with rheumatoid arthritis exposed to COVID-19: A family cluster report. <i>Modern Rheumatology</i> , 2021, 31, 514-517.	0.9	0
1111	Differentiating rheumatoid and psoriatic arthritis: a systematic analysis of high-resolution magnetic resonance imaging features—preliminary findings. <i>Skeletal Radiology</i> , 2021, 50, 531-541.	1.2	8
1112	High Levels of Polypharmacy in Rheumatoid Arthritis—A Challenge Not Covered by Current Management Recommendations: Data From a Large Real-Life Study. <i>Journal of Pharmacy Practice</i> , 2021, 34, 365-371.	0.5	15
1115	Potential applicability of cytokines as biomarkers of disease activity in rheumatoid arthritis: Enzyme-linked immunosorbent spot assay-based evaluation of TNF- α , IL-1 β , IL-10 and IL-17A. <i>PLoS ONE</i> , 2021, 16, e0246111.	1.1	15
1116	COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology. <i>Journal of Korean Medical Science</i> , 2021, 36, e95.	1.1	40
1117	Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. <i>Rheumatology</i> , 2021, 60, 4681-4690.	0.9	20
1118	Development of an Educational Video for Self-Assessment of Patients with RA: Steps, Challenges, and Responses. <i>Mediterranean Journal of Rheumatology</i> , 2021, 31, 66.	0.3	6
1119	Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 73-83.	0.5	3

#	ARTICLE	IF	CITATIONS
1120	<i>Guizhi-Shaoyao-Zhimu</i> decoction attenuates bone erosion in rats that have collagen-induced arthritis via modulating NF- κ B signalling to suppress osteoclastogenesis. <i>Pharmaceutical Biology</i> , 2021, 59, 260-272.	1.3	8
1121	Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs. <i>Journal of Medical Economics</i> , 2021, 24, 299-307.	1.0	3
1122	Biomarkers for interstitial lung disease and acute-onset diffuse interstitial lung disease in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110225.	1.2	11
1123	Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001512.	1.8	42
1124	Remisyonda olan romatoid artritli hastada tedavi kararları. <i>Ege Tıp Dergisi</i> , 0, , 44-48.	0.1	0
1125	Formulation and Characterization of Alginate-Based Membranes for the Potential Transdermal Delivery of Methotrexate. <i>Polymers</i> , 2021, 13, 161.	2.0	29
1126	Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis: an international survey within the GLORIA study. <i>Rheumatology</i> , 2021, 60, 3334-3342.	0.9	13
1127	Quality Indicators for Evaluating the Health Care of Patients with Rheumatoid Arthritis: a Korean Expert Consensus. <i>Journal of Korean Medical Science</i> , 2021, 36, e109.	1.1	3
1128	Review article: safety of new biologic agents for inflammatory bowel disease in the liver. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 623-630.	0.8	5
1129	Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). <i>Arthritis Research and Therapy</i> , 2021, 23, 9.	1.6	17
1130	The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy. <i>Arthritis Research and Therapy</i> , 2021, 23, 26.	1.6	7
1131	The role of ixekizumab in non-radiographic axial spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2098673.	1.2	4
1132	Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy. <i>Journal of Clinical Rheumatology</i> , 2021, Publish Ahead of Print, .	0.5	1
1133	RESPONSE OF ORCHID CUT FLOWERS AS AFFECTED BY FLORAL PRESERVATIVES ON THE POSTHARVEST QUALITY A SYSTEMATIC ANALYSIS ON A POTENTIAL ANTI-INFLAMMATORY AND IMMUNOSUPPRESSANT HERB <i>TRIPTERYGIIUM WILFORDII</i> FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS. <i>Plant Archives</i> , 2021, 21, 2168-2178.	0.1	1
1135	Evaluation of prescription practices in rheumatoid arthritis at the rheumatology clinic in a tertiary care teaching hospital in Uttarakhand: A cross-sectional study. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 745.	0.3	2
1136	Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 697-704.	0.5	5
1137	Biologic therapies for the treatment of rheumatoid arthritis. <i>Journal of the Korean Medical Association</i> , 2021, 64, 95-104.	0.1	0
1138	COVID-19 infection in patients with connective tissue disease: A multicity study in Hubei province, China. <i>MedComm</i> , 2021, 2, 82-90.	3.1	7

#	ARTICLE	IF	CITATIONS
1139	Phenotype and treatment of elderly onset compared with younger onset rheumatoid arthritis patients in international daily practice. <i>Rheumatology</i> , 2021, 60, 4801-4810.	0.9	7
1140	Crossing the barriers: Revisiting the gut feeling in rheumatoid arthritis. <i>European Journal of Immunology</i> , 2021, 51, 798-810.	1.6	33
1141	PAMAM dendrimers functionalised with an anti-TNF antibody and chondroitin sulphate for treatment of rheumatoid arthritis. <i>Materials Science and Engineering C</i> , 2021, 121, 111845.	3.8	21
1142	Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina. <i>Reumatología Clínica</i> , 2021, , .	0.2	0
1143	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. <i>Arthritis Research and Therapy</i> , 2021, 23, 51.	1.6	18
1144	Yishen-tongbi decoction inhibits excessive activation of B cells by activating the FcγRIIb/Lyn/SHP-1 pathway and attenuates the inflammatory response in CIA rats. <i>Biomedicine and Pharmacotherapy</i> , 2021, 134, 111166.	2.5	6
1145	Glucocorticoid and opioid use in rheumatoid arthritis management. <i>Current Opinion in Rheumatology</i> , 2021, 33, 277-283.	2.0	10
1146	Perceptions of patients with rheumatoid arthritis about self-assessment of disease activity after watching an educational video: a qualitative pilot study from the AUTO-DAS in Middle Eastern Arab countries project. <i>Rheumatology International</i> , 2021, 41, 733-740.	1.5	6
1147	Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 359-373.	0.8	24
1148	Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 859-864.	0.5	25
1149	Higher doses of methotrexate associated with discontinuation of oral glucocorticoids after initiation of biological DMARDs: A retrospective observational study based on data from a Japanese multicenter registry study. <i>Modern Rheumatology</i> , 2021, 31, 796-802.	0.9	1
1150	Multimorbidity Burden in Rheumatoid Arthritis: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2021, 48, 1648-1654.	1.0	22
1151	Mindfulness for patients with rheumatoid arthritis: systematic review. <i>Research, Society and Development</i> , 2021, 10, e2610212047.	0.0	1
1153	Genetic markers of osteoarthritis: early diagnosis in susceptible Pakistani population. <i>Journal of Orthopaedic Surgery and Research</i> , 2021, 16, 124.	0.9	10
1154	Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2021, 31, 1079-1086.	0.9	5
1155	Association between Health Literacy, Patient Activation, and Functional Capacity in Individuals with Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , 2021, 15, 1-8.	0.1	4
1156	Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. <i>Drug Safety</i> , 2021, 44, 515-530.	1.4	28
1157	Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. <i>Cells</i> , 2021, 10, 323.	1.8	16

#	ARTICLE	IF	CITATIONS
1158	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 509.	1.0	44
1159	The risk factors and incidence of major infectious diseases in patients with ankylosing spondylitis receiving tumor necrosis factor inhibitors. <i>Modern Rheumatology</i> , 2021, 31, 1192-1201.	0.9	5
1160	Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. <i>BMC Rheumatology</i> , 2021, 5, 3.	0.6	3
1161	Disease activity and its predictors in early inflammatory arthritis: findings from a national cohort. <i>Rheumatology</i> , 2021, 60, 4811-4820.	0.9	8
1162	Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1477-1483.	1.5	1
1163	Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. <i>Journal of Rheumatology</i> , 2021, 48, 1230-1238.	1.0	29
1164	Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis – multicentre study of 263 Caucasian patients. <i>Rheumatology</i> , 2021, 61, 299-308.	0.9	13
1165	Effectiveness and tolerability of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 61, 331-336.	0.9	4
1166	Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. <i>Scientific Reports</i> , 2021, 11, 7266.	1.6	21
1168	Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. <i>ACR Open Rheumatology</i> , 2021, 3, 295-304.	0.9	9
1169	Prognostic Factors for Radiographic Progression in Patients with Seronegative Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2021, 11, 184.	1.1	5
1170	Is methotrexate hepatotoxicity associated with cumulative dose? A systematic review and meta-analysis. <i>Australasian Journal of Dermatology</i> , 2021, 62, 130-140.	0.4	12
1171	Patient perspectives on how to improve education on medication side effects: cross-sectional observational study at a rheumatology clinic in The Netherlands. <i>Rheumatology International</i> , 2021, 41, 973-979.	1.5	2
1172	Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 327-346.	1.1	6
1173	Rheumatoid arthritis relapse in patients with other iatrogenic immunodeficiency-associated lymphoproliferative disorders and its treatment. <i>Modern Rheumatology</i> , 2021, 31, 1087-1093.	0.9	1
1175	Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. <i>Pharmaceuticals</i> , 2021, 14, 251.	1.7	2
1176	Role of comorbidities on therapeutic persistence of biological agents in rheumatoid arthritis: results from the RECORD-linkage On Rheumatic Disease study on administrative healthcare databases. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 333-342.	0.6	4
1178	MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE. <i>Rheumatology</i> , 2021, 61, 270-280.	0.9	5

#	ARTICLE	IF	CITATIONS
1179	Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1239-1242.	1.0	12
1180	Vaccinations in Patients with Rheumatic Disease. <i>Medical Clinics of North America</i> , 2021, 105, 213-225.	1.1	5
1181	The level of thymic stromal lymphopoietin and its gene polymorphism are associated with rheumatoid arthritis. <i>Immunobiology</i> , 2021, 226, 152055.	0.8	1
1182	Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine. <i>RMD Open</i> , 2021, 7, e001560.	1.8	2
1183	2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis. <i>Rheumatology and Immunology Research</i> , 2021, 2, 1-14.	0.2	9
1184	Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 751-760.	0.8	9
1185	Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry. <i>PLoS ONE</i> , 2021, 16, e0250877.	1.1	17
1186	Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors. <i>Rheumatology</i> , 2021, 61, 131-138.	0.9	8
1188	Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0248866.	1.1	21
1189	Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. <i>British Journal of Haematology</i> , 2021, 194, 101-110.	1.2	8
1190	Signalling and putative therapeutic molecules on the regulation of synoviocyte signalling in rheumatoid arthritis. <i>Bone and Joint Research</i> , 2021, 10, 285-297.	1.3	10
1191	Treat-to-target strategy in patients with rheumatoid arthritis: Audit of adherence from real world clinical data. <i>ReumatologĀa ClĀnica</i> , 2021, 17, 212-214.	0.2	5
1192	Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. <i>Cells</i> , 2021, 10, 881.	1.8	29
1193	Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 997-1003.	0.5	15
1194	Tuberculosis in Biologic-naĀve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis Characteristics. <i>Journal of Rheumatology</i> , 2021, 48, 1243-1250.	1.0	7
1195	Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 661-670.	1.3	2
1196	Treat-to-target strategy in patients with rheumatoid arthritis: Audit of adherence from real world clinical data. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 17, 212-214.	0.2	0
1197	Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis BasedĀon a Mapping Algorithm Derived from a Chinese Population. <i>Advances in Therapy</i> , 2021, 38, 2571-2585.	1.3	6

#	ARTICLE	IF	CITATIONS
1198	Malignancy risk in individuals with familial adenomatous polyposis receiving biologics and immunomodulators. <i>Familial Cancer</i> , 2021, , 1.	0.9	1
1199	Association of Rheumatoid Arthritis with Diabetic Comorbidity: Correlating Accelerated Insulin Resistance to Inflammatory Responses in Patients. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 809-820.	1.1	13
1200	Healthcare Costs of Not Achieving Remission in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 2558-2570.	1.3	6
1201	Probabilistic Linkage of Randomized Controlled Trial Data to Administrative Claims: A Case Study of Patients from Baricitinib Clinical Trials. <i>Rheumatology and Therapy</i> , 2021, 8, 793-802.	1.1	0
1202	The Role of Endostatin in Rheumatoid Arthritis. <i>Current Rheumatology Reviews</i> , 2021, 17, 68-75.	0.4	4
1203	Low-intensity pulsed ultrasound inhibits IL-6 in subchondral bone of temporomandibular joint osteoarthritis by suppressing the TGF- β 1/Smad3 pathway. <i>Archives of Oral Biology</i> , 2021, 125, 105110.	0.8	4
1204	The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume. <i>Rheumatology</i> , 2022, 61, 787-793.	0.9	3
1205	Relationship between different anti-rheumatic drug therapies and complementary and alternative medicine in patients with rheumatoid arthritis: an interview based cross-sectional study. <i>Saudi Pharmaceutical Journal</i> , 2021, 29, 462-466.	1.2	2
1206	Safety of the Methotrexate+leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil). <i>Journal of Rheumatology</i> , 2021, 48, 1519-1527.	1.0	8
1207	Bisphosphonates in inflammatory rheumatic diseases. <i>Bone</i> , 2021, 146, 115887.	1.4	9
1208	A double-blind, double-dummy, randomized controlled, multicenter trial of ⁹⁹ Tc-methylene diphosphonate in patients with moderate to severe rheumatoid arthritis. <i>Chinese Medical Journal</i> , 2021, 134, 1457-1464.	0.9	6
1209	The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions. <i>Frontiers in Pharmacology</i> , 2021, 12, 680043.	1.6	62
1210	Traditional Chinese Medicine Qingre Huoxue Treatment vs. the Combination of Methotrexate and Hydroxychloroquine for Active Rheumatoid Arthritis: A Multicenter, Double-Blind, Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 2021, 12, 679588.	1.6	8
1211	Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 349-358.	0.7	4
1212	Systematic Review and Metaanalysis of the Reproducibility of Patient Self-reported Joint Counts in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201439.	1.0	5
1213	Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 71-78.	0.6	1
1214	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. <i>Arthritis and Rheumatology</i> , 2021, 73, 1093-1107.	2.9	146
1215	Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37% patient-years of tofacitinib exposure. <i>RMD Open</i> , 2021, 7, e001595.	1.8	30

#	ARTICLE	IF	CITATIONS
1216	Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis. <i>European Journal of Rheumatology</i> , 2021, 8, 67-72.	1.3	4
1217	Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1124-1129.	0.5	8
1218	Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 746-757.	0.9	26
1219	Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment. <i>Arthritis and Rheumatology</i> , 2021, 73, 2189-2199.	2.9	7
1220	Switch from Infliximab to Infliximab-dyyb for Rheumatology Indications. <i>Journal of Contemporary Pharmacy Practice</i> , 2021, , 32-36.	0.2	0
1222	The characteristics and its contributing factors of refractory rheumatoid arthritis, view of the rheumatologists of China: results of a nationwide cross-sectional survey. <i>Clinical Rheumatology</i> , 2021, 40, 4029-4038.	1.0	1
1223	Influence of Age and Sex on Disease Course and Treatment in Rheumatoid Arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2021, Volume 13, 123-138.	0.8	27
1224	Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months. <i>Arthritis Care and Research</i> , 2022, 74, 131-141.	1.5	5
1225	Initial methotrexate dosage is not associated with an increased risk of liver toxicity in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 4493-4500.	1.0	1
1226	Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis. <i>Journal of Personalized Medicine</i> , 2021, 11, 573.	1.1	7
1227	Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis. <i>Clinical Rheumatology</i> , 2021, 40, 3143-3151.	1.0	6
1228	Monoacylglycerol Lipase Inhibition Using JZL184 Attenuates Paw Inflammation and Functional Deficits in a Mouse Model of Inflammatory Arthritis. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 233-241.	1.5	6
1229	Tele-health interventions to support self-management in adults with rheumatoid arthritis: a systematic review. <i>Rheumatology International</i> , 2021, 41, 1399-1418.	1.5	18
1230	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e30-e45.	2.9	61
1231	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637.	1.8	12
1232	Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study. <i>Rheumatology</i> , 2021, 60, 5257-5270.	0.9	8
1233	Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. <i>Reumatologia Clínica</i> , 2021, 17, 335-342.	0.2	3
1234	Severe lupus induced by the tumor necrosis factor-alpha inhibitor Anbainuo: a case report. <i>Journal of International Medical Research</i> , 2021, 49, 0300060521110225.	0.4	3

#	ARTICLE	IF	CITATIONS
1235	A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor- β Inhibitors: The NETWORK-004 Prospective Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1159-1176.	1.1	16
1236	Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 17, 335-342.	0.2	0
1237	Quinone-rich fraction of <i>Ardisia crispa</i> (Thunb.) A. DC roots alters angiogenic cascade in collagen-induced arthritis. <i>Inflammopharmacology</i> , 2021, 29, 771-788.	1.9	3
1238	Estimated Public Health Impact of the Recombinant Zoster Vaccine. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 596-604.	1.2	3
1239	RecomendaĂo e seguranĂa da vacinaĂo em pacientes com artrite reumatoide utilizando tratamento imunossupressor. <i>Research, Society and Development</i> , 2021, 10, e23910716440.	0.0	0
1240	Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1376-1384.	0.5	5
1241	The maximum dose and duration in the therapy single use methotrexate to achieve remission by rheumatoid arthritis patients through disease activity score 28 (DAS28). <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2021, 32, 675-680.	0.7	0
1242	Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). <i>Joint Bone Spine</i> , 2021, 88, 105221.	0.8	0
1243	Dexamethasone and Fumaric Acid Ester Conjugate Synergistically Inhibits Inflammation and NF- κ B in Macrophages. <i>Bioconjugate Chemistry</i> , 2021, 32, 1629-1640.	1.8	8
1244	Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). <i>RMD Open</i> , 2021, 7, e001673.	1.8	7
1245	Ticagrelor added to methotrexate improves rheumatoid arthritis disease severity. <i>Rheumatology</i> , 2021, 60, 5473-5475.	0.9	3
1246	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939.	1.5	466
1247	Sustained Remission in Rheumatoid Arthritis: Time to Withdraw Treatment?. <i>ACR Open Rheumatology</i> , 2021, 3, 578-580.	0.9	0
1248	Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics. <i>Arthritis Research and Therapy</i> , 2021, 23, 178.	1.6	20
1249	Cold air plasma: A potential strategy for inducing apoptosis of rheumatoid arthritis fibroblast-like synoviocytes. <i>High Voltage</i> , 2022, 7, 106-116.	2.7	9
1250	Using Parallel Streams of Evidence to Inform Guideline Development: The Case of the 2021 American College of Rheumatology Management of Rheumatoid Arthritis Guideline. <i>ACR Open Rheumatology</i> , 2021, 3, 629-635.	0.9	4
1251	Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2021, 10, 205.	2.5	2
1252	Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression. <i>Clinical Rheumatology</i> , 2021, 40, 4861-4867.	1.0	19

#	ARTICLE	IF	CITATIONS
1253	Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan. <i>Frontiers in Pharmacology</i> , 2021, 12, 628548.	1.6	4
1254	Chronic Pain in Patients with Rheumatoid Arthritis. <i>Current Pain and Headache Reports</i> , 2021, 25, 59.	1.3	18
1255	Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends. <i>Pharmacological Research</i> , 2021, 169, 105618.	3.1	23
1256	Predictive analytics for step-up therapy: Supervised or semi-supervised learning?. <i>Journal of Biomedical Informatics</i> , 2021, 119, 103842.	2.5	7
1257	Effectiveness of Mindâ€œBody Intervention for Inflammatory Conditions: Results from a 26-Week Randomized, Non-Blinded, Parallel-Group Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 3107.	1.0	3
1258	Incidence, mortality, and national costs of hospital admissions for potentially preventable infections in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 4845-4851.	1.0	5
1259	Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 413-431.	2.9	6
1260	â€œIt is as if you were taking a shot in the darkâ€: Experiencing ambiguity in the pharmacological treatment of rheumatoid arthritis. <i>Research, Society and Development</i> , 2021, 10, e0110917071.	0.0	0
1261	BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study. <i>BMC Rheumatology</i> , 2021, 5, 22.	0.6	4
1262	Switching TNF± inhibitors: Patterns and determinants. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00843.	1.1	3
1263	Nanomedicine-based combination of dexamethasone palmitate and MCL-1 siRNA for synergistic therapeutic efficacy against rheumatoid arthritis. <i>Drug Delivery and Translational Research</i> , 2021, 11, 2520-2529.	3.0	11
1264	CS-semi5 Inhibits NF-ÎB Activation to Block Synovial Inflammation, Cartilage Loss and Bone Erosion Associated With Collagen-Induced Arthritis. <i>Frontiers in Pharmacology</i> , 2021, 12, 655101.	1.6	5
1265	Anti-adalimumab Antibodies in Patients with Non-infectious Ocular Inflammatory Disease: A Case Series. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1721-1725.	1.0	3
1266	Efficacy and Safety of Polyphenols for Osteoarthritis Treatment: a Meta-Analysis. <i>Clinical Therapeutics</i> , 2021, 43, e241-e253.e2.	1.1	0
1267	GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey. <i>Immunotherapy</i> , 2021, 13, 841-850.	1.0	6
1268	Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2021, 38, 4885-4899.	1.3	3
1269	Guideline for the evaluation of prescription appropriateness. <i>Annals of Translational Medicine</i> , 2021, 9, 1352-1352.	0.7	1
1270	Adherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies. <i>American Journal of Health-System Pharmacy</i> , 2021, , .	0.5	1

#	ARTICLE	IF	CITATIONS
1271	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2. <i>Annals of Internal Medicine</i> , 2021, 174, 1572-1585.	2.0	273
1272	Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis. <i>JAMA Network Open</i> , 2021, 4, e2119400.	2.8	29
1273	Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2022, 49, 104-109.	1.0	5
1274	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.5	104
1275	Has the incidence of total joint arthroplasty in rheumatoid arthritis decreased in the era of biologics use? A population-based cohort study. <i>Rheumatology</i> , 2022, 61, 1819-1830.	0.9	13
1276	Ambulatory Medication Safety: Vaccination and Laboratory Screening for Patients on Immunomodulatory Therapies. <i>Arthritis Care and Research</i> , 2021, , .	1.5	0
1277	Active rheumatoid arthritis in a mouse model is not an independent risk factor for periprosthetic joint infection. <i>PLoS ONE</i> , 2021, 16, e0250910.	1.1	4
1278	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e60-e75.	2.9	126
1279	The effect of nurse-led care on fatigue in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomised controlled studies. <i>Journal of Clinical Nursing</i> , 2022, 31, 832-842.	1.4	5
1280	Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-186.	0.4	1
1281	Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. <i>Arthritis Research and Therapy</i> , 2021, 23, 220.	1.6	2
1282	Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study. <i>BioMed Research International</i> , 2021, 2021, 1-13.	0.9	6
1283	Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry. <i>Arthritis Care and Research</i> , 2023, 75, 231-239.	1.5	6
1284	Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. <i>Clinical Rheumatology</i> , 2022, 41, 63-73.	1.0	4
1285	Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder. <i>Annals of Hematology</i> , 2021, 100, 2849-2850.	0.8	1
1286	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1306-1315.	1.5	8
1287	Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 469-479.	0.5	30
1288	Protease Activated Receptors and Arthritis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9352.	1.8	9

#	ARTICLE	IF	CITATIONS
1289	Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA. Inflammatory Bowel Diseases, 2022, 28, 1012-1018.	0.9	8
1290	Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study. Arthritis Care and Research, 2021, 73, 1322-1331.	1.5	12
1291	Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors. Scientific Reports, 2021, 11, 18013.	1.6	1
1292	PROTECTIVE EFFECT OF THE RAMELTEON, A MELATONIN AGONIST, AGAINST METHOTREXATE-INDUCED BONE-TOXICITY. Sileyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 0, , .	0.0	0
1293	Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2021, 80, 1255-1265.	0.5	77
1294	Differentiating Psoriatic Arthritis from Osteoarthritis and Rheumatoid Arthritis: A Narrative Review and Guide for Advanced Practice Providers. Rheumatology and Therapy, 2021, 8, 1493-1517.	1.1	13
1295	Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. Alzheimer's and Dementia, 2022, 18, 1248-1259.	0.4	7
1296	Methotrexate Intolerance. Orthopaedic Nursing, 2021, 40, 316-321.	0.2	2
1297	Tapering of disease-modifying antirheumatic drugs: an overview for daily practice. Lancet Rheumatology, The, 2021, 3, e659-e670.	2.2	3
1298	Genome-wide association study of liver enzyme elevation in rheumatoid arthritis patients starting methotrexate. Pharmacogenomics, 2021, 22, 973-982.	0.6	6
1299	Risk of Serious Infection With Low-dose Glucocorticoids in Patients With Rheumatoid Arthritis. Epidemiology, 2022, 33, 65-74.	1.2	5
1300	Efficacy and Safety of Metformin Use in Rheumatoid Arthritis: A Randomized Controlled Study. Frontiers in Pharmacology, 2021, 12, 726490.	1.6	27
1302	Importance of Shared Treatment Goal Discussions in Rheumatoid Arthritis—A Cross-Sectional Survey: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed. ACR Open Rheumatology, 2021, 3, 870-878.	0.9	6
1303	Risk of Heart Failure in Rheumatoid Arthritis Patients Treated with Tumor Necrosis Factor Inhibitors. Clinical Pharmacology and Therapeutics, 2021, 110, 1595-1603.	2.3	5
1304	Topical nanocarriers for management of Rheumatoid Arthritis: A review. Biomedicine and Pharmacotherapy, 2021, 141, 111880.	2.5	42
1305	The Role of Bioactive Compounds of Nigella sativa in Rheumatoid Arthritis Therapy—Current Reports. Nutrients, 2021, 13, 3369.	1.7	11
1306	Salazosulfapyridine-induced agranulocytosis in a patient on chronic hemodialysis with seronegative spondyloarthritis: a case report. Renal Replacement Therapy, 2021, 7, .	0.3	1
1307	Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. Arthritis Research and Therapy, 2021, 23, 236.	1.6	10

#	ARTICLE	IF	CITATIONS
1308	Genetic Polymorphisms of GGH and ABCC2 Are Associated with Methotrexate Intolerance in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4070.	1.0	2
1309	Identification of Circular RNAs Circ_0005008 and Circ_0005198 in Plasma as Novel Biomarkers for New-Onset Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2021, 12, 722017.	1.6	13
1311	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. <i>Rheumatology and Therapy</i> , 2021, 8, 1661-1675.	1.1	10
1312	Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With <scp>Metaâ€Analysis</scp>. <i>Arthritis Care and Research</i> , 2023, 75, 260-271.	1.5	7
1313	The first case of methotrexateâ€associated lymphoproliferative disorder presenting as follicular Tâ€cell lymphoma. <i>Pathology International</i> , 2021, 71, 765-770.	0.6	2
1314	Musculoskeletal Ultrasound of Rheumatologic Conditions. <i>Advances in Clinical Radiology</i> , 2021, 3, 169-182.	0.1	1
1315	Pancytopenia after Low-Dose Methotrexate Therapy in Two Hemodialysis Patients with Rheumatoid Arthritis. <i>American Journal of the Medical Sciences</i> , 2022, 363, 185-190.	0.4	1
1316	Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. , 2021, 8, 120-129.		5
1317	Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2021, 8, 1637-1649.	1.1	16
1318	Rheumatoid arthritis treatment using hydroxychloroquine and methotrexate co-loaded nanomicelles: In vivo results. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 206, 111952.	2.5	13
1319	Administration of COVID-19 vaccines in immunocompromised patients. <i>International Immunopharmacology</i> , 2021, 99, 108021.	1.7	51
1320	Prendre un comprimÃ© ou me faire une injection? Point de vue des patients quant au choix des traitements de fond (DMARD) dans la polyarthrite rhumatoÃ©de (PR). <i>Revue Du Rhumatisme (Edition) Tj ETQq1 1 00784314 rgBT /Ove</i>		
1321	A review of liquid biopsy as a tool to assess epigenetic, cfDNA and miRNA variability as methotrexate response predictors in patients with rheumatoid arthritis. <i>Pharmacological Research</i> , 2021, 173, 105887.	3.1	14
1322	Autoimmune diseases: Sex and gender evidence in rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis. , 2021, , 53-73.		1
1323	Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001511.	1.8	12
1324	Excess mortality persists in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 364-372.	0.9	23
1325	Low-dose rituximab protocol in rheumatoid arthritisâ€outcome and economic impact. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa077.	0.3	6
1326	Blockade of translationally controlled tumor protein attenuated the aggressiveness of fibroblast-like synoviocytes and ameliorated collagen-induced arthritis. <i>Experimental and Molecular Medicine</i> , 2021, 53, 67-80.	3.2	11

#	ARTICLE	IF	CITATIONS
1327	Safety and efficacy of interleukin inhibitors in elderly patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis. <i>Arhiv Za Farmaciju</i> , 2021, 71, 101-119.	0.2	1
1328	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 848-858.	0.5	123
1329	miR-34a in extracellular vesicles from bone marrow mesenchymal stem cells reduces rheumatoid arthritis inflammation via the cyclin I/ATM/ATR/p53 axis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1896-1910.	1.6	41
1330	Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis. <i>Pharmacotherapy</i> , 2018, 38, 172-180.	1.2	6
1332	Arzneiverordnungen 2016 im <i>Ärztberblick</i> . , 2017, , 3-32.		7
1333	Antirheumatika und Antiphlogistika. , 2018, , 423-434.		1
1334	Evaluation and monitoring of established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101480.	1.4	2
1335	Immunization Strategies to Span the Spectrum of Immunocompromised Adults. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1530-1548.	1.4	5
1336	Efecto del tratamiento antirresortivo y osteoformador en las erosiones <i>3</i> seas en la artritis reumatoide. <i>Medicina Clínica</i> , 2020, 154, 358-365.	0.3	2
1337	Overview of the Associations Between Cancer and Rheumatic Disease. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 417-427.	0.8	2
1338	Disparities in Rheumatoid Arthritis Care and Health Service Solutions to Equity. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 685-692.	0.8	9
1339	Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. <i>Scientific Reports</i> , 2020, 10, 21907.	1.6	18
1341	OUP accepted manuscript. <i>Rheumatology</i> , 2018, 57, 1135-1144.	0.9	60
1344	Development and validation of an interpretive guide for PROMIS scores. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 16.	0.9	86
1345	Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature. <i>American Journal of Case Reports</i> , 2018, 19, 582-588.	0.3	7
1346	Treatment of Type II Collagen-Induced Rat Rheumatoid Arthritis Model by Interleukin 10 (IL10)-Mesenchymal Stem Cells (BMSCs). <i>Medical Science Monitor</i> , 2019, 25, 2923-2934.	0.5	17
1347	Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments. <i>F1000Research</i> , 2016, 5, 2019.	0.8	4
1348	Role of glucocorticoid-induced leucine zipper (GILZ) in inflammatory bone loss. <i>PLoS ONE</i> , 2017, 12, e0181133.	1.1	9

#	ARTICLE	IF	CITATIONS
1349	Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids. PLoS ONE, 2020, 15, e0244239.	1.1	4
1350	VACCINATION IN RHEUMATIC DISEASES: AN ALLY OR AN ENEMY?. Nauchno-Prakticheskaya Revmatologiya, 2018, 56, 401-404.	0.2	7
1351	INVESTIGATION OF IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Nauchno-Prakticheskaya Revmatologiya, 2018, 56, 433-438.	0.2	7
1352	Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya, 2019, 57, 8-16.	0.2	45
1353	Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I). Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 62-79.	0.2	17
1354	Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study. Nagoya Journal of Medical Science, 2019, 81, 571-585.	0.6	4
1355	Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment. Pathogens and Immunity, 2020, 5, 34.	1.4	9
1356	ANTI-HEPATOTOXIC AND SYNERGISTIC EFFECTS OF SESAME OIL WITH METHOTREXATE IN ADJUVANT INDUCED ARTHRITIS. Egyptian Journal of Biochemistry and Molecular Biology, 2017, 35, 77-92.	0.4	3
1357	Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors. Current Medicinal Chemistry, 2019, 26, 2823-2843.	1.2	20
1358	Immune Mediated Necrotizing Myopathy: Where do we Stand?. Current Rheumatology Reviews, 2018, 15, 23-26.	0.4	9
1359	Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept. Current Rheumatology Reviews, 2020, 16, 61-66.	0.4	9
1360	Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results. Open Rheumatology Journal, 2018, 12, 323-331.	0.1	2
1361	Primary Central Nervous System Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis: Case Report and Review of Literature. NMC Case Report Journal, 2020, 7, 121-127.	0.2	11
1362	A Mobile App With Optical Imaging for the Self-Management of Hand Rheumatoid Arthritis: Pilot Study. JMIR MHealth and UHealth, 2018, 6, e12221.	1.8	45
1363	Acceptance, Usage, and Barriers of Electronic Patient-Reported Outcomes Among German Rheumatologists: Survey Study. JMIR MHealth and UHealth, 2020, 8, e18117.	1.8	35
1364	Capturing a Patient-Reported Measure of Physical Function Through an Online Electronic Health Record Patient Portal in an Ambulatory Clinic: Implementation Study. JMIR Medical Informatics, 2018, 6, e31.	1.3	14
1365	Treatment Update on Rheumatoid Arthritis. The Japanese Journal of Rehabilitation Medicine, 2018, 55, 334-339.	0.0	1
1366	Tuberculosis in patient with psoriasis receiving biologic therapy – case report. Polish Annals of Medicine, 0, , .	0.3	1

#	ARTICLE	IF	CITATIONS
1367	A survey to evaluate the implementation of vaccine recommendations among rheumatologists practicing in Greece. <i>Mediterranean Journal of Rheumatology</i> , 2017, 28, 41-47.	0.3	3
1368	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 27-37.	0.3	13
1369	Exercise participation has increased in patients with Rheumatoid Arthritis: A cross-sectional comparison between two Dutch RA cohorts. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 199-206.	0.3	2
1370	<i>Pneumocystis Jirovecii</i> Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 167.	0.3	6
1371	Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 129.	0.3	16
1372	Predicting Imaging Remission in Rheumatoid Arthritis: a Case-control Ultrasound Study. <i>Journal of Korean Medical Science</i> , 2020, 35, e260.	1.1	2
1373	Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, 87-98.	0.2	8
1374	New guidelines for treatment of rheumatoid arthritis. <i>Interni Medicina Pro Praxi</i> , 2018, 20, 62-67.	0.0	1
1376	Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 4055-4075.	1.4	51
1377	Development of a Patient-centered Quality Measurement Framework for Measuring, Monitoring, and Optimizing Rheumatoid Arthritis Care in Canada. <i>Journal of Rheumatology</i> , 2021, 48, 326-334.	1.0	7
1378	Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 669-677.	0.7	13
1379	Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 465-473.	0.7	8
1380	The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 41-59.	0.7	20
1381	Alteration of Cellular and Humoral Immunity by the Blockage of P2y11 Gene Attenuates on the Rheumatoid Arthritis. <i>International Journal of Pharmacology</i> , 2018, 14, 873-878.	0.1	2
1382	The Practice Guideline for Vaccinating Korean Patients with Autoimmune Inflammatory Rheumatic Disease. <i>Infection and Chemotherapy</i> , 2020, 52, 252.	1.0	14
1383	The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 695-703.	0.6	26
1384	The Impact of the Amendment of the Korean National Health Insurance Reimbursement Criteria for Anti-tumor Necrosis Factor- α Agents on Treatment Pattern, Clinical Response and Persistence in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatic Diseases</i> , 2020, 27, 159-167.	0.4	5
1385	Comparison of the Effect of Disease-Modifying Antirheumatic Drugs Alone or in Combination with Biologic Drugs in the Outcome of Patients with Rheumatoid Arthritis. <i>Advanced Biomedical Research</i> , 2019, 8, 32.	0.2	2

#	ARTICLE	IF	CITATIONS
1386	Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review. <i>Avicenna Journal of Medicine</i> , 2018, 8, 34-36.	0.3	18
1387	Pleuropulmonary manifestation in patients with rheumatoid arthritis in Saudi Arabia. <i>Annals of Thoracic Medicine</i> , 2017, 12, 266.	0.7	9
1388	A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate. <i>Indian Journal of Rheumatology</i> , 2018, 13, 84.	0.2	3
1389	Comorbidity in rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2016, 146, w14290.	0.8	29
1390	Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?. <i>Annals of Dermatology</i> , 2019, 31, 495.	0.3	5
1391	Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms. <i>Reumatologia</i> , 2020, 58, 390-400.	0.5	8
1392	Baricitinib for the treatment of rheumatoid arthritis. <i>Reumatologia</i> , 2020, 58, 407-415.	0.5	15
1393	A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment. <i>European Journal of Rheumatology</i> , 2018, 5, 111-114.	1.3	4
1394	Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain. <i>European Journal of Rheumatology</i> , 2020, 7, 149-157.	1.3	4
1395	Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. <i>Intestinal Research</i> , 2020, 18, 18-33.	1.0	19
1396	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. <i>Drugs in Context</i> , 2020, 9, 1-15.	1.0	6
1397	Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report. , 2020, 24, .		8
1398	Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. <i>Rheumatology</i> , 2022, 61, 2783-2791.	0.9	4
1399	A Medical Records Review Study Assessing Safety of Zoster Vaccine Recombinant, Adjuvanted in Patients With Rheumatic Disease. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e528-e531.	0.5	2
1401	Vaccine considerations for adult dermatology patients on immunosuppressive and immunomodulatory therapies: a clinical review. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	4
1402	Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection. <i>Open Access Rheumatology: Research and Reviews</i> , 2021, Volume 13, 315-323.	0.8	4
1403	Management of Rheumatoid Arthritis: An Overview. <i>Cells</i> , 2021, 10, 2857.	1.8	228
1404	Ischemic Heart Disease and Rheumatoid Arthritis – Two Conditions, the Same Background. <i>Life</i> , 2021, 11, 1042.	1.1	14

#	ARTICLE	IF	CITATIONS
1405	Identification of Five Quality Needs for Rheumatology (Text Analysis and Literature Review). <i>Frontiers in Medicine</i> , 2021, 8, 757102.	1.2	3
1406	Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1242-1250.	1.6	9
1407	Effective factors on Sharp Score in patients with rheumatoid arthritis: a retrospective study. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 865.	0.8	3
1408	Dramatic Effect of Tofacitinib on TNF-Inhibitor Resistant Synovitis: A Case Report. <i>Rheumatology (Sunnyvale, Calif)</i> , 2016, 06, .	0.3	0
1409	An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1092-1106.	0.5	0
1411	Frequency and Factors Associated with Biologic Monotherapy in Patients with Rheumatoid Arthritis; Experience from an Argentine Center. <i>MOJ Orthopedics & Rheumatology</i> , 2016, 6, .	0.2	0
1412	Antirheumatika und Antiphlogistika. , 2017, , 373-384.		0
1413	Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. , 2017, , 389-400.		0
1414	Lupus and Lupus Overlap Diseases: Emerging Therapies. , 2017, , 474-494.		0
1415	Rehabilitation Medicine and Treatment for the Patient with Rheumatoid Arthritis. <i>The Japanese Journal of Rehabilitation Medicine</i> , 2017, 54, 980-985.	0.0	0
1416	Vaccines and Biologics. , 2017, , .		0
1417	Predictor of the Simplified Disease Activity Index 50 (SDAI 50) at Month 3 of bDMARD Treatment in Patients with Long-Established Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , 2017, 11, 106-112.	0.1	1
1418	What Contributes to the Progression of Rheumatoid Arthritis?. <i>Texila International Journal of Clinical Research</i> , 2017, 4, 73-83.	0.0	0
1419	Chapter 26: Arthritis. , 2017, , .		0
1420	Long-Term Outcomes in Puerto Ricans with Rheumatoid Arthritis (RA) Receiving Early Treatment with Disease-Modifying Anti-Rheumatic Drugs using the American College of Rheumatology Definition of Early RA. <i>Open Rheumatology Journal</i> , 2017, 11, 136-144.	0.1	4
1421	Application of LLLT and Medications to Rheumatoid Arthritis. <i>Nippon Laser Igakkaishi</i> , 2018, 38, 439-445.	0.0	0
1423	ASSOCIATION OF PLATELET INDICES WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2018, 5, 95-100.	0.0	1
1424	Detrimental Effects of Endovascular Intervention in Active Rheumatoid Vasculitis. <i>Vascular Specialist International</i> , 2018, 34, 39-43.	0.2	2

#	ARTICLE	IF	CITATIONS
1425	VACCINATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS AND PROSPECTS. Nauchno-Prakticheskaya Revmatologiya, 2018, 56, 373-379.	0.2	2
1426	Association Assessment of Peptidylarginine Deiminase Type 4 (PADI4) rs1748033 polymorphism and susceptibility to rheumatoid arthritis in Gorgan, Northeast of Iran. Journal of Clinical and Basic Research, 2018, 2, 11-16.	0.1	0
1428	Predictors of Remission Maintenance after Etanercept Tapering or Withdrawal in Early Rheumatoid Arthritis: Results from the PRIZE Study. Open Rheumatology Journal, 2018, 12, 179-188.	0.1	1
1430	Antirheumatika und Antiphlogistika. , 2019, , 557-572.		0
1431	A 53-Year-Old Female with Psoriasis and Breast Cancer. , 2019, , 103-108.		0
1432	A IL-6 Receptor Blocker for Rheumatoid Arthritis—Sarilumab. Pharmacy Information, 2019, 08, 1-8.	0.1	0
1436	Romatoid Artritli Kadın Hastalarda Ağrı Ekstremitelerde Hangi Kasların GABAergic Aktivitesi, Fonksiyonellik ve Engellilik ile İlişkilidir?. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2019, 45, 137-144.	0.2	0
1437	Vaccination against yellow fever in rheumatic diseases. Sovremennaya Revmatologiya, 2019, 13, 99-103.	0.1	0
1438	ANALGESIC, ANTI-INFLAMMATORY AND ANTI-ARTHRITIC EFFECTS OF SIDDHA HERBO-MINERAL FORMULATION "THIRILOGA CHINDHAMANI PILLS"™ IN ANIMAL MODELS. British Journal of Medical and Health Research, 2019, 6, 32-47.	0.1	0
1440	Role of physiotherapeutic factors in improving peripheral hemodynamics in patients with rheumatoid arthritis. Medical Alphabet, 2019, 1, 44-48.	0.0	1
1442	Pacientes inmunodeprimidos: definición y precauciones especiales. FMC Formacion Medica Continuada En Atencion Primaria, 2019, 26, 548-562.	0.0	0
1443	Transcultural Lifestyle Medicine. , 2020, , 233-248.		3
1444	Safety and tolerability of a single dose T0001 in Chinese healthy adult volunteers: a first-in-human ascending dose study. Brazilian Journal of Pharmaceutical Sciences, 0, 56, .	1.2	0
1445	Serum COX-2 and FOXO3a in patients with rheumatoid arthritis and correlation with disease activity. Experimental and Therapeutic Medicine, 2020, 20, 910-916.	0.8	0
1446	The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis. Sovremennaya Revmatologiya, 2020, 14, 104-109.	0.1	0
1447	Drug screening and identification of key candidate genes and pathways of rheumatoid arthritis. Molecular Medicine Reports, 2020, 22, 986-996.	1.1	2
1448	THU0104...THE GUT MICROBIOTA AND ITS RELEVANCE TO PERIPHERAL T REGULATORY CELLS AND T HELPER 17 IN PATIENTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 266.1-266.	0.5	0
1449	SAT0103...THE EFFECT OF BODYWEIGHT ON RESPONSE TO INTRAVENOUS OR SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 985.2-985.	0.5	4

#	ARTICLE	IF	CITATIONS
1450	Treatment of systemic lupus erythematosus. Australian Prescriber, 2020, 43, 85-90.	0.5	8
1451	THU0106â€¦PREDICTORS OF FLARE IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY. Annals of the Rheumatic Diseases, 2020, 79, 267.1-267.	0.5	0
1452	ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL). Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 262-267.	0.2	7
1453	Simple Simultaneous Assay of Methotrexate and Non-Steroidal Anti-Inflammatory Drugs by HPLC. Chromatography, 2020, 41, 79-84.	0.8	3
1454	Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection. Turkish Journal of Gastroenterology, 2020, 31, 522-528.	0.4	5
1455	Low-dose Methotrexate Toxicity in the Setting of Vancomycin-induced Acute Kidney Injury. American Journal of Medical Case Reports, 2020, 8, 206-209.	0.1	2
1458	A Bridge Too Far? Realâ€WWorld Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort. ACR Open Rheumatology, 2022, 4, 57-64.	0.9	8
1459	Methotrexate related cutaneous adverse drug reactions: a systematic literature review. Journal of Basic and Clinical Physiology and Pharmacology, 2021, .	0.7	4
1460	Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis. International Journal of Molecular Sciences, 2021, 22, 11592.	1.8	36
1461	Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab. PLoS ONE, 2020, 15, e0241189.	1.1	5
1462	Antirheumatika und Antiphlogistika. , 2020, , 421-436.		2
1465	Rheumatoid Arthritis and Related Disorders. , 2020, , 1-20.		0
1466	Chapter 25: Rheumatology/Musculoskeletal Pain: Azathioprine/TPMT, Celecoxib/CYP2C9 Case. , 2020, , .		0
1467	Rheumatoid arthritis : a joint venture. South African General Practitioner, 2020, 1, 193-195.	0.0	0
1468	Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity. Korean Journal of Internal Medicine, 2020, 35, 231-239.	0.7	1
1469	Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis. Mediterranean Journal of Rheumatology, 2020, 31, 163.	0.3	1
1470	Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects. Translational and Clinical Pharmacology, 2020, 28, 160.	0.3	2
1471	GLUCOCORTICOIDS AND RHEUMATOID ARTHRITIS. Bulletin of Problems Biology and Medicine, 2020, 4, 17.	0.0	1

#	ARTICLE	IF	CITATIONS
1472	Guidelines on the Role of Nursing in Patients with Chronic Inflammatory Arthritis: Do we "AGREE"? Mediterranean Journal of Rheumatology, 2020, 31, 306.	0.3	0
1473	Platelet Rich Plasma for Treatment of Rheumatoid Arthritis: Case Series and Review of Literature. Case Reports in Rheumatology, 2020, 2020, 1-7.	0.2	20
1475	Correlation between NLR, PLR, and LMR and Disease Activity, Efficacy Assessment in Rheumatoid Arthritis. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-6.	0.5	12
1476	Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. Cells, 2021, 10, 3017.	1.8	63
1477	ASP7266, a Novel Antibody against Human Thymic Stromal Lymphopoietin Receptor for the Treatment of Allergic Diseases. Journal of Pharmacology and Experimental Therapeutics, 2022, 380, 26-33.	1.3	8
1478	Pathogenetic significance of the use of a humanized monoclonal antibody to the IL-6 receptor (tocilizumab) in the treatment of immuno-inflammatory diseases. Meditsinskiy Sovet, 2020, , 102-112.	0.1	1
1479	The Practice Guideline for Vaccinating Korean Patients With Autoimmune Inflammatory Rheumatic Disease. Journal of Rheumatic Diseases, 2020, 27, 182-202.	0.4	2
1480	Sustained Remission of Lupus Panniculitis Treated With Hydroxychloroquine in a Patient With Crohn's Disease: A Case Report. Cureus, 2020, 12, e10455.	0.2	0
1481	Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome. Rheumatology, 2021, 60, 2714-2724.	0.9	3
1483	Competition Heats Up in Rheumatoid Arthritis and Other Autoimmune Conditions. American Health and Drug Benefits, 2016, 9, 155-8.	0.5	1
1484	New pharmacological strategies in rheumatic diseases. Journal of Medicine and Life, 2016, 9, 227-234.	0.4	8
1485	Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends. American Health and Drug Benefits, 2017, 10, 27-36.	0.5	22
1486	Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States. American Health and Drug Benefits, 2017, 10, 42-49.	0.5	15
1487	Discovering adverse drug events combining spontaneous reports with electronic medical records: a case study of conventional DMARDs and biologics for rheumatoid arthritis. AMIA Summits on Translational Science Proceedings, 2017, 2017, 95-103.	0.4	9
1488	Interleukin-6 from subchondral bone mesenchymal stem cells contributes to the pathological phenotypes of experimental osteoarthritis. American Journal of Translational Research (discontinued), 2018, 10, 1143-1154.	0.0	14
1489	Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry. American Health and Drug Benefits, 2018, 11, 148-158.	0.5	7
1490	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy. American Health and Drug Benefits, 2018, 11, 192-202.	0.5	9
1491	Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis. American Health and Drug Benefits, 2019, 12, 30-38.	0.5	4

#	ARTICLE	IF	CITATIONS
1492	Correlations between the polymorphism of +869T/C in TGF- β 1 and rheumatoid arthritis. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2019, 19, 127-132.	0.1	3
1493	Recommendations for Initiating Systemic Therapy in Patients with Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2019, 12, 13-26.	0.1	4
1494	Serious and Opportunistic Infections in Elderly Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 593-605.	0.2	2
1495	Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis. <i>American Health and Drug Benefits</i> , 2019, 12, 400-409.	0.5	2
1496	The P2X7 receptor (P2X7R)-specific antagonist A804598 inhibits inflammatory reaction in human fibroblast-like synoviocytes. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 45-53.	0.0	6
1497	Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1023-1030.	0.5	8
1498	Anxiety impacts rheumatoid arthritis symptoms and health-related quality of life even at low levels. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1176-1181.	0.4	1
1499	Systemic pharmacological verification of Baixianfeng decoction regulating TNF-PI3K-Akt-NF- κ B pathway in treating rheumatoid arthritis. <i>Bioorganic Chemistry</i> , 2022, 119, 105519.	2.0	9
1500	Clinical features of Behçet's disease patients with joint symptoms in Japan: A national multicenter study. <i>Modern Rheumatology</i> , 2022, 32, 1146-1152.	0.9	1
1501	Blood MALT1, Th1, and Th17 cells are dysregulated, inter-correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24112.	0.9	6
1502	Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1530-1539.	0.9	8
1503	Cardiac Sarcoidosis: When and How to Treat Inflammation. <i>Cardiac Failure Review</i> , 2021, 7, e17.	1.2	18
1504	Risk of hydroxychloroquine retinopathy in the community. <i>Rheumatology</i> , 2022, 61, 3172-3179.	0.9	5
1505	Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review. <i>Advances in Therapy</i> , 2022, 39, 75-93.	1.3	4
1506	Surgical treatment of wrist joint dysfunction in rheumatoid arthritis: A report of two cases. <i>Modern Rheumatology Case Reports</i> , 2021, . .	0.3	1
1507	Simultaneous measurement of upadacitinib and methotrexate by UPLC-MS/MS and its pharmacokinetic application in rats. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1188, 123071.	1.2	1
1508	Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower [®] Registry. <i>Rheumatology and Therapy</i> , 2022, 9, 207-221.	1.1	12
1509	Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. <i>Rheumatology and Therapy</i> , 2022, 9, 49-71.	1.1	3

#	ARTICLE	IF	CITATIONS
1511	Understanding the Role and Uses of Alternative Therapies for the Management of Rheumatoid Arthritis. <i>Current Rheumatology Reviews</i> , 2022, 18, 89-100.	0.4	3
1512	Microfluidic-assisted electrospinning, an alternative to coaxial, as a controlled dual drug release system to treat inflammatory arthritic diseases. <i>Materials Science and Engineering C</i> , 2022, 134, 112585.	3.8	6
1513	Use of protocol-driven medication refills by pharmacists decreases rheumatologist in-basket work and improves rheumatologist satisfaction. <i>BMJ Open Quality</i> , 2022, 11, e001566.	0.4	3
1514	Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). <i>Clinical Rheumatology</i> , 2022, 41, 1045-1055.	1.0	3
1515	Structure-based simulated scanning of rheumatoid arthritis inhibitors: 2D-QSAR, 3D-QSAR, docking, molecular dynamics simulation, and lipophilicity indices calculation. <i>Scientific African</i> , 2022, 15, e01088.	0.7	5
1516	Yields of mesenchymal stromal cells from synovial fluid reflect those from synovium in patients with rheumatoid arthritis. <i>Tissue and Cell</i> , 2022, 75, 101727.	1.0	3
1517	Vaccination in rheumatic disease patients: results of a pilot quality improvement program. <i>Reumatologia</i> , 2021, 59, 362-366.	0.5	0
1518	Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 206-213.	0.5	25
1519	Rheumatoid Arthritis and Related Disorders. , 2022, , 1615-1634.		0
1520	The pharmacotherapeutics of sarcoidosis. <i>Expert Review of Clinical Pharmacology</i> , 2022, , 1-14.	1.3	1
1521	Patient Perceptions and Preferences Regarding Telemedicine for Autoimmune Rheumatic Diseases Care During the COVID-19 Pandemic. <i>Arthritis Care and Research</i> , 2022, 74, 1049-1057.	1.5	10
1522	Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome. <i>World Journal of Clinical Oncology</i> , 2022, 13, 49-61.	0.9	0
1523	Inter-alpha-trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24231.	0.9	8
1524	Incidence of complications of herpes zoster in individuals on immunosuppressive therapy: A register-based population study. <i>Journal of Infection</i> , 2022, 84, 531-536.	1.7	2
1525	The Hamburg Spondylodiscitis Assessment Score (HSAS) for Immediate Evaluation of Mortality Risk on Hospital Admission. <i>Journal of Clinical Medicine</i> , 2022, 11, 660.	1.0	10
1526	Influenza Vaccine Hesitancy and Its Determinants Among Rheumatology Patients. <i>ACR Open Rheumatology</i> , 2022, 4, 352-362.	0.9	4
1527	Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. <i>Medicine (United States)</i> , 2022, 101, e28501.	0.4	23
1528	Integrating molecular interactions and gene expression to identify biomarkers to predict response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients. <i>Technology and Health Care</i> , 2022, , 1-7.	0.5	1

#	ARTICLE	IF	CITATIONS
1529	Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1246.	1.8	20
1530	Incidence and risk factors for vertebral fracture in rheumatoid arthritis: an update meta-analysis. <i>Clinical Rheumatology</i> , 2022, 41, 1313-1322.	1.0	4
1531	Research progress of the application of mesenchymal stem cells in chronic inflammatory systemic diseases. <i>Stem Cell Research and Therapy</i> , 2022, 13, 1.	2.4	59
1532	Total Hip Replacement in Patients with Rheumatoid Arthritis: Trends in Incidence and Complication Rates Over 35 Years. <i>Rheumatology and Therapy</i> , 2022, 9, 565-580.	1.1	8
1533	Effects of e-health interventions on health outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Journal of Clinical Nursing</i> , 2022, , .	1.4	2
1534	Tofacitinib and risk of cardiovascular outcomes: results from the Safety of Tofacitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 798-804.	0.5	76
1535	Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case-control study. <i>RMD Open</i> , 2022, 8, e001892.	1.8	8
1536	Applying Early Intervention Strategies to Autoimmune Skin Diseases. Is the Window of Opportunity Preclinical? A Dermato-Rheumatology Perspective. <i>Journal of Investigative Dermatology</i> , 2022, 142, 944-950.	0.3	7
1537	Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. <i>Reumatologia Clínica (English Edition)</i> , 2022, 18, 33-41.	0.2	0
1538	Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. <i>Rheumatology</i> , 2022, 61, 3930-3938.	0.9	13
1539	Characteristics of Pooled Wharton's Jelly Mesenchymal Stromal Cells (WJ-MSCs) and their Potential Role in Rheumatoid Arthritis Treatment. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 1851-1864.	1.7	5
1540	Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels. <i>Scientific Reports</i> , 2022, 12, 1877.	1.6	4
1541	Long non-coding RNA TSPEAR Antisense RNA 2 is downregulated in rheumatoid arthritis and inhibits the apoptosis of fibroblast-like synoviocytes by downregulating microRNA-212-3p (miR-212-3p). <i>Bioengineered</i> , 2022, 13, 4166-4172.	1.4	4
1542	Patient Goals for Living with Rheumatoid Arthritis: A Qualitative Study. <i>Clinical Nursing Research</i> , 2023, 32, 40-48.	0.7	1
1543	Oral administration of East Asian herbal medicine for rheumatoid arthritis. <i>Medicine (United States)</i> , 2022, 101, e28819.	0.4	2
1544	Safety of Recombinant Zoster Vaccine in Rheumatology Patients. <i>Southern Medical Journal</i> , 2022, 115, 125-128.	0.3	2
1545	Implementing a Treat-to-Target Approach for Rheumatoid Arthritis During the COVID-19 Pandemic: Results of a Virtual Learning Collaborative Program. <i>Arthritis Care and Research</i> , 2022, 74, 572-578.	1.5	1
1546	Usefulness of noninvasive diagnostic procedures for assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2022, 42, 631-638.	1.5	5

#	ARTICLE	IF	CITATIONS
1547	Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA. <i>Rheumatology and Therapy</i> , 2022, 9, 465-480.	1.1	9
1548	Menopausal hormone therapy in rheumatoid arthritis. <i>Russian Journal of Human Reproduction</i> , 2022, 28, 149.	0.1	1
1550	Ultrasound scoring systems for evaluation of synovitis and tenosynovitis in patients with rheumatoid arthritis. <i>Journal of Medical Ultrasound</i> , 2022, 30, 3.	0.2	1
1551	Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept. <i>Arthritis Research and Therapy</i> , 2022, 24, 47.	1.6	7
1552	JAK inhibitors in crohnâ€™s disease: ready to go?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 145-161.	1.9	2
1553	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 861-867.	0.5	35
1555	Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study. <i>F1000Research</i> , 2022, 11, 187.	0.8	0
1556	To Contrast or Not to Contrast? On the Role of Contrast Enhancement in Hand MRI Studies of Patients with Rheumatoid Arthritis. <i>Diagnostics</i> , 2022, 12, 465.	1.3	4
1557	Development of Open-Angle Glaucoma in Adults With Seropositive Rheumatoid Arthritis in Korea. <i>JAMA Network Open</i> , 2022, 5, e223345.	2.8	7
1558	Autoimmune disease and sickle cell anaemia: â€™Intersecting pathways and differential diagnosisâ€™. <i>British Journal of Haematology</i> , 2022, 197, 518-528.	1.2	8
1559	A narrative review of the role of the Notch signaling pathway in rheumatoid arthritis. <i>Annals of Translational Medicine</i> , 2022, 10, 371-371.	0.7	6
1560	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. <i>Arthritis and Rheumatology</i> , 2022, 74, 570-585.	2.9	11
1561	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. <i>Arthritis Care and Research</i> , 2022, 74, 505-520.	1.5	15
1562	TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area. <i>Scientific Reports</i> , 2022, 12, 4003.	1.6	11
1563	Towards a Better Implementation of Treat-to-Target Strategy in Rheumatoid Arthritis: A Comparison of Two Real-World Cohorts. <i>Rheumatology and Therapy</i> , 2022, 9, 907-917.	1.1	7
1564	Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. <i>Rheumatology</i> , 2022, 61, 4232-4244.	0.9	12
1565	Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study. <i>RMD Open</i> , 2022, 8, e002110.	1.8	5
1566	Factors influencing the Sharp score of 1057 patients with rheumatoid arthritis and anemia: a retrospective study. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210885.	0.4	3

#	ARTICLE	IF	CITATIONS
1567	Treating-to-target in rheumatology: Theory and practice. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101735.	1.4	12
1568	The Microbiome in Osteoarthritis: a Narrative Review of Recent Human and Animal Model Literature. <i>Current Rheumatology Reports</i> , 2022, 24, 139-148.	2.1	12
1569	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <sc>Pharmacogenomics-Driven</sc> Machine Learning Approach. <i>Arthritis Care and Research</i> , 2022, 74, 879-888.	1.5	15
1570	Time-integrated Cumulative Parameters Predictive of Radiographic Progression of Rheumatoid Arthritis: Real-world Data From a Prospective Single-center Cohort. <i>Journal of Rheumatic Diseases</i> , 2022, 29, 98-107.	0.4	1
1571	Development and validation of a self-administered questionnaire measuring essential knowledge in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2022, 42, 1785-1795.	1.5	4
1572	The cardiac effects of hydroxychloroquine in immune-mediated rheumatologic diseases. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2022, 35, 51-53.	0.1	0
1573	Vaccinations in Patients with Rheumatic Disease. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 397-409.	0.8	0
1574	Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review. <i>Healthcare (Switzerland)</i> , 2021, 9, 1726.	1.0	4
1575	Effectiveness of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in conjunction with methotrexate for the treatment of early rheumatoid arthritis: A systematic review of randomized controlled trials. <i>Musculoskeletal Care</i> , 0, , .	0.6	1
1576	Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis. <i>Korean Journal of Internal Medicine</i> , 2021, , .	0.7	0
1577	Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response. <i>Frontiers in Immunology</i> , 2021, 12, 789334.	2.2	23
1578	The development and validation of a Patient-Perceived Methotrexate Intolerance Scale for use in adult rheumatoid arthritis patients. <i>Musculoskeletal Care</i> , 2021, , .	0.6	1
1579	Host Immunity and Francisella tularensis: A Review of Tularemia in Immunocompromised Patients. <i>Microorganisms</i> , 2021, 9, 2539.	1.6	7
1580	Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 391-409.	1.1	3
1581	Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk. <i>Pharmaceuticals</i> , 2022, 15, 11.	1.7	12
1582	Jintiang Capsule Alleviates Rheumatoid Arthritis and Reverses Changes of Serum Metabolic Profile in Collagen-Induced Arthritic Rats. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6685-6706.	1.6	5
1583	Evaluation of an Intervention to Support <sc>Patient-Rheumatologist</sc> Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A <sc>Proof-of-Principle</sc> Study. <i>ACR Open Rheumatology</i> , 2022, 4, 279-287.	0.9	1
1584	Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events. <i>Rheumatology</i> , 2022, 61, 3567-3575.	0.9	9

#	ARTICLE	IF	CITATIONS
1586	Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. <i>Rheumatology and Therapy</i> , 2022, 9, 411-433.	1.1	1
1587	Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. <i>Rheumatology</i> , 2022, 61, 3257-3268.	0.9	11
1588	Association of Tumor Necrosis Factor $\hat{\pm}$ Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010â€“2017. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab641.	0.4	1
1589	Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. <i>Infection</i> , 2022, 50, 295-308.	2.3	19
1590	The infection risks of JAK inhibition. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 253-261.	1.3	21
1592	Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210914.	1.2	3
1593	Evidence-based efficacy of methotrexate in adult Crohnâ€™s disease in different intestinal and extraintestinal indications. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210858.	1.4	4
1594	Chapter 26: Arthritis. , 2022, , .		0
1595	Conversion rate of tuberculosis screening tests among dermatology patients treated with tumor necrosis factor inhibitors. <i>Indian Journal of Dermatology</i> , 2022, 67, 1.	0.1	0
1596	Pharmacokinetics, Pharmacodynamics and Safety of Single-Dose Subcutaneous Sarilumab With or Without Methotrexate in Japanese Patients with Rheumatoid Arthritis: Two Single-Dose Studies. <i>Modern Rheumatology</i> , 2022, , .	0.9	0
1597	Prevalence of adverse reactions to intravenously administered originator biologics in patients with rheumatoid arthritis: A 5-year retrospective study. <i>Saudi Pharmaceutical Journal</i> , 2022, , .	1.2	1
1598	Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. <i>Pediatric Rheumatology</i> , 2022, 20, 25.	0.9	8
1599	New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 2365-2380.	1.6	23
1600	Targeted Therapy for Inflammatory Diseases with Mesenchymal Stem Cells and Their Derived Exosomes: From Basic to Clinics. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 1757-1781.	3.3	37
1601	Treatment of early rheumatoid arthritis: Methotrexate and beyond. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102227.	1.7	22
1636	Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, , .	1.6	0
1637	Medicinal Attributes of Heterocyclic Compounds in Rheumatoid Arthritis: Recent Developments and SAR Studies. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 1821-1846.	1.0	0
1638	Real-world evidence of tofacitinib in rheumatoid arthritis patients in Spain. <i>Drug Discoveries and Therapeutics</i> , 2022, 16, 63-71.	0.6	3

#	ARTICLE	IF	CITATIONS
1639	Rheumatic Disorders. , 2022, , 557-566.		1
1640	American College of Rheumatology Guidance for <sc>COVID</sc>â€19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. Arthritis and Rheumatology, 2022, 74, e21-e36.	2.9	49
1642	Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?. Rheumatology International, 2022, 42, 1797-1806.	1.5	0
1643	Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact. Rheumatology, 2022, 62, 98-107.	0.9	1
1644	Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. Clinical Rheumatology, 2022, , 1.	1.0	7
1645	Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina. ReumatologÃa ClÃnica (English Edition), 2022, 18, 286-292.	0.2	0
1646	Dihydroarteannuin Ameliorates Collagen-Induced Arthritis Via Inhibiting B Cell Activation by Activating the FcÎ³RIIb/Lyn/SHP-1 Pathway. Frontiers in Pharmacology, 2022, 13, 883835.	1.6	0
1647	Musculoskeletal ultrasound for treating rheumatoid arthritis to targetâ€”a systematic literature review. Rheumatology, 2022, 61, 4590-4602.	0.9	4
1648	Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort. RMD Open, 2022, 8, e002040.	1.8	0
1649	Dexamethasone-Loaded Radially Mesoporous Silica Nanoparticles for Sustained Anti-Inflammatory Effects in Rheumatoid Arthritis. Pharmaceutics, 2022, 14, 985.	2.0	12
1650	Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? â€” A Case Report. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 465-475.	0.4	2
1651	Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study. Seminars in Arthritis and Rheumatism, 2022, 55, 152019.	1.6	1
1652	Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study. Rheumatology Advances in Practice, 2022, 6, .	0.3	1
1653	Implementation of the treat-to-target approach and treatment satisfaction in patients with rheumatoid arthritis: perspectives of Chinese rheumatologists. Clinical Rheumatology, 2022, 41, 2659-2668.	1.0	1
1654	Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. Rheumatology, 2023, 62, S1170-S1180.	0.9	4
1655	Robust drug bioavailability and safety for rheumatoid arthritis therapy using D-amino acids-based supramolecular hydrogels. Materials Today Bio, 2022, 15, 100296.	2.6	4
1656	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Annals of the Rheumatic Diseases, 2022, 81, 925-936.	0.5	59
1657	The Efficacy of <sc>Shortâ€Term</sc> Bridging Strategies With Highâ€and <sc>Lowâ€Dose</sc> Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A <sc>Doubleâ€Blind</sc>, Randomized, <sc>Placeboâ€Controlled</sc> Trial. Arthritis and Rheumatology, 2022, 74, 1628-1637.	2.9	9

#	ARTICLE	IF	CITATIONS
1658	Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review. <i>Advances in Therapy</i> , 2022, 39, 3072-3087.	1.3	2
1659	Safety of Intravenous Methylprednisolone in Refractory and Severe Pediatric Uveitis. <i>Clinical Ophthalmology</i> , 0, Volume 16, 1697-1706.	0.9	1
1660	Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib+Oral Methotrexate Combination. <i>Clinical Therapeutics</i> , 2022, , .	1.1	2
1661	Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	1
1662	Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152036.	1.6	1
1663	Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US. <i>Arthritis and Rheumatology</i> , 2022, 74, 1833-1841.	2.9	5
1664	Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry. <i>Rheumatology and Therapy</i> , 2022, 9, 1143-1155.	1.1	3
1665	Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. <i>Rheumatology</i> , 2023, 62, 583-595.	0.9	3
1666	Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	1
1667	Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0270391.	1.1	1
1668	Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018. <i>Advances in Therapy</i> , 2022, 39, 3711-3734.	1.3	4
1669	CP-25 enhances OAT1-mediated absorption of methotrexate in synoviocytes of collagen-induced arthritis rats. <i>Acta Pharmacologica Sinica</i> , 0, , .	2.8	1
1670	Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study. <i>World Journal of Diabetes</i> , 2022, 13, 454-465.	1.3	2
1671	Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. <i>BioNanoScience</i> , 2022, 12, 1436-1454.	1.5	2
1672	Development of an interdisciplinary early rheumatoid arthritis care pathway. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	4
1673	Effects of yoga on depressive symptoms, anxiety, sleep quality, and mood in patients with rheumatic diseases: Systematic review and meta-analysis. <i>PM and R</i> , 2023, 15, 899-915.	0.9	5
1674	Prediction of hidden patterns in rheumatoid arthritis patients records using data mining. <i>Multimedia Tools and Applications</i> , 0, , .	2.6	0
1675	Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 56, 152050.	1.6	8

#	ARTICLE	IF	CITATIONS
1677	Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies. <i>Rheumatology International</i> , 0, , .	1.5	0
1678	Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013â€”2018. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	1
1679	Evaluation of Access Disparities to Biologic Disease-Modifying Antirheumatic Drugs in Rural and Urban Communities. <i>Cureus</i> , 2022, , .	0.2	1
1680	Computerâ€Assisted Image Analysis in Assessment of Peripheral Joint <scp>MRI</scp> in Inflammatory Arthritis: A Systematic Review and Metaâ€Analysis. <i>ACR Open Rheumatology</i> , 0, , .	0.9	1
1681	Genetic variations in methotrexate metabolic pathway genes influence methotrexate responses in rheumatoid arthritis patients in Malaysia. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1682	Pneumococcal vaccination in rheumatic diseases: 10 years of application experience at the V.A. Nasonova Research Institute of Rheumatology. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 261-266.	0.2	3
1683	Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? â€ A Cohort Study in a Colombian Population. <i>Biologics: Targets and Therapy</i> , 0, Volume 16, 107-117.	3.0	0
1684	Trivalent chromium supplementation ameliorates adjuvant induced rheumatoid arthritis through up-regulation of FOXP3 and decrease in synovial Cathepsin G expression. <i>Inflammopharmacology</i> , 0, , .	1.9	0
1685	Treatment Guidelines in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 679-689.	0.8	21
1686	ACCP-negative rheumatoid arthritis â€ clinical and immunological features. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 314-326.	0.2	2
1687	Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study. <i>Modern Rheumatology</i> , 2023, 33, 460-471.	0.9	1
1688	Xanthonones from <i>Securidaca inappendiculata</i> antagonizes the anti-rheumatic effect of methotrexate by inhibiting reduced folate carrier 1. <i>Immunopharmacology and Immunotoxicology</i> , 0, , 1-27.	1.1	0
1689	Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	14
1690	Safety and Feasibility of Infliximab Therapy in Children With Kawasaki Disease Who Received Live Vaccinations. <i>Pediatric Infectious Disease Journal</i> , 0, Publish Ahead of Print, .	1.1	2
1691	Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 737-752.	1.4	8
1692	Acute effects of exercise on pain symptoms, clinical inflammatory markers and inflammatory cytokines in people with rheumatoid arthritis: a systematic literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211141.	1.2	2
1693	Differential diagnosis of inflammatory arthritis from musculoskeletal ultrasound view. <i>Rheumatology and Immunology Research</i> , 2022, 3, 54-60.	0.2	0
1694	Adipose-Derived Stem Cell Exosomes as a Novel Anti-Inflammatory Agent and the Current Therapeutic Targets for Rheumatoid Arthritis. <i>Biomedicines</i> , 2022, 10, 1725.	1.4	17

#	ARTICLE	IF	CITATIONS
1695	Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	5
1696	Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases. <i>Stem Cells International</i> , 2022, 2022, 1-8.	1.2	7
1697	Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial. <i>Trials</i> , 2022, 23, .	0.7	2
1698	Predictors of flare in rheumatoid arthritis patients with persistent clinical remission/low disease activity: Data from the TARAC cohort. <i>Medicine (United States)</i> , 2022, 101, e29974.	0.4	1
1699	The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 1231-1241.	0.7	3
1700	Vaccine Prophylaxis of Herpes Zoster In Rheumatic Diseases: Paradigm Revision and New Opportunities. <i>Antibiotiki I Khimioterapiya</i> , 2022, 67, 70-76.	0.1	0
1701	The association between dietary total antioxidant capacity with risk of rheumatoid arthritis in adults: A caseâ€“control study. <i>Clinical Nutrition ESPEN</i> , 2022, 51, 391-396.	0.5	4
1702	Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
1703	Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators. <i>Journal of Medical Economics</i> , 2022, 25, 1118-1126.	1.0	1
1704	Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting. <i>Rheumatology</i> , 2023, 62, 1476-1484.	0.9	1
1705	Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 773-787.	0.5	11
1706	Inflammation Modulating Activity of the Hydroethanol Stem Bark Extract of <i>Bombax costatum</i> in Murine Models. <i>Scientifica</i> , 2022, 2022, 1-10.	0.6	1
1707	Does persistence to methotrexate treatment in early rheumatoid arthritis have a familial component?. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	1
1708	A Multicenter, Prospective, Randomized, <scp>Parallelâ€“Group</scp> Trial on the Effects of Temporary Methotrexate Discontinuation for One Week Versus Two Weeks on Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2023, 75, 171-177.	2.9	7
1709	Twenty Years of Targeted and Biologic Immunomodulatory Drugs. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1512-1522.	1.4	0
1710	Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2022, 41, 3615-3627.	1.0	10
1711	Assessment of disease activity in patients with rheumatoid arthritis using plasma tumour M2-pyruvate kinase test. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1712	A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing $\hat{3}c$ cytokineâ€“related JAK-STAT signal. <i>Science Advances</i> , 2022, 8, .	4.7	19

#	ARTICLE	IF	CITATIONS
1713	Comparative study of cannabinoid receptor 2 agonist and dexamethasone in experimentally induced rheumatoid arthritis. <i>Journal of Advanced Pharmacy Education and Research</i> , 2022, 12, 44-53.	0.2	0
1714	Correlation between anti-mutated citrullinated vimentin and bone turnover markers (CTX-1 and P1NP) in patients with rheumatoid arthritis in remission and low-disease activity. <i>Reumatologia</i> , 2022, 60, 252-257.	0.5	0
1715	Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	2
1716	Association of Interleukin-10 Genotypes and Anticyclic Citrullinated Peptide Antibodies with Rheumatoid Arthritis. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , .	0.9	0
1717	The role of resveratrol on rheumatoid arthritis: From bench to bedside. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
1718	Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. <i>Annals of the Rheumatic Diseases</i> . 2022, 81, 1661-1668.	0.5	11
1719	Scientific Knowledge of Rheumatoid Arthritis: A Bibliometric Analysis from 2011 to 2020. <i>Journal of Pain Research</i> , 0, Volume 15, 2761-2772.	0.8	5
1720	Bibliometric analysis of research relating to the use of herbal medicine for rheumatoid arthritis between 1991 to 2021. <i>Medicine (United States)</i> , 2022, 101, e30413.	0.4	3
1721	Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing Patients. <i>Drugs and Aging</i> , 2022, 39, 841-849.	1.3	8
1722	Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. <i>World Journal of Virology</i> , 0, 11, 275-282.	1.3	2
1724	Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1311-1322.	1.4	5
1725	Genome-wide association study of liver enzyme elevation in an extended cohort of rheumatoid arthritis patients starting low-dose methotrexate. <i>Pharmacogenomics</i> , 2022, 23, 813-820.	0.6	5
1726	Clinical evidence construction of East Asian herbal medicine for inflammatory pain in rheumatoid arthritis based on integrative data mining approach. <i>Pharmacological Research</i> , 2022, 185, 106460.	3.1	12
1727	Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study. <i>Rheumatology International</i> , 2023, 43, 523-531.	1.5	2
1728	Development of Methotrexate Complexes Endowed with New Biological Properties Envisioned for Musculoskeletal Regeneration in Rheumatoid Arthritis Environments. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10054.	1.8	1
1729	New insights into the pathogenesis and management of rheumatoid arthritis. <i>Chronic Diseases and Translational Medicine</i> , 2022, 8, 256-263.	0.9	2
1730	Fatal Manifestations of Methotrexate Overdose in Case of Psoriasis Due to Dosing Error. <i>Cureus</i> , 2022, , .	0.2	1
1731	Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	6

#	ARTICLE	IF	CITATIONS
1732	Monitoring Appropriate Monoclonal Antibodies Prescribing via Administrative Data: An Application to Psoriasis. <i>Pharmaceuticals</i> , 2022, 15, 1238.	1.7	0
1733	Translation suppression underlies the restrained COVID-19 mRNA vaccine response in the high-risk immunocompromised group. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1734	A chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
1735	American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 74-80.	0.5	23
1736	Dimethyl Fumarate Inhibits Fibroblast Like Synoviocytes-mediated Inflammation and Joint Destruction in Rheumatoid Arthritis. <i>Inflammation</i> , 0, , .	1.7	3
1737	Assessment of mesenchymal stem/stromal cell-based therapy in K/BxN serum transfer-induced arthritis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1738	Attitudes and practices in the laboratory monitoring of conventional synthetic disease modifying anti-rheumatic drugs by rheumatologists and rheumatology trainees. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	0
1739	Physicians' Agreement on and Implementation of the 2019 European Alliance of Associations for Rheumatology Vaccination Guideline: An International Survey. <i>Journal of Rheumatic Diseases</i> , 2022, , .	0.4	3
1740	Machine Learning Applied to <sc>Patientâ€Reported</sc> Outcomes to Classify <sc>Physicianâ€Derived</sc> Measures of Rheumatoid Arthritis Disease Activity. <i>ACR Open Rheumatology</i> , 0, , .	0.9	2
1741	Risk of tuberculosis among renal transplant recipients receiving rituximab therapy. <i>Transplant Infectious Disease</i> , 0, , .	0.7	1
1742	American College of Rheumatology/<sc>EULAR</sc> Remission Criteria for Rheumatoid Arthritis: 2022 Revision. <i>Arthritis and Rheumatology</i> , 2023, 75, 15-22.	2.9	18
1743	Testing and Treating Mycobacterium tuberculosis Infection. <i>Medical Clinics of North America</i> , 2022, 106, 929-947.	1.1	2
1744	Physician Perspectives on Vaccination in Patients With Autoimmune Inflammatory Rheumatic Diseases: An International Survey. <i>Journal of Rheumatology</i> , 2023, 50, 246-251.	1.0	4
1745	Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. <i>PLoS ONE</i> , 2022, 17, e0277566.	1.1	2
1746	American College of Rheumatology Guidance for <sc>COVID</sc>â€19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. <i>Arthritis and Rheumatology</i> , 2023, 75, .	2.9	45
1747	Assessment of risk factors in patients with rheumatoid arthritis-associated interstitial lung disease. <i>Jornal Brasileiro De Pneumologia</i> , 0, , e20220145.	0.4	2
1748	Examining the safety of relaxed drug monitoring for methotrexate in response to the COVID-19 pandemic. <i>Rheumatology Advances in Practice</i> , 2022, 6, .	0.3	1
1749	Ankilozan Spondilit ve Romatoid Artrit HastalarÄ±nÄ±n Sosyodemografik ve Klinik DeÄYiÅYkenlere GÃ¶re Å°laÅ° UyumlarÄ±: Betimsel bir Å°salÄ±ÅYma. <i>Health Care Academician Journal</i> , 0, , .	0.0	1

#	ARTICLE	IF	CITATIONS
1750	Effects of Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2023, 29, 16-22.	0.5	0
1751	JAK Inhibitors in Atopic Dermatitis Associated With Risk of Viral Infections: A Critical Appraisal. <i>Actas Dermo-sifiligráficas</i> , 2022, 114, 277-277.	0.2	1
1752	Validity of clinical disease activity index (CDAI) to evaluate the disease activity of rheumatoid arthritis patients in Sri Lanka: A prospective follow up study based on newly diagnosed patients. <i>PLoS ONE</i> , 2022, 17, e0278285.	1.1	1
1753	Busting the myth of methotrexate chronic hepatotoxicity. <i>Nature Reviews Rheumatology</i> , 2023, 19, 96-110.	3.5	11
1754	Healthcare resource utilization and costs in stable patients with rheumatoid arthritis: Comparing nurse-led and rheumatologist-led models of care delivery. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 59, 152160.	1.6	0
1755	Olokizumab's Effectiveness and Safety in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Densitometry</i> , 2023, 26, 61-82.	0.5	1
1756	Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data). <i>Sovremennaya Revmatologiya</i> , 2022, 16, 32-37.	0.1	1
1757	Methotrexate-Induced Liver Injury Is Associated with Oxidative Stress, Impaired Mitochondrial Respiration, and Endoplasmic Reticulum Stress In Vitro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15116.	1.8	4
1758	Trends in Total Joint Arthroplasty Among Patients With Rheumatoid Arthritis: The Effect of Recent Disease Modifying Antirheumatic Drug Utilization Guidelines. <i>Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews</i> , 2022, 6, .	0.4	0
1759	Adherence to methotrexate and associated factors considering social desirability in patients with rheumatoid arthritis: a multicenter cross-sectional study. <i>BMC Rheumatology</i> , 2022, 6, .	0.6	2
1760	Chronic viral hepatitis B and rheumatic diseases: Modern view on problem. <i>Medical Alphabet</i> , 2022, , 20-28.	0.0	1
1761	Efficacy and Safety of <i>ABBV</i> <i>3373</i> , a Novel Anti- <i>Tumor Necrosis Factor</i> Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial. <i>Arthritis and Rheumatology</i> , 2023, 75, 879-889.	2.9	11
1762	Association between Diabetes and Rheumatoid Arthritis: A Systematic Literature Review. <i>Open Rheumatology Journal</i> , 2022, 16, .	0.1	0
1763	Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies. <i>Clinical Drug Investigation</i> , 2023, 43, 97-108.	1.1	2
1764	The association between Disease Activity Score and rheumatoid arthritis-associated cervical deformity: radiological evaluation of the BeSt trial. <i>Journal of Neurosurgery: Spine</i> , 2023, 38, 465-472.	0.9	0
1765	From Bench to Bedside in Rheumatoid Arthritis from the 2022 GISEA International Symposium. <i>Journal of Clinical Medicine</i> , 2023, 12, 527.	1.0	1
1766	Increased Galectin-9 Levels Correlate with Disease Activity in Patients with DMARD-Na ^{-ve} Rheumatoid Arthritis and Modulate the Secretion of MCP-1 and IL-6 from Synovial Fibroblasts. <i>Cells</i> , 2023, 12, 327.	1.8	2
1767	Continuity of Care Within a Single Patient Support Program for Patients with Rheumatoid Arthritis Prescribed Second or Later Line Advanced Therapy. <i>Advances in Therapy</i> , 2023, 40, 990-1004.	1.3	1

#	ARTICLE	IF	CITATIONS
1768	Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. <i>Annals of Medicine</i> , 2023, 55, 241-252.	1.5	15
1771	Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies. <i>Rheumatology and Therapy</i> , 2023, 10, 463-476.	1.1	1
1772	Genome-wide Association Study of Methotrexate-induced Liver Injury in Rheumatoid Arthritis Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 916-923.	2.3	0
1773	Efficacy and pharmacokinetics of ozoralizumab, an anti-TNF- α NANOBODY [®] compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. <i>Arthritis Research and Therapy</i> , 2023, 25, .	1.6	9
1774	Salivary and serum levels of neutrophil proteases in periodontitis and rheumatoid arthritis. <i>Oral Diseases</i> , 0, , .	1.5	3
1775	Multi-Organ System Screening, Care, and Patient Support in Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 211-248.	0.8	2
1776	Development of triamcinolone acetonide-hyaluronic acid conjugates with selective targeting and less osteoporosis effect for rheumatoid arthritis treatments. <i>International Journal of Biological Macromolecules</i> , 2023, 237, 124047.	3.6	3
1777	An innovative immunotherapeutic strategy for rheumatoid arthritis: Selectively suppressing angiogenesis and osteoclast differentiation by fully human antibody targeting thymocyte antigen-1. <i>Experimental Cell Research</i> , 2023, 424, 113490.	1.2	4
1778	Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 Weeks: An Indirect Treatment Comparison. <i>Rheumatology and Therapy</i> , 0, , .	1.1	0
1779	Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population. <i>Pathogens</i> , 2023, 12, 233.	1.2	7
1780	Krankheitsmodifizierende Arzneistoffe für Autoimmunerkrankungen. , 2022, , 423-429.		0
1782	HAS-Flow May Be an Adequate Method for Evaluating Human T-Cell Leukemia Virus Type 1 Infected Cells in Human T-Cell Leukemia Virus Type 1-Positive Rheumatoid Arthritis Patients Receiving Antirheumatic Therapies: A Retrospective Cross-Sectional Observation Study. <i>Viruses</i> , 2023, 15, 468.	1.5	0
1783	Global trends in research of fibroblasts associated with rheumatoid diseases in the 21st century: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1784	Systemic Lupus Erythematosus May Be a Risk Factor for Antimalarial-induced Retinopathy Compared With Other Rheumatologic Diseases. <i>ACR Open Rheumatology</i> , 2023, 5, 173-179.	0.9	2
1785	The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis. <i>Clinical Rheumatology</i> , 2023, 42, 1503-1520.	1.0	3
1786	Withdrawal of biologic therapy in juvenile idiopathic arthritis due to remission: predictors of flare and outcomes. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 305-313.	1.4	1
1787	Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. <i>RMD Open</i> , 2023, 9, e002789.	1.8	4
1788	Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease. <i>Rheumatology International</i> , 2023, 43, 969-973.	1.5	1

#	ARTICLE	IF	CITATIONS
1789	A Summary on Tuberculosis Vaccine Development“Where to Go?. Journal of Personalized Medicine, 2023, 13, 408.	1.1	8
1790	2-Styrylchromones Prevent IL-1 β -Induced Pro-Inflammatory Activation of Fibroblast-like Synoviocytes while Increasing COX-2 Expression. Pharmaceutics, 2023, 15, 780.	2.0	0
1791	Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. , 2023, , 407-422.		0
1792	Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial. Chinese Medical Journal, 2023, 136, 331-340.	0.9	1
1793	Simultaneous quantitative analysis and in vitro anti-arthritic effects of five polyphenols from Terminalia chebula. Frontiers in Physiology, 0, 14, .	1.3	1
1794	TNF promotes DECTIN2 family C-type lectin receptor expression in human macrophages. Journal of Leukocyte Biology, 2023, 113, 615-625.	1.5	2
1795	Optimal Timing of Serial 18 F-Fluoro-2-Deoxyglucose Positron Emission Tomography after Prednisolone Treatment Introduction for Cardiac Sarcoidosis. International Heart Journal, 2023, 64, 196-202.	0.5	1
1797	Methotrexate intolerance in Rheumatoid Arthritis. Translational Medicine Communications, 2023, 8, .	0.5	1
1798	Medications to Avoid When Treating Heart Failure. , 2023, , 285-306.		0
1799	Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry. JMIR Research Protocols, 0, 12, e43230.	0.5	0
1800	Rheumatoid Arthritis from Easy to Complex Disease: From the “2022 GISEA International Symposium” Journal of Clinical Medicine, 2023, 12, 2781.	1.0	2
1801	Management of Rheumatoid Arthritis With a Digital Health Application. JAMA Network Open, 2023, 6, e238343.	2.8	8
1802	Choice of and response to treatment in patients with early-diagnosed rheumatoid arthritis: Real-world data from an inception cohort in Japan (NICER-J). Journal of Orthopaedic Science, 2023, , .	0.5	0
1803	Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis. Rheumatology International, 2023, 43, 1515-1523.	1.5	2
1804	Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid Arthritis. Journal of Rheumatology, 0, , jrheum.2022-1008.	1.0	0
1805	Evaluating key performance indicators of the process of care in juvenile idiopathic arthritis. Pediatric Rheumatology, 2023, 21, .	0.9	1
1806	The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study. Arthritis Research and Therapy, 2023, 25, .	1.6	0
1807	A Unique Case of Acute Respiratory Distress Syndrome Secondary to Rheumatoid Lung Disease With Administration of Anti-Tumor Necrosis Factor Alpha (TNF \pm) Agent. Cureus, 2023, , .	0.2	0

#	ARTICLE	IF	CITATIONS
1820	What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines. <i>Clinical Rheumatology</i> , 2023, 42, 2267-2278.	1.0	5
1826	The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases. <i>BioDrugs</i> , 0, , .	2.2	1
1863	Beware of the Indeterminate Interferon-Gamma Release Assay (IGRA) Tuberculosis Test. , 2023, , 483-486.		0
1864	Side Effects of Neurosurgical Therapy in Cancer Patients. , 2024, , 1-10.		0
1870	Mesenchymal Stem Cell Engineering. <i>Methods in Molecular Biology</i> , 2024, , 169-174.	0.4	0
1874	Total Hip Replacement in Rheumatoid Arthritis. , 2023, , 359-372.		0
1879	Case report: Management of Epstein-Barr virus positive and methotrexate-associated B-cell lymphoma. <i>International Journal of Rheumatic Diseases</i> , 2024, 27, .	0.9	0